Parasites revive hope for cancer therapy.

Introduction

Cancer is a worldwide life-threatening concern that imposes heavy health and economic burdens every year. Approximately 20 million new cancer cases and 10 million deaths are reported annually [ 1 ]. By 2040, it is expected that the global burden of new cancer cases will increase to 30 million [ 2 ]. This emphasizes the value of exploring new therapeutic horizons to chase safe, efficient drugs and detour away from traditional cancer treatments such as chemotherapy, radiotherapy, and surgery that inevitably have lethal drawbacks [ 3 ]. Recent advancements in cancer therapeutic and preventive methods include immunotherapy, targeted therapy, precision medicine, and gene therapy [ 4 ].

Cancer immunotherapy is a promising approach to fighting cancer by restoring the balance of the immune system. It is an emerging and revolutionary weapon with various successful trials, offering hope in the battle against cancer [ 5 ]. Advancements in cancer immunotherapy have been significant every decade. It effectively targets cancer cells by engaging the immune system creating biological stimulation to break the tolerance and eliciting a hostile environment for tumor growth . Multiple categories are included under the umbrella of cancer immunotherapy, such as adoptive T-cell transfer, immune checkpoint inhibitors (negative regulators of T cells), cytokine therapies, and cancer vaccines [ 6 ]. Aside from the immunomodulatory agents in cancer pipeline immunotherapeutic trials, pathogens have evolved as promising candidates [ 7 ].

Recently, pathogens and their products have been included within the framework of cancer immunotherapy by referring to the hygiene hypothesis [ 8 ]. It attributes immune-related diseases such as autoimmune and allergic diseases to a lack of exposure to different microorganisms during childhood [ 9 ]. This theory has been re-evaluated and stated cancer as another outcome of the hygiene hypothesis, explaining the relevant use of pathogens and their products to fight cancer. Therefore, pathogens and their products have been included within the framework of cancer immunotherapy [ 10 ].

Cancer vaccines, a wide category in cancer immunotherapy, can be industrialized either by utilizing cancer antigens, immune cells, pathogens, or their products to excite the immune system [ 7 , 11 ]. One of the main challenges in the development of an efficient anti-cancer vaccine is the limited ability of tumor-associated antigens to overcome immune tolerance [ 12 ]. This can be explained by the nature of cancer cells and their antigens being familiar and not foreign to the patient’s body, thus eliciting a weak antigenic immune response if any. In addition, cancer cells have evoked various tools to evade the immune response [ 13 ]. On the contrary, pathogens are foreign to the host and are more easily recognized by the immune cells than cancer cells, and thus can elicit a stronger immune response [ 14 ]. Therefore, a wide range of pathogens and their products, including viruses and bacteria, have been added to the growing list of cancer immunotherapy trials to stimulate the immune response [ 10 ]. For instance, the usage of the human papilloma virus (HPV) vaccine [ 15 ] and hepatitis B virus (HBV) vaccine [ 16 ] as preventive cancer vaccines that can preclude cervical cancer and hepatocellular carcinoma, respectively. Bacillus Calmette–Guérin (BCG) is a type of therapeutic cancer vaccine. BCG vaccine harboring attenuated Mycobacterium bovis ; a prophylactic tuberculosis vaccine is now repurposed as a therapeutic vaccine against bladder cancer [ 11 ] and metastatic melanoma [ 17 ].

Parasites are harmful organisms that can cause debilitating diseases, within which some are approved biological carcinogens. Schistosoma haematobium ( S. haematobium ) infection is known to cause bladder cancer, and Clonorchis sinensis ( C. sinensis ) and Opisthorchis viverrini ( O. viverrini ) are associated with cholangiocarcinoma [ 18 ]. However, the immunomodulatory benefits of parasites cannot be ignored and have drawn attention as talented immunomodulatory and anti-neoplastic armamentariums [ 14 , 19 ]. Numerous studies have revealed their potential benefits for various autoimmune diseases, including arthritis [ 20 ], and bronchial asthma [ 21 ], and ulcerative colitis [ 22 ] among others [ 23 , 24 ]. For cancer, different research groups reported an adverse relationship between certain parasitic infections and cancer in the human population. Lower cancer prevalence has been observed in patients with hydatid cyst disease or chagasic megacolon compared to the normal population [ 25 , 26 ]. Likewise, a negative correlation was found between malaria incidence and cancer mortality [ 27 ]. Additionally, a state of resistance to cancer was observed in individuals with a low titer of anti- Toxoplasma antibody [ 28 ]. This was in line with the other epidemiological data that reported longer survival rates of cancer patients; simultaneously infected with certain parasites than non-infected patients [ 29 , 30 ].

Antineoplastic mechanistic strategies of parasites

Relying on multi-mechanistic strategies, parasites have successfully promoted anti-neoplastic potency in various experimental cancer models [ 10 , 19 ]. Immunomodulation, inhibition of angiogenesis, and the molecular mimicry theory are the three main cornerstones that undoubtedly build the anti-neoplastic power of parasites (Fig. 1 ) [ 31 – 35 ]. Fig. 1 Diagrammatic illustration of the variuos anti-neoplastic mechanistic strategies of parasites

Cancer has recently been included in the re-evaluated hygiene hypothesis illustrating that the lack of exposure to pathogens accelerates and promotes cancer development [ 10 , 35 ]. As a consequence of the persistence of long-term parasitic infections along with the release of their by-products, the host’s immune system is in a continuous specific immune-stimulatory state to combat the parasitic infection, especially with their highly provoked immune-evasive strategies [ 32 , 35 ]. Thus, this can be exploited as an extremely valuable credit to stimulate the hijacked immune system within the suppressed cancer microenvironment [ 35 ]. Initially, at the molecular level, parasites promote an increase in co-stimulatory molecules expression. This initiates a cycle of Th 1 immune stimulation including both innate and adaptive immune cells [ 36 ]. Via restoring an imbalanced immune system, parasites and their antigens were able to stimulate the MyD88 pathway and release robust pro-inflammatory cytokines such as INF-γ, TNF-α, IL-1, IL-2, IL-12, and others, thus creating an immunostimulant environment that is hostile to tumor cells. These factors promote the differentiation of macrophages to M1 form, thus stimulating dendritic cells (DCs) and activating NK cells and T helper cells toward Th 1 responses [ 10 , 14 , 19 , 32 , 37 ]. The proliferation of parasite-specific immune cells such as eosinophils within some parasitic infections is another cancer-combating strategy [ 35 ]. Additionally, parasites suppress IL-10 and tumor growth factor (TGF) expression [ 34 , 38 ]. At the level of cytotoxic T cells, parasitic infections stimulate CD8 + T cells to harbor more granzymes and perforin, thus amplifying their cytotoxic potency. Eventually, parasites promote tumor-selective cytotoxic T-cell invasion and suppress T regulatory (Treg) cell recruitment to the tumor tissue. The efficient rise in CD8 + T-cell/Treg ratio is a vital prognostic factor that has been efficiently achieved by parasites [ 36 , 39 – 41 ].

Furthermore, the influence of parasites on the induction of apoptotic pathways was also reported. It is interesting to note that certain parasite molecules trigger apoptosis only in cancer cells while leaving normal cells unaffected. For instance, the T. cruzi surface molecule gp82 has been found to induce apoptosis in melanoma cells without impacting normal melanocytes [ 42 ]. Additionally, the use of hydatid cyst fluid has been shown to trigger apoptosis in various tumor cells [ 41 ].

Additionally, T. spiralis is one of those missionary parasites. Despite its potency in the induction of Th 2 immune response that conflicts with its usage as an anti-neoplastic agent, its excretory–secretory antigen; especially during the early phase of muscle invasion is different. Those antigens independently and efficiently induce mitochondrial apoptotic and death-receptor pathways such as Bax, and caspases, as well as activation of p53, signifying an anti-neoplastic potency. This is achieved in addition to the stimulation of immune cells, including macrophages, NK cells, and cytotoxic T cells, releasing INF-γ, TNF-α, and many other interleukins [ 43 , 44 ]. Thus, identifying parasitic molecules that can selectively induce apoptosis in cancer cells could be a promising approach for cancer therapy. This would allow for targeting cancer cells without causing harm to normal ones.

Along with the novel emerging era of the use of checkpoint inhibitors in cancer immunotherapy to unleash the activity of the immune cells, interestingly some parasites, such as Toxoplasma and Plasmodium effectively inhibited programmed cell death and its ligand (PD-1/PDL-1). Thus, they simultaneously work as a checkpoint inhibitor, unleashing the power of T-cell activity, especially on CD8 + T cells [ 11 , 36 , 45 ].

Angiogenesis is an essential factor in tumor growth. Failure to achieve this factor declares tumor cell death. Through a direct strategy, parasites suppress vascular development within tumor tissue via suppression of vascular endothelial growth factor (VEGF). Interestingly, via an indirect mechanism, VEGF has an immune-suppressor activity. Consequently, interfering with angiogenesis stimulates the immune system [ 46 ]. Thus, parasites can attack two birds with one stone, inhibit angiogenesis, and stimulate the suppressed immune system [ 35 , 39 , 40 ].

A unique criterion that discriminates parasites from other immunotherapeutic agents is the molecular mimicry theory [ 19 , 47 ]. The sharing of antigenic epitopes between parasites and cancer cells has exceeded being a theory to a verified phenomenon with excellent experimental applications. Mucin-type O -glycan structures (Tn, Tk, sial Tn, TF) that are crucial cancer cell invasion and metastasis markers were documented to be expressed in many parasites including trematodes, cestodes, and protozoa as well [ 14 , 48 – 50 ]. The use of these heterogenic purified shared antigens separately induced anti-neoplastic activity in an experimental breast cancer model in mice [ 51 ] denoting their ability to break immune tolerance and demonstrate good immunogenicity. Therefore, these parasites and their antigens could offer a new direction for cancer biotherapy. On the other hand, several studies have shown that anti-parasite antibodies could target those shared antigens bound to specific cancer cells [ 52 , 53 ], induce their death, and reduce experimental tumor growth [ 54 ]. Therefore, anti-parasite antibodies that selectively react with cancer cells but not with normal cells may be potential candidates for targeted cancer therapy in humans. These results probably justify the occurrence of anti-neoplastic activity selectively between certain parasites and specific cancer cell lines and not others [ 14 , 39 , 55 ]. Hence, this phenomenon adds a privilege for the use of parasites and their products as favored anti-neoplastic candidates.

Thus, parasites use a multifactorial approach to combat cancer, using a variety of strategies, such as inhibiting proliferative signals, regulating inflammatory responses, promoting apoptosis, activating the immune response, preventing metastasis, and interfering with angiogenesis [ 19 , 35 ].

Thus, researchers are currently heavily investigating certain parasites as potential allies in the battle against cancer. Experimental studies have successfully demonstrated the potency of certain parasites as cancer warriors. Therefore, this review article summarizes up-to-date literature conducted on various cancer types showing promising response to parasite therapy both in vitro and in vivo. The responsible mechanisms hypothesized to be involved in modulating cancer progression were also elaborated. The goal is to shed light on this intriguing emerging field and emphasize the importance of collaborative multidisciplinary research projects between different areas of science for the potential development of novel, highly immunogenic, and nature-based cancer therapeutics for incurable cancers.

Database search

To examine the most relevant literature used in this review, we searched electronic databases including ScienceDirect, PubMed, Egyptian Knowledge Bank, Scopus, and Google Scholar. Search terms used in various combinations were “parasites, helminths, Echinococcus granulosus , Trichinella spiralis , protozoa, Trypanosoma cruzi , Plasmodium , Toxoplasma gondii , parasite antigens/antibodies/derivatives” and “anti-cancer, anti-neoplastic, anti-tumor, cancer immunotherapy”. Articles published up to January 2024 have been searched, and comprehensively reviewed, and their bibliographies were checked for other relevant publications. This review included experimental research conducted either in vitro or in vivo, for the results to be controlled and validated.

Parasites’ anti-neoplastic activity against various cancers

Until January 2024, a total of 182 research articles have demonstrated the potency of a wide range of parasites and their derivatives as potent anti-neoplastic activity verified in both in vitro and in vivo. The anti-neoplastic response of parasites against different cancer types is presented and summarized in Tables 1 , 2 , 3 , 4 , 5 , 6 , 7 , and 8 . Table 1 a and b: in vitro and in vivo studies of the anti-neoplastic activity of different parasites against gastrointestinal cancers (colorectal cancer, gastric and esophageal cancers) a. Colorectal carcinoma Parasite Type of study Antineoplastic activity References Schistosoma mansoni Autoclaved S. mansoni cercarial antigen In vivo Inhibited colon carcinogenesis as demonstrated by a notable reduction in the size and number of neoplasms per mouse and induced immunomodulatory potential [ 55 ] Echinococcus granulosus Hydatid cyst fluid In vitro Induced apoptosis in C26 mouse colon cancer cells [ 71 ] Anti-hydatid cyst fluid antibodies Flow cytometry Reacted with antigens on CT26 mouse cancer colon cells [ 72 ] Human hydatid cyst fluid In vivo Protected against colon cancer growth both prophylactically and therapeutically [ 72 ] Hydatid cyst fluid, 78 kDa fraction, and live protoscolices In vivo Significantly inhibited colon cancer growth [ 73 ] Taenia solium Recombinant T. solium Calreticulin (r Ts CRT) alone and in combination with 5-fluorouracil In vitro Inhibited colon cancer cell growth (SW480 cell line) in a dose-dependent manner [ 75 ] Taenia crassiceps T. crassiceps infection In vivo Inhibited the colonic inflammatory responses and CRC formation [ 78 ] Trichinella spiralis T. spiralis infection In vivo Inhibited HCT-8 human colorectal carcinoma growth as demonstrated by a decrease in size and weight of tumors in BALB/c mice [ 80 ] Toxocara canis T. canis -derived peptides [fraction from the excretory–secretory Troponin protein peptide (ES TPP)] In vitro Induced cellular changes, decreased cellular viability, and significantly altered expression of gene (Bcl-2, APAF1, ZEB1, VEGF, cyclin-D1, and caspase-3) in colon carcinoma cell lines (HT-29, and Caco2) in a dose-dependent manner [ 82 ] Heligmosomoides polygyrus H. polygyrus adult - derived antigen and excretory/secretory products (HES) In vitro Significantly reduced the proliferation of CT26.WT murine colorectal cancer cells HES alone significantly reduced HCT116 human colorectal cancer cell proliferation [ 61 ] Trypanosoma cruzi T. cruzi infection In vivo Low incidence of chemically induced colon cancer in rats [ 87 ] T. cruzi e pimastigote lysates In vivo Strongly inhibited colon cancer development in a rat model and evoked an integrated anti-tumor response involving both the cellular and humoral components of the immune response [ 52 ] Anti- T. cruzi polyclonal antibodies Immunohistochemistry Cross-reacted with human colon cancer cells [ 52 ] Plasmodium spp. Infection with Plasmodium yoelii 17XNL-infected erythrocytes In vivo Reduced weight and size of tumors by inhibiting proliferation and promoting mitochondria-mediated apoptosis in colon cancer cells [ 89 ] Recombinant malarial protein VAR2 CSA as a carrier for anti-cancer drug delivery, VDC886 [hemiasterlin analog (KT886) conjugated rVAR2] In vitro Strong cytotoxicity to human colon cancer cells (Colo 205) [ 90 ] Recombinant malaria’s sporozoite circumsporozoite protein In vitro Inhibited the proliferation of the human colon cancer cell line, SW480 in a dose-dependent manner and induced apoptosis by suppressing the activation of the NF-κB [ 91 ] Toxoplasma gondii GRA16, a dense granule protein of T. gondii In vitro Induce apoptosis of HCT116 human colorectal cancer cells by down-regulation of the expression of human telomerase reverse transcriptase [ 93 ] Recombinant dense granular protein GRA8 of T. gondii in conjugation with the acidity-triggered rational membrane(ATRAM) [rATRAM-GRA8-M/AS] In vitro and in vivo Induced cell death of HCT116 human colorectal cancer cells in a dose-dependent manner and significantly inhibited tumor growth in HCT116 xenograft animal model [ 94 ] Attenuated RH-ΔGRA17 T. gondii strain in combination with programmed death ligand-1 (PD-L1) blockade In vivo Combination therapy significantly haltered tumor growth compared to each treatment alone, increased lymphocyte infiltration, and sensitized the tumor microenvironment in local and distal tumors to PD-L1 blockade [ 95 ] T. gondii lysate antigen In vivo Reduced tumor growth in CT26 colorectal carcinoma euthymic and athymic murine models [ 96 ] T. gondii , profilin-like protein ( Tg PLP) as an adjuvant to autologous whole-tumor cell vaccine treatment In vivo Enhanced anti-tumor immune responses of autologous whole-tumor cell vaccine as demonstrated by a smaller tumor in CT26 colorectal carcinoma murine model and increased their survival [ 97 ] T. gondii rGRA6Nt protein as an adjuvant to non-replicable MC38 colorectal cancer cells immunization In vivo Significantly inhibited the growth of the implanted tumors and increased CD8 + infiltration within the tumor microenvironment in a murine model of MC38 CRC [ 98 ] Exosomes derived from T. gondii -infected dendritic cells (Me49-DC-Exo) In vivo Significantly slowed the tumor growth, inhibited macrophage polarization to M2 phenotype, and regulated the suppressor of cytokine signaling 1 SOCS1 expression by delivering functional miR-155-5p in a mouse model of CRC [ 100 ] Exosomes derived from dendritic cells infected with T. gondii (DC-Me49-Exo) In vivo Significantly inhibited tumor growth by reducing the proportion of myeloid-derived suppressor cells (MDSCs) in a mouse model of CRC [ 99 ] Eimeria stiedae E. stiedae oocyst soluble protein In vivo Enhanced the anti-tumor immune response, inhibited tumor growth, lung metastasis, and angiogenesis in the murine model of colon cancer (CT26) [ 102 ] b. Gastric and esophageal carcinomas Parasite Type of study Antineoplastic activity References Trichinella spiralis Crude T. spiralis extract from adult worms and newborn larvae In vivo Inhibited tumor growth in mice grafted with murine forestomach carcinoma (cell line MFC) [ 104 ] Toxocara canis T. canis -derived peptides [synthesized peptide fraction from the excretory–secretory Troponin protein peptide (ES TPP)] In vitro Induced cellular changes, decreased cellular viability, and significantly altered the cellular expression of gene (BCL-2, APAF1, ZEB1, VEGF, cyclin-D1, and caspase-3) in a gastric cell line (AGS) in a dose-dependent manner [ 82 ] Toxoplasma gondii T. gondii tachyzoites In vitro Significant inhibitory effect on human esophageal squamous cell carcinoma cell line EC109 proliferation [ 105 ] T. gondii culture supernatant In vitro Inhibited the proliferation and induced apoptosis in human gastric cancer BGC-823 cells in a concentration- and time-dependent manner [ 106 ] Live T. gondii or T. gondii lysate In vitro Reduction of the multidrug resistance of human gastric cancer cell line against cytostatic drugs [ 107 ] Table 2 a and b: in vitro and in vivo studies of the anti-neoplastic activity of different parasites against hepato-pancreatic cancers (hepatocellular carcinoma and pancreatic cancer) a. Hepatocellular carcinoma Parasite Type of study Antineoplastic activity References Schistosoma japonicum S. japonicum Sja-miRNA-7-5p In vitro and in vivo Significantly inhibited the migration of mouse and human hepatoma cells and significantly inhibited tumor growth in a xenograft animal model through down-regulation of the S-phase kinase-associated protein 2 gene [ 111 ] S. japonicum Sja-miR-3096 In vitro and in vivo Significantly inhibited the migration of both murine and human hepatoma cell lines and significantly inhibited tumor growth in the murine model by targeting phosphoinositide 3-kinase class II alpha (PIK3C2A) [ 112 ] S. japonicum Sja-miR-61 In vitro and in vivo Significantly inhibited the migration of both mouse and human hepatoma cells and significantly inhibited tumor growth in the murine model through anti-angiogenesis activity by targeting the PGAM1 gene [ 113 ] S. japonicum Sja-miR-71a In vitro and in vivo Significantly inhibited the migration of both mouse and human hepatoma and human HCC cell lines and significantly inhibited tumor growth in a xenograft mouse model by targeting the FZD4 gene [ 114 ] Fasciola hepatica F. hepatica (biologically active substances) In vitro Significant inhibitory effect on MC29 hepatoma cell line proliferation [ 116 ] Trichinella spiralis T. spiralis crude antigens (mixture from adult and newborn larvae) In vitro Apoptosis of ascitic hepatoma (cell line H22), and hepatoma cell line (H7402) [ 104 ] T. spiralis Excretory secretory products (ESP) from adult worms or muscle larvae In vitro Inhibited cellular proliferation and induced apoptosis in liver cancer (H22) cells through the mitochondrial pathway [ 117 ] T. spiralis infection In vivo Significantly inhibited mouse ascitic hepatoma H22 in ICR mice [ 117 ] T. spiralis protein encoded by the A200711 gene In vitro Induced apoptosis in human hepatoma H7402 cells [ 118 ] T. spiralis larval extract (peptide2 matched the hypothetical protein T01_4238 of T. spiralis ) In vitro Inhibition of proliferation of HepG2 cells in a dose-dependent manner [ 119 ] T. spiralis infection In vivo Significantly inhibited hepatoma Hep1-6 carcinoma growth in the C57BL/6 mice [ 120 ] T. spiralis infection In vivo Decreased progression of the tumor with increased rate of apoptosis as shown by the decreased expression of Bcl-2 and increased rat survival time [ 121 ] Angiostrongylus cantonensis A. cantonensis , excretory–secretory products (ESPs) and recombinant Calreticulin (rCRT) (a key effector protein of ESPs) In vitro Both induced apoptosis in human hepatoma HepG2 cells. rCRT had a stronger inhibitory effect on HepG2 cells compared to ESPs [ 123 ] A. cantonensis , excretory–secretory products (ESPs) In vivo Significantly reduced tumor growth in Hepa1-6 mouse tumor model [ 123 ] Setaria equina S. equina excretory–secretory products ( Se ES) alone and in combination with diethylcarbamazine citrate (DEC) In vivo Had a beneficial effect on HCC development in the rat model by increasing the activity of antioxidant enzymes and decreasing the expression of NF κB. Combination with DEC modulates the antioxidant effect of Se ES and induces immunomodulatory and protective effects on rat HCC [ 124 , 125 ] Rabbit anti- S. equina extract and diethylcarbamazine citrate polyclonal IgG antibodies Indirect ELISA and Western blotting Cross-reactive protein bands in S. equina and Huh-7 hepatoma cells at 75 and 70 kDa by anti- S. equina and anti-diethylcarbamazine antibodies, respectively [ 126 ] Plasmodium spp. P. berghei infection In vivo Reduced hepatic carcinoma development induced by aflatoxin B1 in rats [ 128 ] P. yoelii 17 XNL infection In vivo Significantly inhibited tumor progression in murine implanted hepatoma model and prolonged their survival time through suppression of angiogenesis within the tumor microenvironment [ 129 ] Plasmodium -based vector ( P . y -GPC3) P. yoelii 17XNL expressing murine glypican-3 protein (expressed in Hepa1-6 cells) In vivo Significantly inhibited Hepa1-6-induced tumor growth in the implanted HCC murine model, prolonged their survival time, and induced tumor antigen-specific T-cell-mediated immunity [ 131 ] P. yoelii infection In vivo Significantly inhibited the recurrence and metastasis and improved the prognosis of HCC in both non-resection and resection murine orthotopic HCC models [ 132 ] Toxoplasma gondii T. gondii tachyzoites RH strain In vitro Inhibited the proliferation and induced apoptosis of HCC (H7402) cells in a concentration-dependent manner [ 133 ] GRA16, a dense granule protein of T. gondii In vitro and in vivo Decreased cell proliferation, anti-apoptotic factors, p‐AKT/AKT ratio, cell migration, and invasive activity of hepatocellular carcinoma (HepG2) cells and decreased tumor size in HepG2 cell‐xenograft nude mice [ 134 ] T. gondii GRA15II-polarized macrophages In vitro and in vivo Significantly inhibited migration and invasion of the Hepa1-6 cells and markedly restricted tumor growth in tumor-bearing C57BL/6 mice [ 135 ] b. Pancreatic cancer Parasite Type of study Antineoplastic activity References Echinococcus granulosus E. granulosus live protoscolex to induce secondary hydatidosis In vivo Significantly inhibited the development of precursor foci of neoplastic changes in the pancreas in the azaserine-rat model [ 138 ] Toxoplasma gondii A live, non-replicating avirulent uracil auxotroph vaccine strain (cps) of T. gondii In vivo Significantly regressed established tumor in pancreatic ductal adenocarcinoma mouse model [ 139 ] A live, non-replicating avirulent uracil auxotroph vaccine strain (cps) of T. gondii In vivo Induced significant therapeutic benefit through generating anti-tumor immune responses in established aggressive disseminated pancreatic cancer in a mouse model [ 140 ] A live, non-replicating avirulent uracil auxotroph vaccine strain (cps) of T. gondii In vivo Stimulated long-term strong immune protection against the recurrence of pancreatic cancer in mice that survived the primary pancreatic tumor after cps treatment [ 141 ] Attenuated Toxoplasma NRTUA strain and combination therapy with anti-PD-1 antibody In vivo Monotherapy with attenuated Toxoplasma NRTUA inhibited tumor growth in a mouse model of PDAC and its combination with anti-PD1 antibody enhanced its anti-tumor activity and controlled tumor growth in Pan02 tumor-bearing mice [ 142 ] T. gondii soluble antigen and T. gondii profilin In vivo Significantly decreased tumor volume and increased tumor infiltration with CD4 + and CD8 + T cells [ 143 ] Table 3 In vitro and in vivo studies of the anti-neoplastic activity of different parasites against lung cancer Parasite Type of study Antineoplastic activity References Echinococcus granulosus Human hydatid cyst fluid In vivo Induced strong anti-tumor immune response that significantly inhibited LLC growth both in prophylactic and therapeutic settings and significantly increased mouse survival [ 147 ] Hydatid cyst fluid Immunoelectrophoresis Reacted with the serum from a patient with pulmonary carcinoma forming a broad and intense precipitin band [ 148 ] Sera of patients with hydatid diseases In vitro Cytotoxic effects on NCI-H209/An1 lung cancer cells [ 149 ] Trichinella spiralis T. spiralis infection In vivo Inhibited tumor growth which is dependent on the time of tumor challenge to T. spirals infection [ 150 ] T. spiralis muscle-larva excretory–secretory proteins In vitro Inhibited proliferation and induced apoptosis in small-cell lung cancer cells (H446 SCLC) and non-small-cell lung cancer line A549 in a dose and time-dependent manner [ 151 – 153 ] T. spiralis recombinant small Heat Shock Proteins (sHSP) Western immunoblotting Reacted with anti-LLC antiserum [ 154 ] T. spiralis small Heat Shock Protein (sHSP) gene using invasive Lactobacillus plantarum (NC8) as vector vaccine (NC8-sHSP) In vivo Inhibited tumor growth in both prophylactic and therapeutic experiments through induction of humoral, cellular, and mucosal immunity [ 155 ] Trichomonas vaginalis T. vaginalis trophozoites In vitro Elicited cytotoxic effect and induced apoptosis in human lung alveolar basal carcinoma epithelial cell line A549 [ 158 ] Trypanosoma spp . T. cruzi epimastigote-derived protein lysate In vivo Prevented tumor growth in murine lung cancer model through induction of both humoral and cellular anti-tumor immune responses in therapeutic and preventive settings [ 157 ] T. brucei hypoxanthine–guanine phosphoribosyltransferase (TbHGPRT) In vitro Had cytotoxic effects and induced apoptosis in one murine lung cancer cell line (M27) and four human non-small cell lung carcinoma cell lines (A549, H460, H661, H520) [ 163 ] Plasmodium spp . Plasmodium infection alone and in combination with a lung cancer DNA vaccine [pcDNA3.1-hMUC1] In vivo Inhibited the growth and metastasis of lung cancer and increased the survival of tumor-bearing mice and when combined with lung cancer DNA vaccine it boosted the immune response and had a synergistic anti-tumor effect [ 164 ] Plasmodium -infected red blood cells In vivo Reduced Treg and myeloid-derived suppressor cells and elevated CD8 + T-cell-mediated cytotoxicity within the tumor microenvironment [ 165 ] Exosomes derived from the plasma of Plasmodium- infected mice In vivo Significantly reduced LLC growth in mice [ 160 ] Genetically attenuated Plasmodium sporozoites In vivo Inhibited lung cancer growth and angiogenesis [ 166 ] Attenuated Plasmodium sporozoite as a novel vector to lung cancer-specific antigen [MAGE-A3] In vivo Inhibited tumor growth, increased mice survival rate, and induced a strong MAGE-A3-specific CD8 + T-cell response [ 167 ] Plasmodium circumsporozoite protein overexpression Flow cytometry, colony analysis, laser confocal microscopy assay and western blotting Increased sensitivity of A549 and H1975 cancer cell lines to gefitinib as demonstrated by significant apoptosis and decreased viability of cells and significant inhibition of autophagy [ 168 ] Plasmodium circumsporozoite protein overexpression In vivo Synergistically inhibited cancer growth by enhancing the chemotherapeutic effect of gefitinib by inhibition of autophagy [ 168 ] Plasmodium circumsporozoite protein In vitro Inhibited the proliferation of the human lung cancer cell line, A549 in a dose-dependent manner and induced apoptosis by suppressing the activation of NF-κB [ 169 ] Plasmodium yoelii -infected red blood cells In vivo Inhibited tumor growth and progression in LLC mouse model [ 170 ] P. yoelii infection combined with radiotherapy In vivo Induced synergistic anti-tumor effects in a subcutaneous model of mouse non-small cell lung cancer (LLC, CRL-1642) and significantly inhibited tumor growth and extended the life span of tumor-bearing mice [ 171 ] P. chabaudi infection alone and in combination with Gemcitabine treatment In vivo Significantly inhibited tumor growth, metastasis, and prolonged mice survival in a subcutaneous implanted murine LLC model, and combination therapy was more effective than monotherapy [ 172 ] Toxoplasma gondii T. gondii tachyzoites In vitro Significant inhibitory effect and induced apoptosis in non-small-cell lung cancer cells (cell line A549) in a dose-dependent manner with up-regulation of p53 and down-regulation of Bcl-2 gene expression [ 105 ] Formalin-fixed T. gondii organisms In vivo Potent anti-tumor effects against LLC [ 159 ] T. gondii Me49 strain infection In vivo Inhibited LLC growth through induction of Th1 immune responses and inhibition of angiogenesis [ 174 ] T. gondii excretory–secretory antigen In vivo Inhibited tumor growth in LLC-bearing mice and reduced the proportion of splenic Treg cells in splenocytes [ 175 ] GRA16, a dense granule protein of T. gondii alone and in combination with the anti-cancer irinotecan In vivo Reduced tumor size in a xenograft mouse model of non-small-cell lung carcinoma with synergistic promotion of the anti-cancer effects of Irinotecan [ 176 ] Attenuated RH-ΔGRA17 T. gondii strain in combination with programmed death ligand-1(PD-L1) blockade In vivo Combination therapy reduced tumor size compared to each treatment alone with up-regulated innate and adaptive immune responses, increased lymphocyte infiltration, and sensitized the tumor microenvironment in local and distal tumors to PD-L1 blockade treatment [ 95 ] Table 4 In vitro and in vivo studies of the anti-neoplastic activity of different parasites against breast cancer Parasite Type of study Antineoplastic activity References Echinococcus granulosus Hydatid cyst fluid antigens such as antigen B, glycolipid, glycoprotein, and 78 kDa fractions In vitro Induced apoptosis in mouse breast cancer cells (4T1 cell line) [ 179 ] Infection with hydatid cyst In vivo Reduced the development of breast cancer tumors by 50% in DMBA-induced breast cancer rat model [ 180 ] Hydatid cyst wall antigens Western immunoblotting A considerable cross-reactivity with breast cancer patients’ sera at a specific band (~ 27/28 kDa) [ 51 ] Hydatid cyst wall antigen (the protein bands with cross-reactivity with breast cancer patients’ sera (~ 27/28 kDa) In vivo Significant inhibition of 4T1 breast tumor growth in murine mammary carcinoma model [ 51 ] Hydatid cyst wall antigen antigens, including crude extract of HCW (laminated layer) 28 and 27 kDa protein bands (upper and lower bands) In vivo Significantly Inhibited breast tumor growth and metastasis and improved survival in 4T1 tumor-bearing mice [ 181 ] Hydatid cyst fluid and antigen B In vivo Significantly reduced breast tumor size with polarization of the Th1/Th2 ratio toward the Th1 pathway [ 182 ] Recombinant Kunitz-type protease inhibitor EgKI-1 from E. granulosus In vitro and in vivo Inhibited the growth and migration of breast cancer cell lines (MCF-7, T47D, and MDA-MB-231) in a dose-dependent manner and induced significant tumor growth reduction in triple-negative breast cancer (MDA-MB-231) murine model [ 186 ] Rabbit antisera raised against hydatid cyst antigens (hydatid cyst fluid, germinal and laminated, protoscolex, and excretory–secretory) In vitro Induced cell death of 4T1 breast cancer cell line [ 187 ] Rabbit antisera raised against hydatid cyst wall antigen Flow cytometry A significant high % of 4T1 breast cancer cell reaction [ 51 ] Rabbit antisera raised against hydatid cyst antigens (protoscolex, cell wall, and cystic fluid antigens) Flow cytometry Reacted with the breast cancer cell line (4T1) [ 188 ] Hydatid cyst antigens (hydatid fluid, laminated and germinal layer antigens, and excretory–secretory antigens of protoscolices) and rabbit antisera raised against laminated and germinal layers of hydatid cyst Western immunoblotting A reaction between hydatid cyst antigens and sera of patients with breast cancers. Antisera raised against laminated and germinal layers of hydatid cyst reacted with excretory–secretory products of breast cancer cells [ 48 ] Taenia solium Recombinant T. solium Calreticulin (r Ts CRT) either alone or in combination with 5-fluorouracil In vitro Inhibited growth of breast (MCF-7) cancer cells by interacting with scavenger receptors [ 75 ] Trichinella spiralis T. spiralis infection In vivo Increased survival rate in mice breast tumor [ 189 ] T. spiralis infection In vivo Inhibited mammary gland cancer [ 190 ] Setaria equina Rabbit anti- S. equina extract and diethylcarbamazine citrate polyclonal IgG antibodies Indirect ELISA and Western blotting Cross-reactive protein bands in S. equina and MCF-7 cells at 75 and 70 kDa by anti- S. equina and anti-diethylcarbamazine antibodies respectively [ 126 ] Leishmania spp . Live attenuated L. infantum and L. tropica In vivo Both Leishmania species induced regression of 4T1 breast cancer in mice after intratumoral injection [ 191 ] Trypanosoma cruzi T. cruzi epimastigote lysate In vitro Inhibition of breast cancer cell growth [ 192 ] Recombinant T. cruzi Calreticulin ( rTc CRT) In vivo Antiangiogenic and anti-tumor properties inhibited the growth of the murine mammary tumor (TA3 MTXR tumor cell line) [ 194 ] Rat anti- T. cruzi polyclonal antibodies In vitro, flow cytometry, and Immunohistochemical analysis Reacted with human mammary cancer cells (T47D and MCF-7 tumor cell lines) and capable of mediating antibody-dependent cellular cytotoxicity [ 52 ] T. cruzi epimastigote lysates In vivo Protective immune response against breast cancer [ 52 ] T. cruzi infection and epimastigote extract In vivo Inhibited the growth of an aggressive mammary adenocarcinoma cell line (TA3-MTXR) in mice and identified that nTcCRT is responsible for the anti-tumor activity [ 195 ] T. cruzi recombinant protein 21 (rP21) In vitro Reduced migration, invasion, and progression in triple-negative breast cancer cells MDA-MB-231 cells [ 197 ] T. cruzi infection In vitro Inhibited proliferation and migration of triple-negative breast cancer cell line (MDA-MB-231) [ 199 ] Plasmodium spp . Recombinant malarial VAR2 CSA as a carrier for anti-cancer drug delivery, VDC886 [hemiasterlin analog (KT886) conjugated rVAR2] In vitro and in vivo S trong cytotoxicity to human breast cancer cells (MDA-MB-231 and 4T1 breast cancer cell lines) and increased survival of mice with 4T1 with no metastasis as compared to control mice, all of which died of metastatic disease [ 90 ] P. yoelii infection In vivo Significantly inhibited tumor growth, and increased the survival rate of the tumor-bearing mice in a murine triple-negative breast cancer model (4T1) [ 200 ] Toxoplasma gondii T. gondii tachyzoites In vitro Significant inhibitory effect on MCF-7 breast cancer cell line proliferation in a dose-dependent manner [ 105 ] T. gondii tachyzoites In vitro Marked destruction of Her2/Neu-expressing mammary cancer cell lines (TUBO cells) in a dose- and time-dependent manner [ 201 ] T. gondii tachyzoites In vitro Marked destruction of Her2/Neu-expressing mammary cancer cell lines (TUBO cells) in a dose- and time-dependent manner [ 202 ] Rabbit anti- T. gondii antibodies Flow cytometry Reacted with breast cancer cells (4T1 cell line) [ 53 ] Human anti- Toxoplasma antibodies Flow cytometry Strongly reacted with breast cancer cells (4T1 and MCF-7 cell lines) [ 203 ] T. gondii chronic infection In vivo Significant resistance to the development of mammary tumors in C 3 H/ He mice [ 204 ] Attenuated uracil auxotroph strain of T. gondii In vivo Intratumoral inoculation of this attenuated Toxoplasma strain inhibited tumor growth, and metastasis, increased survival of the 4T1 tumor-bearing mice, and increased the secretion of IL-12 and INF-γ in both the serum and tumor microenvironment [ 205 ] Neospora caninum N. caninum tachyzoites In vitro Invaded and multiplied within human breast carcinoma cells (MCF-7 cell line) leading to their destruction [ 208 ] Besnoitia jellisoni B. jellisoni chronic infection In vivo Significant resistance to the development of mammary tumors in C 3 H/ He mice [ 204 ] Table 5 a–d: in vitro and in vivo studies of the anti-neoplastic activity of different parasites against hematological cancers (leukemia, lymphomas, multiple myeloma, and mastocytoma) a. Leukemia Parasite Type of study Antineoplastic activity References Schistosoma japonicum S. japonicum recombinant protein (r Sj 16) In vitro Significantly suppressed the proliferation of murine myeloid leukemia WEHI-3B JCS cells in a dose and time-dependent manner by inducing G0/G1 cell cycle arrest and apoptosis via activation of the caspase-mediated mechanism by regulating the expression of Bcl-2 family [ 38 , 211 ] Echinococcus granulosus Protoscolex hydatid cyst somatic antigens In vitro Induced programmed cell death in human chronic myeloid leukemia cell line K562 cells in a dose and time-dependent manner [ 212 ] Trichinella spiralis T. spiralis crude antigens In vitro Inhibited proliferation and induced apoptosis of human chronic myeloid leukemia cell line K562 cells [ 104 ] T. spiralis excretory/secretory (ES) products from muscle larvae In vitro Induced cell death with high apoptotic index 72 h following treatment of acute myeloid leukemia cell line (U937 cells) [ 214 ] Peritoneal macrophages from T. spiralis- infected mice one week post-infection In vitro Strong cytotoxic effect on the R1 leukemia cells [ 215 ] Marshallagia marshalli M. marshalli somatic antigen In vitro Inhibited proliferation and induced apoptosis in human chronic myeloid leukemia K562 cells [ 216 ] Trypanosoma cruzi Rabbit polyclonal antibodies against T. cruzi Confocal microscopy assay Showed the presence of antigenic proteins by immunodetection in acute lymphoblastic leukemia cells with antibodies against T. cruzi [ 217 ] Plasmodium spp . Recombinant malarial protein VAR2 CSA as a carrier for anti-cancer drug delivery, VDC886 [hemiasterlin analog (KT886) conjugated rVAR2] In vitro Induced strong cytotoxicity to myeloid leukemia cells (KG-1 cell line) [ 90 ] P. yoelii infection In vivo Significantly reduced the growth of murine WEHI-3 leukemia cells in mice, marked decrease in tumor cell infiltration into the liver and spleen, and elicited anti-leukemia activity by promoting immune response [ 218 ] Toxoplasma gondii T. gondii tachyzoites In vitro Inhibited proliferation and induced apoptosis in human chronic myeloid leukemia K562 cells [ 213 ] Chronic T. gondii infection In vivo Induced resistance to the development of leukemia in AKR mice [ 204 ] Besnoitia jellisoni B. jellisoni chronic infection In vivo Induced resistance to the development of leukemia in AKR mice [ 204 ] b. Lymphoma Parasite Type of study Antineoplastic activity References Trichinella spiralis T. spiralis activated macrophages from T. spiralis- infected mice In vitro Induced powerful cytotoxic effect on syngeneic EL-4 lymphoma cells [ 222 ] Trypanosoma cruzi T. cruzi infection In vivo Inhibited growth and metastasis of solid L5178Y-R lymphoma transplanted to BALB/c mice due to the production of cytotoxic/cytostatic substances and cross antibodies against both the parasite and the tumor antigens [ 223 ] Plasmodium spp . Recombinant malarial protein VAR2 CSA as a carrier for anti-cancer drug delivery, VDC886 [hemiasterlin analog (KT886) conjugated rVAR2] In vitro and in vivo Induced strong cytotoxicity to MyLa2059 T-cell lymphoma and significantly inhibited the growth of non-Hodgkin’s lymphoma (Karpas 299) in the murine model [ 90 ] Toxoplasma gondii Formalin-fixed T. gondii organisms In vivo Induced a potent anti-tumor effect and a significant suppression of tumor growth [ 224 ] T. gondii lysate In vivo Enhanced the cytotoxicity of feline spleen cells against feline leukemia virus-producing lymphoma cells [ 225 ] T. gondii lysate antigen, spleen cells from Toxoplasma lysate antigen sensitized mice In vivo and in vitro Inhibited tumor growth induced by 20-methylcholanthrene in BALB/c mice and induced cytolytic effect on YAC-1 murine lymphoma cell line [ 226 ] Live T. gondii or T. gondii lysate In vitro Reduction of the multidrug resistance of mouse lymphoma cell lines (Mdr L 5718 and Par 5718) against cytostatic drugs [ 107 ] c. Multiple myeloma Parasite Type of study Antineoplastic activity References Fasciola hepatica F. hepatica (biologically active substances) In vitro Slight inhibitory effect on myeloma cell culture proliferation [ 116 ] Trichinella spiralis T. spiralis antigen and positive sera Enzyme-linked immunosorbent assays (ELISA) Cross reaction between antigens of the myeloma cell SP2/0 and positive sera to T. spiralis , and antigens of T. spiralis versus positive sera to myeloma cell SP2/0 [ 231 ] Antisera against a novel gene product of T. spiralis Immunoscreened a T. spiralis cDNA expression library Cross-reacted with Sp2/0 myeloma cells [ 232 ] T. spiralis infection In vivo Suppression-subtractive hybridization identified genes encoding RpL41, NKTR, Rbbp4, and AN-XA2 as possible proteins involved in tumor growth inhibition in SP2/0 myeloma model BALB/c mice [ 233 ] d. Mastocytoma (mast cell tumor) Parasite Type of study Antineoplastic activity References Trichinella spiralis Activated macrophages from T. spiralis- infected mice In vitro Inhibitory effect on allogeneic P815 mastocytoma cells [ 222 ] Toxoplasma gondii T. gondii lysate antigen In vitro Strong cytolytic activity on P-815, a murine mastocytoma cell line [ 226 ] Table 6 a and b: in vitro and in vivo studies of the anti-neoplastic activity of different parasites against connective tissue and bone cancers (sarcomas and bone tumors) a. Sarcomas Parasite Type of study Antineoplastic activity References Schistosoma mansoni S. mansoni infection In vivo Induced resistance against a transplantable sarcoma 180 ascites tumor [ 241 ] Echinococcus granulosus E. granulosus live protoscolices In vitro Inhibited proliferation and induced cell death in WEHI-164 fibrosarcoma Cells [ 242 ] Trichinella spiralis T. spiralis crude antigens In vitro Anti-proliferative activity on sarcoma cells (cell line S180) [ 104 ] T. spiralis infection In vivo Modify the host reaction to S-180 that is dependent on the time of tumor inoculation post-infection and prolonged the survival time [ 243 ] T. spiralis infection In vivo Inhibited tumor growth under selected conditions of larval dose and tumor cells challenge interval [ 244 ] T. spiralis infection, crude extracts of adult and newborn larvae In vivo Inhibited tumor growth in a dose-dependent manner [ 104 ] Toxocara canis T. canis egg antigens In vivo Inhibited WEHI-164 fibrosarcoma growth in BALB/c mouse model [ 245 ] Leishmania spp . L. donovani sphingolipid-1 In vitro and in vivo Induced significant cytotoxic effects on murine sarcoma 180 cells in vitro via alteration of mitochondrial pathway. Improved the survival rate of tumor-bearing mice and reduced tumor growth in a sarcoma 180 murine model [ 247 , 248 ] Toxoplasma gondii T. gondii infection In vivo Induced resistance to the development of sarcoma 180 in Swiss mice [ 204 ] T. gondii antigen In vivo Inhibited WEHI-164 fibrosarcoma growth in BALB/c mouse model [ 245 ] Dendritic cells treated with protein components of T. gondii In vivo Induced tumor infiltration with CD8 + T cells and improved the survival of the mice in a mouse model of fibrosarcoma (WEHI-164) [ 249 ] Dendritic cells treated with protein components of T. gondii In vivo Inhibited tumor growth and increased activity of cytotoxic T-cell-mediated anti-tumor response in a mouse model of fibrosarcoma (WEHI-164) [ 250 ] T. gondii lysate antigen In vivo Reduced tumor size and reduced the expression of CD31, an angiogenesis marker in the tumor tissue in sarcoma 180 mouse model [ 251 ] Live T. gondii tachyzoites In vitro Decreased fibrosarcoma WEHI-164 cell proliferation and increased cell lyses [ 252 ] Eimeria tenella Soluble protein extract of E. tenella sporulated oocysts (native or recombinant protein) In vivo Induced potent immunostimulatory effects and significantly reduced tumor growth, prolonged survival time, and cure rates of above 80% in the murine model of sarcoma (S-180) [ 253 ] Besnoitia jellisoni B. jellisoni infection In vivo Significant resistance to the development of sarcoma 180 in Swiss mice [ 204 ] b. Bone tumors (malignant: osteosarcoma, Ewing sarcoma, chondrosarcoma and other malignant tumors and Benign tumors: osteochondroma, giant tumor, exostosis, and other benign tumor) Parasite Type of study Antineoplastic activity References Echinococcus granulosus E. granulosus , crude extract of the laminated layer antigens (43 kDa and 70 kDa) Western blot Both antigens reacted with the serum of different bone cancers [ 256 ] Trichinella spiralis Anti- T. spirals antiserum and anti-TPD52 antiserum (prepared against cross-antigen between T. spiralis and osteosarcoma) In vitro and in vivo Inhibited proliferation of human osteosarcoma MG-63 cells and induced apoptosis in a dose-dependent manner. In the osteosarcoma murine model, both anti- T. spiralis antiserum and anti-TPD52 antiserum inhibited osteosarcoma growth by inducing apoptosis and enhancing immunity without causing histopathological damage but anti-TPD52 antiserum was more effective than anti- T. spiralis antiserum [ 54 ] Table 7 a and b: in vitro and in vivo studies of the anti-neoplastic activity of different parasites against skin cancers (melanoma and Merkel-cell carcinoma) a. Melanoma Parasite Type of study Antineoplastic activity References Echinococcus granulosus Hydatid cyst fluid, fraction of hydatid cyst fluid, alive protoscolices or their excretory–secretory antigen In vivo Inhibited melanoma cancer growth in C57/black mice [ 261 – 263 ] Hydatid cyst fluid (fertile/infertile) In vitro Induced apoptosis on A375 human melanoma cancer cells [ 264 ] Antigen B from hydatid cyst fluid In vitro Inhibited proliferation and promoted apoptosis of B16F10 melanoma cancer cell line [ 265 ] Recombinant Kunitz-type protease inhibitor EgKI-1 from E. granulosus In vitro Inhibited the growth and migration of melanoma (CJM) cells in a dose-dependent manner through disruption of the cell cycle and induction of apoptosis [ 186 ] Taenia crassiceps GK-1, an 18-amino acid peptide from T. crassiceps cysticerci either alone or in combination with anti-programmed death ligand 1 In vivo Administration of GK1 as monotherapy induced significant prolongation of survival time of melanoma-bearing mice, delayed tumor development with increased tumor necrosis. Combination therapy induced significant prolongation of melanoma-bearing mice survival time compared to monotherapy with GK1 alone and decreased TNF-α, IL-4, IL-5, IL-6, and IL-10 serum levels [ 266 , 267 ] Trichinella spiralis T. spiralis infection In vivo No detectable tumor in infected mice [ 268 ] T. spiralis infection In vivo Reduced tumor growth and lung metastasis of B16–F10 melanoma cells [ 269 ] T. spiralis chronic infection In vivo Reduced tumor size [ 270 ] T. spiralis chronic infection In vivo Inhibited tumor development, longer tumor induction interval with significant reduction in tumor size [ 271 ] T spiralis excretory–secretory antigen of the first larval stage In vitro Induced apoptosis in B16 melanoma cells [ 270 ] Leishmania spp . L. donovani sphingolipid-1 In vitro and in vivo It has cytotoxic effects and induces apoptosis in murine and human melanoma cells (B16F10 and A375 cell lines). In murine melanoma model, it induced improvement of survival time, immunostimulatory response, significant reduction in rumor volume, and reduced the metastatic flare of angiogenic factors [ 247 , 272 , 273 ] Acanthamoeba castellanii Viable A. castellanii and parasite lysates In vitro and in vivo Induced extensive cytolysis of human melanoma (OCM-1) and murine melanoma (D5.1G4) cells and intratumoral injection led to a reduction in tumor mass [ 275 ] Trypanosoma cruzi T. cruzi surface molecule gp82 (a recombinant protein J18) In vitro and in vivo Induced cell death and apoptosis in melanoma cells and reduced melanoma tumor size in C57BL/6 mice [ 42 ] T. cruzi calreticulin in combination with plasmid encoding survivin, a tumor-associated antigen In vivo Induced as synergistic inhibitory effect on tumor growth in a B16-F10 melanoma murine mode [ 276 ] T. cruzi derived Toll-Like Receptor (TLR) agonists (glycoinositolphospholipids and CpGs oligodeoxynucleotides) In vivo Induced significant protective immunity and cause a significant delay in the growth of B16F10 melanoma cells expressing NY-ESO-1 in a murine model [ 277 ] A recombinant non-pathogenic clone of T. cruzi as a vaccine vector expressing a cancer-testis antigen (NY-ESO-1) In vivo Induced strong and long-term T-cell-mediated immunity and solid protection against melanoma in mice [ 278 ] Combination of non-pathogenic clone of T. cruzi expressing a cancer-testis antigen (NY-ESO-1) with blockade of Cytotoxic T Lymphocyte Antigen 4 In vivo Induced significant therapeutic response and controlled the development of an established melanoma in the murine model [ 279 ] Plasmodium spp . P. yoelii infection (17XL strains) In vivo Delayed occurrence of tumor and inhibited the growth of melanoma in B16F10 melanoma-bearing mice [ 280 ] Recombinant malarial protein VAR2 CSA as a carrier for anti-cancer drug delivery, VDC886 [hemiasterlin analog (KT886) conjugated to rVAR2] In vitro Induced strong cytotoxicity to C32 human and B16 murine melanoma cells [ 90 ] Recombinant malaria protein VAR2 CSA-malaria mimicking erythrocyte nanoparticles loaded with the anti-neoplastic agent, docetaxel In vitro and in vivo Killed melanoma cells in vitro and effective targeting and therapeutic efficacy in a xenografted melanoma model [ 281 ] Recombinant malaria protein VAR2 CSA-modified activated platelet-mimicking nanoparticles (rVAR2-PM/PLGA-ss-HA) loaded with the anti-neoplastic agent, docetaxel In vivo Exhibited a significant synergistic and active tumor-targeting, anti-neoplastic effect against primary and lung metastasis in a mouse model of melanoma (B16F10) [ 282 ] Toxoplasma gondii T. gondii infection In vivo A significant suppression of melanoma growth and strong systemic suppression of angiogenesis [ 283 ] Excreted/secreted antigens of T. gondii In vivo Suppressed tumor growth by down-regulation of CD4 + CD25 + Treg cells while up-regulation of NK cells [ 284 ] T. gondii tachyzoites antigens (fraction A1 and C14-dendritic cells) In vivo A1 matured dendritic cells are more potent than C14 to induce immune response leading to slowing tumor growth and prolonged survival time in the melanoma mouse mode [ 285 ] Non-replicating uracil auxotroph strain of T. gondii (cps strain) In vivo Effectively haltered tumor growth, stimulated systemic anti-tumor immunity, and modified tumor microenvironment [ 286 ] Attenuated T. gondii mutants lacking two lactate dehydrogenases (ME49 Δldh1–Δldh2 ) In vivo Intratumoral administration of Δldh1-Δldh2 repressed the growth of established tumors and helped to inhibit lethal tumor development in the mouse melanoma (B16F1) model [ 287 ] Attenuated RH-ΔGRA17 T. gondii strain in combination with programmed death ligand-1 (PD-L1) blockade In vivo Combination therapy arrested tumor growth compared to each treatment alone with up-regulation of innate and adaptive immune pathways and sensitized the tumor microenvironment in local and distal tumors to PD-L1 blockade [ 95 ] Rabbit anti- Toxoplasma antibodies Flow cytometry Reacted strongly with mouse melanoma cancer cells [ 53 ] Neospora caninum N. caninum tachyzoites In vivo Significant inhibition of tumor growth, significant increase in the mRNA expression levels of IL-12, IFN-γ, IL-2, IL-10, TNF-α, and PD-L1 in the tumor microenvironment, and IL-12 and IFN-γ in the spleen of tumor-bearing mice and increased infiltration of CD8 + T cells and macrophages in the tumor microenvironment [ 288 ] Wild N. caninum and engineered N. caninum secreting IL-15/IL 15Rα In vivo Engineered N. caninum was more potent than wild N. caninum in impairing lung metastasis progression and induced a marked increase in natural killer cells, CD8 + T cells, and macrophages polarization toward M1 Phenotype in lung tissue of syngeneic C57BL6 mouse model of B16-F10 melanoma lung metastases [ 289 ] Babesia microti B. microti infection In vivo Inhibited the growth of melanoma in tumor-bearing mice and prolonged their survival time through activation of immune responses [ 291 ] b. Merkel-cell carcinoma Parasite Type of study Antineoplastic activity References Neospora caninum N. caninum tachyzoites In vitro and in vivo They infected and destroyed Merkel-cell carcinoma [The WaGa (RRID:CVCL E998)]. They triggered potent anti-tumor immune response leading to a threefold reduction in tumor size in a model of NOD/SCID mice-bearing human Merkel-cell carcinoma [ 294 ] Table 8 a–e: in vitro and in vivo studies of the anti-neoplastic activity of different parasites against miscellaneous cancers (gynecological cancers, prostate cancer, neuroglial and neural crest cancers, thymoma, and head and neck squamous cell carcinoma) a. Gynecological cancers a.1. Ovarian cancer Parasite Type of study Antineoplastic activity References Taenia solium Recombinant T. solium Calreticulin (rTsCRT) either alone or in combination with 5-fluorouracil In vitro Inhibition of the growth of ovarian cancer cells (SKOV3 cell line) in a dose-dependent manner [ 75 ] Toxoplasma gondii Nonreplicating uracil auxotroph strain of Toxoplasma (cps strain) In vivo Induced therapeutic anti-tumor immunity through reversed immunosuppression in the tumor microenvironment [ 300 ] Secretion of rhoptry and dense granule effector proteins by non-replicating T. gondii uracil auxotrophs strain In vivo Induced anti-tumor immunity through host responses involving CD8 + , α dendritic cells, the IL-12/IFN-γ Th 1 axis, as well as CD4 + and CD8 + T cells and reverting immunosuppression in the ovarian cancer microenvironment [ 301 ] T. gondii extract In vitro Inhibited proliferation of susceptible (A2780) and resistant (A2780-CP) ovarian cancer cell lines to cisplatin [ 302 ] Leishmania spp . L. major extract In vitro Inhibited proliferation of susceptible (A2780) and resistant (A2780-CP) ovarian cancer cell lines to cisplatin [ 302 ] a.2. Cervical cancer Parasite Type of study Antineoplastic activity References Echinococcus granulosus Recombinant Kunitz-type protease inhibitor EgKI-1 from E. granulosus In vitro Inhibited the growth and migration of cervical epithelial adenocarcinoma HeLa cells in a dose-dependent manner through disruption of the cell cycle and triggering of apoptosis [ 186 ] Taenia solium Recombinant T. solium Calreticulin (r Ts CRT) either alone or in combination with 5-fluorouracil In vitro Inhibited the growth of cervical HeLa cancer cell line in a dose-dependent manner through interaction with scavenger receptors [ 75 ] Hookworm Nippostrongylus brasiliensis N. brasiliensis L3 antigen In vitro Reduced cervical cancer cell migration in the following lines [HeLa (HPV18-positive epithelial adenocarcinoma cells), Ca Ski (HPV16 positive epithelial epidermoid carcinoma cells), and C33-A (HPV negative epithelial carcinoma cells)] and significantly reduced the expression of vimentin and N-cadherin, and decreased HPV type16 pseudovirion internalization [ 61 ] N. brasiliensis infection In vivo Significant reduction of vimentin expression within the female genital tract in the murine model [ 61 ] Trichinella spiralis Biologically active substances isolated from the livers of T. spiralis-infected rats In vitro Induced a mild inhibiting effect on the growth of human cervical carcinoma HeLa cells by inhibition of proliferation and promotion of apoptosis [ 304 ] Trichomonas vaginalis Culture supernatant of T. vaginalis In vitro Inhibited the growth of HeLa cervical cancer cells by inhibition of proliferation and promotion of apoptosis [ 305 ] Live T. vaginalis and excretory–secretory product In vitro Induced apoptosis in human cervical mucosal epithelial SiHa cells through the dissociation of Bcl-xL/Bim and Mcl-1/Bim complexes [ 306 ] Live T. vaginalis In vitro Induced apoptosis in human cervical mucosal epithelial SiHa cells by parasite dose-dependent reactive oxygen species production through an NF- κ B-regulated, mitochondria-mediated pathway [ 307 ] Live T. vaginalis and T. vaginalis excretory and secretory product In vitro Live parasite-induced cytotoxicity and mitochondrial reactive oxygen species production in human cervical mucosal epithelial SiHa cells in a parasite burden and infection time-dependent manner T. vaginalis excretory/secretory product induced apoptosis through mitochondria reactive oxygen species and endoplasmic reticulum stress responses, and also promoted endoplasmic reticulum stress-mediated mitochondrial apoptosis via the IRE1/ASK1/JNK/Bcl-2 family protein pathways [ 308 ] b. Prostate cancer Parasite Type of study Antineoplastic activity References Trichomonas vaginalis Culture supernatant of T. vaginalis In vitro Inhibited proliferation and promoted apoptosis of PC-3 and DU145 prostate cancer cell lines cells, through up-regulation of p21 and down-regulation of Bcl-2 [ 312 ] Plasmodium spp . Recombinant malarial rVAR2-DT fusion protein and VDC886 [hemiasterlin analog (KT886) conjugated rVAR2] In vitro and in vivo Induced strong cytotoxicity to human prostate cancer cells (PC-3) and significantly inhibited the growth of prostate cancer (CP-3) in a mouse model [ 90 ] Toxoplasma gondii T. gondii tachyzoites In vitro Significant inhibitory effect on DU-145 prostate cancer cell line proliferation [ 105 ] c. Neuroglial and neural crest cancer c. 1. Glioma Parasite Type of study Antineoplastic activity References Trichinella spiralis T. spiralis infection (different muscle larvae doses) In vivo Induced a parasite load-dependent anti-tumor effect [ 315 ] Trichomonas vaginalis T. vaginalis purine nucleoside phosphorylase ( Tv PNP) as an activating enzyme for F-araAMP or deoxyadenosine analogs cancer therapy In vivo Excellent anti-tumor activity in Tv PNP/D54 glioma-bearing tumors in mice [ 316 ] Plasmodium spp . Recombinant malarial protein VAR2 CSA as a carrier for anti-cancer drug delivery, VDC886 [hemiasterlin analog (KT886) conjugated rVAR2] In vitro Induced strong cytotoxicity to glioma cells [ 90 ] P. yoelii infection alone and combined with radiotherapy In vivo Induced synergistic anti-tumor effects in orthotopic and subcutaneous models of mouse glioma (GL261). The combination therapy significantly slowed tumor growth and extended the life span of tumor-bearing mice more than monotherapy. Most importantly, the combination therapy could cure approximately 70 percent of gliomas [ 171 ] Toxoplasma gondii Toxoplasma lysate antigen alone and in combination with Quil-A In vitro and in vivo S uppressed proliferation and invasion of human glioma U373MG and U87MG cells in a dose-dependent manner and reduced tumor growth in athymic nude mice transplanted with human malignant glioma cells. The addition of Quil-A significantly enhanced its anti-tumor effects [ 317 ] c.2. Medulloblastoma Parasite Type of study Antineoplastic activity References Toxoplasma gondii T. gondii infection In vivo Reduced tumor incidence and transformed the non-supportive tumor microenvironment into a supportive one for T cells [ 319 ] c.3. Ependymoblastoma Parasite Type of study Antineoplastic activity References Toxoplasma gondii T. gondii infection In vivo Significant reduction in tumor growth with strong inflammatory response surrounding the tumor with more necrosis in a mouse model of ependymoblastoma [ 322 ] Peritoneal macrophages from Toxoplasma- infected mice In vitro Cytotoxic to ependymoblastoma cells [ 322 ] c.4. Neuroblastoma Parasite Type of study Antineoplastic activity References Trypanosoma cruzi Rabbit polyclonal antibodies against T. cruzi Confocal microscopy assay Showed the presence of antigenic proteins by immunodetection in neuroblastoma cells reacted with antibodies against T. cruzi [ 217 ] d. Thymoma Parasite Type of study Antineoplastic activity References Toxoplasma gondii T. gondii (RH) strain tachyzoites In vivo In the murine thymoma EG7 mouse model, intratumoral inoculation of T. gondii tachyzoites induced strong inhibition of tumor development and total clearance of tumors in some mice within 25 days post-treatment [ 294 ] Neospora caninum N. caninum tachyzoites and engineered N. caninum strain (NC1-IL15hRec) In vitro and in vivo In vitro, N. caninum tachyzoites successfully infected and multiplied inside murine thymoma cells (cell line EG7) and caused their lysis. In murine thymoma EG7 mouse model, intratumoral or distal inoculation of N. caninum tachyzoites induced strong anti-tumor immunity and significantly inhibited tumor growth, often leading to complete eradication. Engineered N. caninum significantly enhanced its immunological properties [ 294 ] e. Head and neck squamous cell carcinoma Parasite Type of study Antineoplastic activity References Trichomonas vaginalis T. vaginalis purine nucleoside phosphorylase ( Tv PNP) as an activating enzyme for deoxyadenosine analogs cancer therapy In vivo Exhibited robust tumor regressions in human head and neck squamous cell carcinoma (FaDu /Tv PNP) xenografts in nude mice [ 316 ]

Gastrointestinal cancers

Table 1 a, b shows the in vitro and in vivo studies of the anti-neoplastic activity of different parasites against gastrointestinal cancers (Colorectal, Gastric, and Esophageal cancers).

Colorectal cancer (CRC)

Globally, colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer-related deaths [ 56 ]. An effective therapy still does not exist, which necessitates an in-depth exploration of promising cancer immunotherapeutic modalities. Being an inflammatory-driven malignancy, the CRC microenvironment plays a crucial role in the behavior of the disease through the involvement of innate immunity. On the other hand, adaptive immunity has been found to play a role in cancer immunosurveillance [ 57 ].

Antineoplastic activity of helminth parasites against CRC

Despite the multiple factors that are listed to impose CRC, schistosomiasis is still a query-predisposing factor. Schistosomiasis is a neglected tropical parasitic disease that affects approximately 200 million people in the world’s tropical areas [ 58 ]. While there is conflicting evidence regarding the association between schistosomiasis and colon carcinogenesis in humans and experimental animals, the association between CRC and Schistosoma mansoni ( S. mansoni ) specifically is unjustified [ 59 ]. Interestingly, S. mansoni soluble egg antigen regulated the host’s immune system and achieved immunomodulation in an experimentally induced colitis model. It induced expansion of Foxp3 + Treg probably via an indirect antigen-presenting cells-mediated mechanism and direct effects on T cells. It attenuated experimentally trinitrobenzene sulfonic acid-induced colitis and protected mice from lethal inflammation [ 60 ]. Surprisingly, the soluble egg antigen of S. mansoni , which contains oncogenic antigens, was recently reported to have an unpredictable negative effect on colon cancer cell (CT26.WT) proliferation in vitro, even at high concentrations [ 61 ]. Interestingly, an earlier study in 1991 demonstrated the anti-neoplastic activity of S. mansoni antigen in a murine cancer model [ 62 ]. This is in agreement with a recent study by Eissa et al. [ 55 ] who reported a protective effect of the autoclaved S. mansoni cercarial antigen against chemically induced colon carcinogenesis in a murine model. It resulted in a notable reduction in the average size of lesions and the number of neoplasms per mouse. Additionally, schistosomal antigen provoked an immunomodulatory potential, as evidenced by a significant increase in serum interlukin-10 (IL-10), the percentage of splenic clusters of differentiation 4 T cells (CD4 + T cells), intestinal FoxP3 + Treg cells, and a significant decrease in serum IL-17 [ 55 ]. It is worth noting that in a series of previous studies, autoclaved parasitic antigens induced potent homologous protective immunity against experimental schistosomiasis [ 63 ], trichinellosis [ 64 ], toxoplasmosis [ 65 ], and leishmaniasis [ 66 ], as well as anti-cancer activity [ 39 , 40 , 55 ]. Their strong immunogenic potential was also capable of alleviating adjuvant-induced arthritis in a rat model [ 20 ] and has been demonstrated to be safe in both experimental studies and human clinical trials against leishmaniasis [ 67 , 68 ]. These findings suggest that autoclaved parasitic antigens could be a promising, safe, and potent immunotherapeutic treatment. With advancements in technology, it will be possible to overcome challenges such as standardization or identification of the most antigenic components of these antigens. This could be a significant advancement in the pharmaceutical industry to develop nature-based therapeutics of parasitic origin that could target cancer, autoimmune diseases, and infectious diseases as well.

Another helminth parasite is Echinococcus granulosus ( E. granulosus ), the tapeworm that causes hydatid disease in humans; a cosmopolitan zoonotic disease [ 69 ]. It is transmitted by dogs or other canines, who act as definitive hosts, while herbivorous animals serve as intermediate hosts [ 70 ]. Humans can be sporadically infected and act as accidental intermediate hosts. Interestingly, there have been reports of anti-cancer effects associated with hydatid disease in humans [ 25 , 29 ]. In an in vitro study, hydatid cyst fluid has been shown to exhibit anti-neoplastic activity by inducing apoptosis in a colon cancer cell line (C26) [ 71 ]. Moreover, vaccination with hydatid cyst fluid induced anti-neoplastic activity in a murine model, protecting against colon tumor growth in both prophylactic and therapeutic experimental trials [ 72 ]. Similarly, it was shown by Rostamirad et al. [ 73 ] that hydatid cyst antigens (hydatid cyst fluid, the 78 kDa fraction or live protoscolices); especially hydatid cyst fluid fraction significantly inhibited colon cancer tumor growth in BALB/c mice [ 73 ]. Furthermore, anti-hydatid cyst antibodies were able to identify cell surface and intracellular antigens in colon cancer cells (CT26) using flow cytometry. Proteomic analysis of colon cancer CT26 antigens cross-reacted with anti-hydatid cyst antibodies and hydatid cyst fluid identified two proteins: mortalin and creatine kinase M-type. Interestingly, CT26 mortalin showed 60% homology with E. granulosus hsp70 [ 72 ]. Thus, the anti-neoplastic activity of E. granulosus against CRC may be attributed to shared antigens and the development of an effective cross-reactive immune response against cancer cells.

Taenia solium ( T. solium ) is an intestinal tapeworm that is acquired by eating undercooked pork. Ingestion of pork meat that contains the larval stage, cysticercus cellulose, leads to human taeniasis. On the other hand, human cysticercosis/neurocysticercosis is a fecal–oral infection caused by ingesting eggs excreted in the feces of a human carrier of T. solium [ 74 ]. Interestingly , recombinant T. solium Calreticulin (r Ts CRT) was documented to promote an in vitro anti-tumoral effect. It inhibited the growth of the colon cancer cells (SW480 cell line) in a dose-dependent manner by interacting with scavenger receptors [ 75 ]. Although the main role of calreticulin, an endoplasmic reticulum protein, in T. solium , is to control intracellular Ca +2 homeostasis, it also participates in the assembly and surface expression of major histocompatibility complex (MHC) class I molecules for antigen presentation to CD8 + T cells, as well as in cell motility, secretion pathways, gene transcription regulation, protein synthesis, cellular adhesion, and apoptosis [ 76 ].

Taenia crassiceps ( T. crassiceps ) is another tapeworm that inhabits the intestine of carnivores, with rodents acting as its natural intermediate hosts. Human infection is rare and usually described in individuals with severe immunodeficiency. In such cases, humans act as an accidental intermediate host where the cysticerci, the larval stage of T. crassiceps can be found in skeletal muscles, subcutaneous tissue, or even intraocular [ 77 ]. The impact of T. crassiceps infection on the progression of colon cancer and colitis-associated colorectal tumorigenesis in mice was investigated. Infection with this mesocestod parasite inhibited the colonic inflammatory responses and CRC formation as well as prevented goblet cell loss. It also led to increased expression of IL-4, activated macrophage markers in colonic tissue, and negatively affected the expression of pro-inflammatory cytokines. Additionally, T. crassiceps infection prevented the up-regulation of β-catenin and CXCR2 expression, which are both markers associated with colitis-associated colorectal tumorigenesis [ 78 ].

Trichinella spiralis ( T. spiralis ), a tissue-dwelling helminth, causes human trichinellosis through ingestion of undercooked pork meat containing the parasite’s infective larvae. It possesses potent immunomodulatory properties and can stimulate anti-tumor immunity [ 79 ]. Trichinella spiralis infection has been shown to induce inhibition of HCT-8 colorectal carcinoma in BALB/c mice as demonstrated by a decrease in size and weight of tumors [ 80 ].

Toxocara canis ( T. canis ), a dog-specific nematode that can infect humans and cause visceral larva migrans and ocular larva migrans syndrome, has also shown an anti-neoplastic activity against colon cancer [ 81 , 82 ]. Toxocara canis- derived peptides, specifically the synthesized peptide fraction from the excretory–secretory Troponin protein peptide, were able to induce cellular changes and decrease cellular viability in colon carcinoma cell lines (HT-29 and Caco2) in a dose-dependent manner and significantly altered the cellular expression of gene (Mcl-2, APAF1, ZEB1, VEGF, cyclin-D1, and caspase-3) involved in cancer progression [ 82 ].

In another study, derived antigens as well as excretory/secretory products (ES) from adult Heligmosomoides polygyrus ( H. polygyrus ), a gastrointestinal helminth parasite of rodents, significantly reduced the in vitro proliferation of murine (CT26.WT) colorectal cancer cells. Heligmosomoides excretory/secretory products (HES) alone are also significantly reduced the in vitro proliferation of human (HCT116) colorectal cancer cells, potentially through an increase in cell cycle arrest rather than cell apoptosis [ 61 ].

Antineoplastic activity of protozoan parasites against CRC

Apart from helminths, Trypanosoma cruzi ( T. cruzi ), a flagellated protozoan parasite that causes Chagas’ disease in humans possesses anti-cancer activities. This finding was first reported by Russian researchers Roskin and Exempliarskaia in 1931 who observed the tropism of T. cruzi toward tumor cells [ 83 ]. Later on, the anti-cancer activity of T. cruzi was further reported in several studies [ 84 – 86 ]. The anti-neoplastic activity of T. cruzi against CRC has been demonstrated in several in vitro and in vivo studies. Rats chronically infected with T. cruzi demonstrated a low incidence of chemically induced colon cancer [ 87 ]. Additionally, vaccination with T. cruzi epimastigote lysates strongly inhibited colon cancer development in a rat model and evoked an integrated anti-tumor response involving both the cellular and humoral components of the immune response. Interestingly, rats developed specific antibodies upon vaccination with T. cruzi epimastigote lysates that cross-reacted in vitro with human colon cancer cells. This indicates that T. cruzi and colon cancer cells could share common antigens and were capable of mediating antibody-dependent cellular cytotoxicity [ 52 ]. A candidate probable antigen is the mucin-type cancer-associated sialyl-Tn antigen (sialic acid-GalNAc-O-Ser/Thr), previously characterized in T. cruzi [ 88 ]. Thus, protection induced by T. cruzi infection or antigens against colon cancer in rat models possibly explains the absence of colorectal cancer in patients with chagasic megacolon [ 26 ].

Malaria is a disease caused by an intracellular protozoan parasite, Plasmodium ( P. ). It is the most common parasitic infection in both humans and animals. Studies have indicated that Plasmodium infection can activate the immune system’s defense against cancer. In a recent experimental study, infecting colon-cancer-bearing mice with P. yoelii 17XNL-infected erythrocytes resulted in a reduction in tumor weight and size. This was achieved by inhibiting proliferation and promoting mitochondria-mediated apoptosis in colon cancer cells [ 89 ]. It was also reported that the refined malaria protein rVAR2 binds specifically and with high affinity to chondroitin sulfate from various cancer cell lines. This targeted tumor characteristic makes rVAR2 a promising candidate for anti-cancer drug delivery. In fact, a complex formed by conjugating rVAR2 with a hemiasterlin analog (KT886) named (VDC886) was found to have strong cytotoxicity to 33 cancer cell lines in vitro including human colon cancer cells (Colo 205) with inhibitory concentrations 50 (IC50) values ranging from 0.2 pM to 30 nM [ 90 ]. Interestingly, in an in vitro study, it was demonstrated that a recombinant circumsporozoite protein, the main surface protein of the malaria parasite’s sporozoite stage, inhibited the proliferation of the human colon cancer cell line, SW480 in a dose-dependent manner. It also induced apoptosis in SW480 cells by suppressing the activation of the nuclear factor κB (NF-κB). Blocking NF-κB activation is a promising strategy for cancer treatment. Further research is needed to investigate the potential use of circumsporozoite protein as a novel NF-κB inhibitor for treating colorectal cancer [ 91 ].

Toxoplasma gondii ( T. gondii ) is a protozoan parasite that has attracted attention for its potential anti-cancer effects. It infects a wide variety of warm-blooded animals, and about one-third of the world’s population is infected with it. T. gondii is able to infect many different types of cells and alter the immune response of the host, which makes it a possible candidate for use in human medicine as a potential oncolytic protozoan [ 92 ]. In vitro studies demonstrated that the dense granular protein 16 of T. gondii (GRA16) can act as a new telomerase inhibitor, an excellent candidate for gene therapy targeting cancer. It induced apoptosis in HCT116 human colorectal cancer cells by down-regulating the expression of human telomerase reverse transcriptase. This led to the shortening of telomere through the inactivation of telomerase, which was achieved by activating the tumor suppressor phosphatase and tension homolog [ 93 ]. Interestingly, conjugation of GRA8, a dense granule protein of T. gondii , with the acidity-triggered rational membrane (ATRAM) forming (rATRAM-GRA8-M/AS) induced HCT116 cell death in a dose-dependent manner via mitochondrial metabolic resuscitation pathways. Furthermore, rATRAM-GRA8-M/AS demonstrated significant therapeutic effects in a mouse model with HCT116 xenografts, with noticeable inhibition in tumor growth in mice [ 94 ]. Additionally, in a mouse model of colon adenocarcinoma (MC38), intratumoral administration of attenuated T. gondii tachyzoites (RH-ΔGRA17) strain with programmed death ligand-1 (PD-L1) blockade significantly improved the survival of mice and halted tumor growth compared to each treatment alone. This treatment also increased lymphocyte infiltration and sensitized the microenvironment in local and distant tumors to systemic PD-L1 blockade treatment [ 95 ]. Likewise, intratumoral injection of Toxoplasma lysate antigen in CT26 tumor-bearing Athymic nude mice and euthymic mice reduced tumor growth and TIMP-1 level, a metastatic marker, in both mouse models. In Athymic mice, Toxoplasma lysate antigen treatment led to a sharp increase in serum IL-12, and MyD88 signals in bone marrow-derived macrophages, suggesting activation of innate immunity. The selective induction of IL-12 by Toxoplasma lysate antigen treatment had an anti-tumorigenic effect [ 96 ].

In T. gondii , the profilin-like protein (TgPLP) acts as a Toll-like receptor (TLR) agonist. A study demonstrated that recombinant profilin-like protein in T. gondii ( Tg PLP) could serve as a TLR-based vaccine adjuvant, enhancing anti-tumor immune responses upon vaccination with autologous whole-tumor cell vaccine (AWV) that was exhibited by prolonged mice survival and smaller CT26 tumors . Additionally, Tg PLP treatment triggered immune responses as evidenced by increased expression of antigen-presenting cell markers (MHC class I and II, B7.1, and B7.2) in bone marrow-derived macrophage and increased IL-12 and IFN-γ expression in mice. Mice vaccinated with AWV and Tg PLP showed more immune cells [CD4 + and CD8 + T cells, natural killer (NK) cells, and macrophages] in the spleen and higher total IgG and IgG2a concentrations in the blood than mice vaccinated with AWV alone [ 97 ].

Similarly, the amino-terminus region of the dense granule protein 6 (GRA6Nt) of T. gondii has been shown to activate cancer-specific immunity. In a mouse model of MC38 CRC, the recombinant GRA6Nt (rGRA6Nt) protein acts as an effective adjuvant when combined with non-replicable MC38 colorectal cancer cells treated with mitomycin C or a lethal dose of ionizing radiation. This immunization approach markedly activates protective immunity against replicable MC38 tumor cells challenge, leading to significant inhibition of tumor growth and a marked increase in the infiltration of CD8 + T cells in the tumor microenvironment. The CD8 + T cells also showed increased activity in secreting granzyme B and IFN-γ in response to cancer cells in vitro. Importantly, this immunization approach is specific to MC38 CRC cells and did not significantly inhibit the growth of EL4 lymphoma tumors [ 98 ]. Therefore, both the recombinant Profilin-like protein (r Tg PLP) and the recombinant GRA6Nt of T. gondii have the potential as powerful adjuvants for cancer cell vaccines used in cancer immunotherapy to effectively activate their specific protective immunity.

Recent studies have shown that the use of an exosome-based strategy instead of live parasite infections could be a safe alternative approach for clinical applications in treating cancer [ 99 , 100 ]. Exosomes derived from culture supernatants of DCs infected with T. gondii Me49 strain induced an anti-tumor effects CRC mouse model. These exosomes significantly slowed tumor growth, inhibited macrophage polarization to M2 phenotype, and regulated the suppressor of cytokine signaling 1 (SOCS1) expression by delivering functional miR-155-5p [ 100 ]. Furthermore, a subsequent study showed that these exosomes reduced the proportion of polymorphonuclear granulocytic bone marrow-derived suppressor cells (G-MDSCs, CD11b + Ly6G + ) and monocytic myeloid-derived suppressor cells (M-MDSCs, CD11b + Ly6C + ), while significantly increased the proportion of DCs (CD45 + CD11c + ). There was also a significant decrease in the levels of IL-6 and granulocyte–macrophage colony-stimulating factor. The exosomes achieved such an impact by inhibiting the signal transducer and activator of the transcription signaling pathway. Thus, exosomes derived from DCs infected with T. gondii could potentially be a new cancer treatment strategy decreasing the proportion of MDSCs and altering the “cold” tumor to a “hot” tumor. These exosomes could also be modified for drug and antibody delivery. These findings could lead to a new approach for treating CRC [ 99 ].

Eimeria spp . is another apicomplexan intestinal protozoan parasite of domestic animals. Interestingly, domestic animals known to maintain this parasite in their small intestinal tissues have a very low incidence of colon cancer. In humans, cyst-forming coccidia parasites belonging to phylum Apicomplexa, with life cycles like Eimeria , are maintained through the use of night soil as fertilizer . Therefore, a research study investigated the impact of using human excrement (night soil) as a fertilizer on the development of human colon cancer. Japan’s mortality data demonstrated that colon cancer increased after the cessation of night soil use [ 101 ]. Thus, the presence of protozoa within intestinal tissue layers may enhance the immune system and prevent colon cancer, and the loss of these organisms could lead to a higher incidence of colon cancer. The authors consider this to be similar to the helminth hypothesis and an extension of the hygiene hypothesis [ 101 ].

These findings were further supported by a recent study by Huang and colleagues, who demonstrated that Eimeria stiedae ( E. stiedae ) soluble protein is an extremely effective activator of innate immunity in mice. In the murine model of colon cancer (CT26), it enhanced the anti-tumor immune response, inhibited tumor growth, promoted dendritic cell maturation, and activated natural killer cells and CD8 + T cells. Additionally, it inhibited angiogenesis and metastasis as demonstrated by the significant reduction in the number of metastatic lung nodules. Thus, Eimeria surface protein could play an important role in the treatment of cancer and has the potential to prevent tumor metastasis, which is a leading cause of cancer-related death in patients with colorectal cancer as well as other solid tumors [ 102 ].

Gastric and esophageal cancers

Gastric and esophageal cancers are prevalent and have high mortality rates. Patients are usually diagnosed at an advanced stage, leading to poor survival outcomes. Despite advancements in cancer treatments, survival rates remain low, highlighting the need for ongoing research to improve treatment strategies [ 103 ].

Antineoplastic activity of helminth parasites against gastric and esophageal cancers

Studies have shown that the helminth nematode parasites T. spiralis and T. canis have anti-neoplastic activity against gastric cancer. In an in vitro study, T. canis synthesized Troponin protein peptide, a fraction from the excretory–secretory antigens, was able to induce cellular changes and decrease cellular viability in a gastric cancer cell line (AGS) in a dose-dependent manner. It also significantly altered the cellular expression of genes (Mcl-2, APAF1, ZEB1, VEGF, cyclin-D1, and caspase-3) involved in cancer progression [ 82 ]. In addition, the extract of T. spiralis from adults and newborn larvae inhibited tumor growth in mice grafted with murine forestomach carcinoma (cell line MFC) [ 104 ].

Antineoplastic activity of protozoan parasites against gastric and esophageal cancers

Apart from helminths, live T. gondii tachyzoites have been found to have a significant inhibitory effect on human esophageal carcinoma cells (EC-109 cell line) in a dose-dependent manner [ 105 ]. Furthermore, another study demonstrated that the culture supernatant of T. gondii inhibited the proliferation and induced apoptosis in human gastric cancer BGC-823 cells in a concentration- and time-dependent manner. This effect may be linked to the up-regulation of p53 expression and the down-regulation of Bcl-2 expression [ 106 ]. Interestingly, T. gondii infection of a multi-drug-resistant gastric cancer cell line, or its incubation with T. gondii cell lysate, has been shown to reduce their resistance to cytostatic drugs by enhancing drug accumulation through reducing the activity of ATP-dependent efflux pump. These findings are intriguing and warrant further investigation [ 107 ].

Hepato-pancreatic cancers

Table 2 a, b shows the in vitro and in vivo studies of the anti-neoplastic activity of different parasites against hepato-pancreatic cancers (Hepatocellular Carcinoma and Pancreatic Cancer).

Hepatocellular carcinoma (HCC)

Hepatocellular carcinoma (HCC) is a common tumor worldwide and accounts for 85–90% of primary liver cancers. It ranks fifth in frequency and fourth in cancer-related deaths. Loco-regional treatments such as surgical resection, radio-frequency ablation, trans-arterial chemoembolization, or liver transplantation can be effective when HCC is diagnosed early. However, most cases are diagnosed at advanced stages, rendering these treatments ineffective. In such cases, systemic therapy is the only viable option. Unfortunately, neither surgical treatment nor nonsurgical one can effectively improve the outcome of liver cancer patients, highlighting the need for further research to find better treatment options [ 108 ].

Antineoplastic activity of helminth parasites against HCC

Although infection with S. haematobium has been linked to bladder cancer [ 109 ], it is less clear and controversial the association between S. japonicum infection and hepatocellular carcinoma (HCC). Studies have shown that dysregulated expression of certain miRNAs plays a viable role in the development of various diseases including cancer [ 110 ]. Interestingly, research studies concluded that S. japonicum miRNA is present in the hepatocytes of mice infected with the parasite, which may enhance the host’s resistance to liver cancer. In fact, in vitro experiments have shown that Sja -miRNA-7-5p, Sja -miR-3096, Sja -miR-61, and Sja -miR-71a mimics significantly inhibited the migration of mouse hepatoma (Hepa1-6), human hepatoma (HepG2), and human HCC (SMMC-7721) cell lines [ 111 – 114 ]. Additionally, in a xenograft animal model, mice inoculated with cells transfected with Sja -miRNA-7-5p, Sja -miR-3096, Sja -miR-61, or Sj a-miR-71a mimics inhibited tumor growth and experienced significant reductions in tumor volume and weight. This anti-tumor activity was achieved through the modulation of tumor-related genes. For instance, Sja -miRNA-7-5p down-regulates the S-phase kinase-associated protein 2 gene [ 111 ], Sja -miR-3096 targets phosphoinositide 3-kinase class II alpha (PIK3C2 A) gene [ 112 ], Sja -miR-61 induces an anti-angiogenesis activity by targeting the PGAM1 gene [ 113 ], and Sja -miR-71a targets the FZD4 gene [ 114 ]. The suppression of tumor growth in vivo by Sja -miR suggests that the application of these exogenous miRNAs could potentially provide a novel and promising approach to cancer therapy.

Fasciola spp., a liver fluke, is the cause of fascioliasis, a common zoonotic helminth disease. It is a major food-borne disease that currently affects approximately 2 million people in over 70 countries [ 115 ]. While two other liver flukes O. viverrini and C. sinensis have been recognized as definitive causes of cancer [ 18 ], fascioliasis caused by Fasciola hepatica ( F. hepatica ) has not been linked to cancer. This may be due to the findings of Tsocheva et al . [ 116 ] who demonstrated that biologically active substances isolated from F. hepatica tissue had a significant inhibitory effect on hepatoma cells (MC29 cell line) proliferation.

The nematode helminth parasite T. spiralis ensures its survival and immune dialog within the host by releasing excretory–secretory products (ESPs). In vitro studies have shown that a mixture of crude extracts from T. spiralis adult worms and newborn larvae exhibited anti-neoplastic activity and induced apoptosis of ascitic hepatoma (cell line H22) and hepatoma cell line (H7402) [ 104 ]. Similarly, ESPs from T. spiralis adults or muscle larvae inhibited cellular proliferation and induced apoptosis in the liver cancer H22 cell line through the mitochondrial pathway [ 117 ]. Furthermore, a T. spiralis protein encoded by the A200711 gene was reported to induce apoptosis in human hepatoma (H7402) cells [ 118 ]. Recently, T. spiralis larval extract (peptide 2 matched the hypothetical protein T01_4238 of T. spiralis ) induced an in vitro anti-tumor effect on HepG2 cells in a dose-dependent manner, by inducing reactive oxygen species accumulation, leading to the inhibition of cell proliferation [ 119 ]. In vivo studies revealed that ICR mice inoculated with mouse ascitic hepatoma H22 cells and C57BL/6 mice inoculated with hepatoma Hepa1-6 carcinoma cells followed by their infection with T. spiralis resulted in a significant inhibition in tumor growth [ 117 , 120 ]. Similar results were obtained by another study where T. spiralis infection in hepatocellular carcinoma (HCC) animal model prolonged rats’ survival and decreased progression of the tumor with an increased rate of apoptosis as shown by the decreased expression of Bcl-2 at 30 and 40 days post-infection [ 121 ].

Angiostrongylus cantonensis ( A. cantonensis ) is another helminth nematode parasite that causes angiostrongyliasis, the most common cause of eosinophilic meningitis in Southeast Asia and the Pacific Basin [ 122 ]. Angiostrongylus cantonensis ESPs and recombinant Calreticulin (rCRT) (a key effector protein of ESPs) induced apoptosis in human hepatoma HepG2 cells via endoplasmic reticulum stress. Moreover, rCRT had a stronger inhibitory effect on HepG2 cells compared to ESPs while showing no effect on the proliferation of HL-7702 normal human liver cells [ 123 ]. In Hepa1-6 mouse tumor models, ESPs from A. cantonensis significantly reduced tumor growth [ 123 ].

Adult Setaria equina ( S. equina ) is a filarial parasite commonly found in the peritoneal cavity of equines worldwide. In a rat model of chemically induced HCC, it was found that repeated administration of S. equina ESPs had a beneficial effect on preventing the development of HCC. These products contain antioxidant substances that can reduce oxidative stress by increasing the activity of antioxidant enzymes (CAT, SOD, and GPX), particularly catalase. They also decreased the expression of NF-κB, which plays a role in cancer treatment. Combined treatment with diethylcarbamazine citrate (DEC) was found to modulate the antioxidant effect of S. equina ESPs [ 124 ]. Another study also showed that repeated doses of this combination therapy (DEC + Se ES) had immunomodulatory and protective effects on rat HCC. It increased anti- S. equina ESPs IgG, IFN-γ levels, and NK cell infiltration while reducing the expression of MHC I, PCNA, Bcl2, and p53 [ 125 ]. Therefore, repeated administration of the combined treatment of DEC and S. equina ESPs induced antioxidant, immunomodulatory, and protective effects on rat chemically induced HCC [ 124 , 125 ].

Interestingly, another study demonstrated the existence of cross-reactive protein bands in S. equina adult worms and Huh-7 hepatoma cells at 70 and 75 kDa by anti-DEC and S. equina extract antibodies, respectively, using indirect ELISA and western blotting. The existence of shared proteins could also explain the anti-tumor activity of S. equina against HCC [ 126 ]. Further research is needed to identify and evaluate the antioxidant components of S. equina ESPs, as well as the shared proteins with hepatoma cells, as potential novel treatments for HCC.

Antineoplastic activity of protozoan parasites against HCC

Infection with Plasmodium is known to regulate the host’s immunity by inducing the release of cytokines, activating certain immune cell populations, and altering the function of macrophages [ 127 ]. Angsubhakorn and colleagues have shown that P. berghei infection in rats reduced the development of hepatic carcinoma induced by dietary aflatoxin B1 [ 128 ]. In the same line, another study demonstrated that P. yoelii 17 XNL infection effectively inhibited tumor progression in a murine implanted hepatoma model (murine Hepa1–6 or H22 hepatoma cell line) and prolonged their survival time by suppressing tumor angiogenesis. This was attributed to the decreased infiltration of tumor-associated macrophages within the tumor microenvironment that produces matrix metalloprotease 9 (MMP-9) which is well documented to play a crucial role in the process of angiogenesis [ 129 ]. Thus, parasite-induced reduction in MMP-9 expression in tumor-associated macrophages resulted in the suppression of tumor angiogenesis. Additionally, Plasmodium -derived hemozoin that accumulated in tumor-associated macrophages inhibited IGF-1 signaling through the PI3-K and MAPK signaling pathways and thereby decreased the expression of MMP-9 in tumor-associated macrophages [ 130 ].

In another study, Liu et al. [ 131 ] validated the use of P. yoelii as a novel vaccine vector for hepatocellular carcinoma (HCC) immunotherapy. They reported that P. yoelii 17XNL strain expressing murine glypican-3 protein ( P . y -GPC3), which is highly expressed in Hepa1-6 cells, significantly inhibited Hepa1-6-induced tumor growth in the implanted HCC murine model and prolonged their survival time. It also induced a significant GPC3-specific cytotoxic T lymphocyte (CTL) response. This suggests that a Plasmodium -based vector is highly effective in inducing tumor antigen-specific T-cell-mediated immunity. Additionally, it increased concentrations of Th1-associated cytokines, such as IL-2, IFN-γ, and TNF-α, in serum and favored expansion of the CD8α + dendritic cell subset with higher expression of CD80 and CD86 molecules [ 131 ]. Moreover, P. yoelii infection alone inhibited the recurrence and metastasis of HCC and improved the prognosis in both non‑resection and resection murine orthotopic HCC models. This was achieved through suppressing CC‑chemokine receptor 10‑mediated PI3K/Akt/GSK‑3β/Snail signaling and preventing epithelial–mesenchymal transition. These findings show potential for the development of new therapies for HCC recurrence and metastasis [ 132 ]. As a result, a clinical trial of Plasmodium immunotherapy for advanced liver and breast cancer [ NCT03474822 ] has been approved and is currently underway in China [ 36 ].

A study on the apicomplexan protozoan parasite T. gondii has shown that T. gondii tachyzoites RH strain inhibited the in vitro proliferation and induced apoptosis of HCC (H7402) in a concentration-dependent manner. This effect was associated with the down-regulation of cyclinB1 and cdc2 (cell cycle-related genes), an increase in the apoptosis-related protein Caspase-3, and a decrease in Bcl-2 expression [ 133 ].

Another study demonstrated that GRA16, a dense granule protein of T. gondii , has anti-cancer activity against hepatocellular carcinoma. In an in vitro study, GRA16 decreased cell proliferation, anti-apoptotic factors, p‐AKT/AKT ratio, cell migration, and invasive activity of hepatocellular carcinoma (HepG2) cells. In addition, it decreased tumor size in HepG2 cell‐xenograft nude mice. The study revealed that GRA16 acts as a Herpes virus ‐associated ubiquitin‐specific protease inhibitor, targeting the nuclear localization of phosphatase and tensin homolog and inducing an anti-cancer effect against HCC in a p53‐dependent manner [ 134 ]. Similarly, the effector molecule Toxo GRA15II; a T. gondii virulence-associated molecule of dense granule protein, can induce macrophage polarization to M1. An in vitro study demonstrated that Toxo GRA15II-polarized macrophage induced significant inhibition of migration and invasion of the Hepa1-6 cells and decreased expressions of matrix metalloproteinase (MMP)-9 and MMP-2 without notable apoptosis. In parallel to that study, Toxo GRA15II-polarized macrophages inoculated to tumor-bearing C57BL/6 mice induced marked restriction of tumor growth through its related cytokines profile in tumor and spleen tissues. Thus, Toxo GRA15II, due to its ability to activate specific cell populations early while being non-toxic to mammals, could be a promising new approach to enhance host innate immunity to fight cancer [ 135 ].

Pancreatic cancer [pancreatic ductal adenocarcinoma (PDAC)]

Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease and is expected to become the second leading cause of cancer death in USA by 2030 [ 136 ]. Yet, multiple challenges are obvious in its treatment including limitations in patients who are eligible for surgical tumor resection, and a high rate of tumor recurrence (around 70%). Additionally, immune checkpoint inhibitors are not effective in controlling most PDAC tumors due to the tumor’s strong immunosuppressive microenvironment and lack of immune cell infiltration [ 137 ]. Therefore, it is crucial to find new methods to improve the effectiveness of immunotherapy in PDAC.

Antineoplastic activity of helminth parasites against PDAC

Recently, E. granulosus has been studied concerning pancreatic cancer. Induction of secondary hydatidosis in a rat model of pancreatic cancer induced by azaserine significantly inhibited the development of precursor foci of neoplastic changes in the pancreas. Although the study used live protoscolex to induce secondary hydatidosis, the authors highlighted that using dead protoscolex yielded the same results in their pilot study [ 138 ]. Thus, exploring the antigenic derivatives of this parasite against pancreatic cancer is noteworthy to be investigated.

Antineoplastic activity of protozoan parasites against PDAC

There is evidence suggesting that certain protozoan parasites, such as T. gondii , have the potential to be used as an effective immunotherapeutic agent even in an immunosuppressive cancer such as PDAC. Thus, a number of studies investigated that theory with attenuated strains of T. gondii gaining the biggest chunk of those trials. Attenuated auxotroph strain of virulent T. gondii (cps), which is capable of selective invasion of cells without replication, promoted immunotherapeutic effect against PDAC [ 139 – 141 ]. Treating pancreatic ductal adenocarcinoma in mice by intratumoral inoculation of the attenuated T. gondii strain cps induced regression of established tumors in mice [ 139 ]. In another study, the treatment of established aggressive disseminated pancreatic cancer in a mouse model with the attenuated T. gondii strain cps induced stimulation of the immune system at a multi-level platform. It promoted a significant decrease in tumor-associated macrophages, a marked increase in DCs infiltration of the pancreatic tumor microenvironment, an increase in the expression of co-stimulatory molecules CD80 and CD86, and the production of IL-12. Additionally, cps treatment led to an increase in CD4 + and CD8 + T-cell infiltration into the tumor microenvironment, activation of tumor-resident T cells, and increased production of IFN-γ [ 140 ]. Furthermore, mice that survived the primary pancreatic tumor after cps treatment showed strong immune protection against the recurrence of pancreatic cancer. These findings indicate that a variety of cell-mediated and humoral antibody-mediated anti-tumor immune responses generated by primary immunotherapy may be crucial in developing long-lasting protective immunity against aggressive cancers like PDAC [ 141 ]. These studies highlight the importance of targeting and neutralizing suppressive myeloid cell populations as an effective immunotherapeutic mechanism to fight pancreatic cancer. They also identified cps immunotherapy as the first treatment to provide a long-term survival benefit [ 140 , 141 ].

In another study, the use of another variant of attenuated Toxoplasma (NRTUA strain) as a monotherapy inhibited PDAC tumor growth in a subcutaneous mouse model by activation of DCs and increasing CD8 + T-cell infiltration in the tumor microenvironment. NRTUA strain efficiently enhanced the anti-tumor activity of anti-PD1 antibody when used in combination, induced a significant immune response, and controlled tumor growth in Pan02 tumor-bearing mice. This was achieved by targeting the tumor immunosuppressive myeloid-derived suppressor cell population and modifying the tumor microenvironment [ 142 ].

For safety concerns, it is worth noting that instead of using live parasites, Pyan and colleagues demonstrated that treatment with soluble T. gondii or T. gondii profilin in pancreatic cancer tumors in C57BL/6J mice decreased tumor volume and increased tumor infiltration with CD4 + and CD8 + T cells [ 98 , 143 ]. These studies suggest that T. gondii and its derived products could be promising targets for novel pancreatic cancer treatment, which could potentially be translated into future therapeutics for this most aggressive, resistant, and lethal cancer.

Lung cancer

Table 3 shows the in vitro and in vivo studies of the anti-neoplastic activity of different parasites against lung cancer.

Lung cancer is a highly common and deadly form of cancer, causing approximately 1.35 million deaths each year and accounting for around 30% of all cancer-related deaths worldwide [ 144 ]. There are two main types of lung cancer: small cell (SCLC) and non-small cell lung cancer (NSCLC). The latter accounts for over 80% of lung cancer cases [ 1 ]. The development of drug resistance and frequency of metastasis are important factors imposing its high mortality rate. Even with aggressive treatments like surgery, radiation, and chemotherapy, the survival rates are still low [ 145 , 146 ]. Contrarily, biological therapy is considered a safe and effective treatment approach, justifying the conduction of numerous experimental studies including those investigating the anti-neoplastic activity of parasites.

Antineoplastic activity of helminth parasites against lung cancer

Several studies have shown the anti-tumor activity of E. granulosus against lung cancer. In a murine model, vaccination with human hydatid cyst fluid induced a strong anti-tumor immune response involving both the innate and adaptive immune components that significantly inhibited Lewis lung carcinoma (LLC) cell growth both in prophylactic and therapeutic settings and significantly increased mouse survival. Flow cytometry analysis revealed that hydatid cyst fluid-specific antibodies recognized both membrane and intracellular molecules in lung cancer cells [ 147 ]. This is in agreement with the earlier result obtained by immunoelectrophoretic analysis where a broad and intense band was formed when the serum from a patient suffering from pulmonary carcinoma was tested using hydatid cyst fluid [ 148 ]. It also supports the potential of anti-hydatid cyst fluid antibodies to generate an anti-tumor effect, as observed in vitro with the serum of patients with hydatid cyst and their ability to induce a cytotoxic effect on NCI-H209/An1 human SCLC cells [ 149 ].

The anti-tumor effect of T. spiralis was observed against lung cancer cells (A549) inoculated into a T. spiralis -infected animal which was dependent on the time of tumor challenge to T. spiralis infection [ 150 ]. In other studies, the inhibition of proliferation and induction of apoptosis was observed in SCLC cells (H446 SCLC) and the NSCLC cells (A549) when co-cultured with T. spiralis muscle larvae excretory–secretory proteins. This effect was found to be dose and time-dependent. The apoptosis was triggered by activating the mitochondrial apoptotic pathway, as evidenced by the low expression of anti-apoptotic genes (Bcl-2 and Livin) and increased expression of pro-apoptosis genes (sit-in, Apaf-1, caspase-9, and caspase-3) [ 151 , 152 ]. Furthermore, T. spiralis muscle larvae proteins significantly altered the transcriptome profiling of A549 lung cancer cells, with the expression of 2860 genes being altered. There were an up-regulation of 1634 genes and a down-regulation of 1226 genes, which are known to be associated with pathways in cancer and metabolic processes. Moreover, there was a down-regulation of glycolysis-related genes which may be detrimental to A549 cells [ 153 ]. A small Heat Shock Protein (sHSP-DQ 986457) was identified as an associated antigen between T. spiralis and LLC cells, and Western blotting analysis revealed that recombinant sHSP reacted with anti-LLC cell antiserum [ 154 ]. Trichinella spiralis sHSP using invasive Lactobacillus plantarum (NC8) as a vector vaccine (NC8-sHSP) successfully inhibited tumor growth in both prophylactic and therapeutic experiments in the LLC murine model, through the induction of humoral, cellular, and mucosal immunity [ 155 ].

Antineoplastic activity of protozoan parasites against lung cancer

Several studies have shown that certain protozoal infections, such as T. cruzi , Trichomonas vaginalis ( T. vaginalis ), Plasmodium spp., and T. gondii , and their derivatives have been deeply investigated experimentally and have successfully shown anti-neoplastic activity against lung cancer and can interfere with tumor growth [ 156 – 160 ].

Trichomonas vaginalis is a flagellated protozoan parasite that causes trichomoniasis, a sexually transmitted disease [ 161 ] . It typically inhabits the genitourinary tract, but there have been cases, supported by molecular identification, where it has been found in the respiratory tract of neonates born to mothers infected with T. vaginalis and in adults with a history of urogenital contact [ 162 ]. In an in vitro study, it was found that T. vaginalis can adhere, cause cytotoxic effects, and induce apoptosis in the human lung alveolar basal carcinoma epithelial cell line A549 [ 158 ].

In a pre-clinical murine lung cancer model, an anti-tumoral effect was achieved by a protein lysate derived from T. cruzi epimastigote both in preventive and therapeutic settings. It prevented tumor growth and induced both humoral and cellular anti-tumor immune responses. This was associated with the activation of natural killer cells, INF-γ production, and tumor cell cytotoxicity. Flow cytometry analysis showed that the antibodies induced by T. cruz i lysate recognized both membrane and intracellular molecules in lung cancer cells. The anti-tumor effects of T. cruzi lysate are likely due to its ability to activate both innate and adaptive immune responses, with carbohydrate components playing a crucial role [ 157 ].

In addition to their immunostimulatory role in cancer therapy, parasites can also contribute to cancer gene therapy through certain enzymes. One such enzyme is hypoxanthine–guanine phosphoribosyltransferase (HGPRT), which is produced by the parasite Trypanosoma brucei ( T. brucei ), the cause of African sleeping sickness disease. Hypoxanthine–guanine phosphoribosyltransferase can convert allopurinol, a purine analog, into nucleotides more effectively than its human homologue. A study generated a new suicide gene/prodrug system showed that specific cancer cells modified to express Tb HGPRT were able to convert the non-toxic allopurinol into cytotoxic metabolites, selectively induced apoptosis in five NSCLC cell lines, one murine lung cancer cell line (M27), and four human NSCLC cell lines (A549, H460, H661, H520). However, the bronchioalveolar carcinoma cell line (H322), mouse mammary tumor cell line (DA3), three human breast carcinoma cell lines (MCF7, MDA231, ZR75), and human hepatocellular carcinoma (HepG2) and neuroblastoma (IMR32) cell lines were not affected by the treatment. The reason for the selective efficacy in certain cancer cell lines is unknown. Neither the expression of the Tb HGPRT gene nor the cellular accumulation of the prodrug are responsible for the differences in cytotoxicity observed among the cell lines tested. However, this differential selectivity is an important observation and can be used to improve prodrug-based suicide gene therapy. Other allopurinol derivatives or parasitic enzymes can be explored for therapeutic use. The development of the Tb HGPRT/allopurinol system has the potential to be a therapeutic approach for gene therapy of lung cancer [ 163 ].

Malaria has been found to stimulate the immune system in the host, which is believed to be effective in fighting certain types of cancer [ 36 ]. In a murine LLC model, Plasmodium infection inhibited the growth and metastasis of lung cancer and increased the survival of tumor-bearing mice. Malaria infection induced anti-tumoral effects via triggering a strong immune response, releasing IFN-γ and TNF-α, and the activation of NK cells. It also enhanced the body’s adaptive immune response, leading to increased proliferation of tumor-specific T cells and the activity of CD8 + T cells, as well as inhibiting angiogenesis. Additionally, when combined with a lung cancer DNA vaccine [pcDNA3.1-hMUC1], malaria infection boosted the immune response and had a synergistic effect against the tumor [ 164 ]. Within the same context, Plasmodium infection inhibited the accumulation of immunosuppressive myeloid-derived suppressor cells and Tregs with a consequent elevation of CD8 + T-cell-mediated cytotoxicity within the tumor microenvironment. Furthermore, it inhibited the release of cytokines and chemokines from tumors by releasing exosome-like vesicles rather than direct cell-to-cell contact [ 165 ]. Consequently, intratumoral injection of plasma exosomes derived from Plasmodium -infected mice significantly reduced the growth of LLC in mice. This was achieved by inhibiting tumor angiogenesis through plasma exosomes containing endogenous functional microRNAs [ 160 ].

Parallel to those studies, immunization with genetically attenuated Plasmodium sporozoites activated innate immunity and inhibited lung growth and angiogenesis [ 166 ]. Interestingly, when these attenuated Plasmodium sporozoites were used as a vector for a lung cancer-specific antigen (MAGE-A3), they induced strong MAGE-A3-specific CD8 + T-cell responses, inhibited tumor growth, and increased the survival rate of mice [ 167 ].

Interestingly, Plasmodium circumsporozoite protein significantly inhibited autophagy, making A549 and H1975 lung cancer cell lines more sensitive to Gefitinib showing a significant increase in apoptosis and decreased cell viability. Moreover, in nude mice with lung adenocarcinoma cells xenografts, inhibition of autophagy by Plasmodium circumsporozoite protein suppressed cell growth and increased apoptosis when exposed to Gefitinib. Therefore, Plasmodium circumsporozoite protein could potentially be used as an autophagy inhibitor to enhance the effectiveness of tyrosine kinase inhibitors target therapy for epidermal growth factor receptor-mutant-resistant lung adenocarcinoma [ 168 ].

In the same line, another study found that recombinant circumsporozoite protein has a dose-dependent inhibitory effect on the proliferation of the human lung cancer cell line A549. It also triggered apoptosis by suppressing the activation of the NF-κB [ 169 ]. These findings are similar to the previous research results on the human colon cancer cell line SW480 [ 91 ].

Infection of LLC-bearing mice with the non-lethal P. yoelii was found to inhibit tumor growth. This was achieved via up-regulation of F63, a novel long non-coding RNA (lncRNA) that inhibited the secretion of tumor vascular endothelial growth factor A and endothelial cell clone formation, migration, invasion, and tube formation. The study suggested that F63 could be a promising candidate for gene therapy in lung cancer [ 170 ]. Moreover, combined therapy of Plasmodium immunotherapy ( P. yoelii infection) with radiotherapy significantly inhibited tumor growth and extended the life span of tumor-bearing mice in the subcutaneous model of mouse NSLLC. The combination therapy was more effective in up-regulating the perforin-expressing effector CD8 + T cells and down-regulating the myeloid-derived suppressor cells, thus is considered effective cancer treatment [ 171 ].

Plasmodium chabaudi , a rodent Plasmodium spp., is extensively used to model human infection in laboratory mice. Infection of mice with P. chabaudi in a subcutaneously implanted murine LLC model, either alone or in combination with Gemcitabine treatment significantly inhibited tumor growth and metastasis. The combination therapy was more effective than the monotherapy with significant prolongation of mice survival, and evidence of a synergistic inhibitory effect. This may be partially attributed to the inhibition of the epithelial–mesenchymal transition of tumor cells, because of blocking the CXCR2/TGF-β-mediated PI3K/Akt/GSK-3β/Snail signaling pathway. Hence, it is noteworthy to consider introducing Plasmodium immunotherapy and gemcitabine combination to clinical trials for lung cancer patients [ 172 ].

Based on the ability of Plasmodium to induce a strong anti-tumor effect, clinical trials (Phase 1–2) of Plasmodium immunotherapy for advanced NSCLC ( ClinicalTrials.gov ID NCT02786589 ) have been approved and are ongoing in China [ 36 ]. The clinical trial for advanced NSCLC began in 2016 and was originally supposed to be completed in 2020. However, the estimated study completion has been extended to December 2023, most likely due to the negative impact of the Corona virus epidemic. These trials aim to improve the outcomes for advanced NSCLC patients. Controlled infection with blood-stage Plasmodium vivax by co-administration of antimalarial drugs could obtain a safe level of parasitemia capable of activating the immune response without complications [ 173 ] . Thus, it is expected that genetically modified attenuated human malaria parasites could offer a significant opportunity to be explored as a potential cancer vaccine vector or as a form of immunotherapy for cancer patients.

Regarding the protozoan parasite T. gondii , in vitro study has shown that live T. gondii tachyzoites have a significant inhibitory effect and induced cell apoptosis in non-small-cell lung cancer cells (cell line A549) in a dose-dependent manner with up-regulation of p53 and down-regulation of Bcl-2 gene expression. Numerous in vivo studies have demonstrated the anti-cancer activity of T. gondii against lung cancer. Intralesional injection of formalin-fixed Toxoplasma tachyzoites induced potent anti-tumor effects against LLC [ 159 ]. Furthermore, infection of mice with T. gondii M49 strain inhibited LLC growth in the murine model by inducing Th1 immune responses and inhibiting angiogenesis [ 174 ]. Moreover, T. gondii excretory–secretory antigens inhibited tumor growth in LLC-bearing mice and reduced the proportion of splenic Treg cells in splenocytes [ 175 ]. Interestingly, the dense granule protein of T. gondii (GRA16) demonstrated anti-cancer activity by reducing tumor size in a mouse xenograft model of NSCLC. Interestingly, it enhanced the effects of the anti-cancer drug Irinotecan. The co-administration of Irinotecan and GRA16 promoted the anti-cancer effects of Irinotecan by inhibiting NF-κB and cell cycle arrest induced by GRA16, ultimately increasing the effectiveness of Irinotecan in treating non-small-cell lung carcinoma [ 176 ]. Furthermore, a combination therapy using intratumoral administration of attenuated RH-ΔGRA17 T. gondii strain tachyzoites, along with programmed death ligand-1 (PD-L1) blockade, induced synergistic therapeutic activity. This resulted in the up-regulation of innate and adaptive immune responses, increased lymphocyte infiltration, and sensitized the microenvironment in local and distant tumors to systemic PD-L1 blockade treatment. This ultimately led to a reduction in tumor size and improved survival in most treated mice [ 95 ].

Breast cancer

Table 4 shows the in vitro and in vivo studies of the anti-neoplastic activity of different parasites against breast cancer.

Breast cancer is the most prevalent and heterogeneous malignancy affecting women worldwide. It is also a leading cause of cancer-related deaths in women. The main treatments include surgery, radiation, hormonal therapy, and chemotherapy. However, chemotherapy has adverse effects due to being non-selective in targeting cancer cells. Furthermore, resistance to therapy is a major emerging challenge. Therefore, it is crucial to discover more effective anti-cancer treatments with fewer side effects [ 177 , 178 ].

Antineoplastic activity of helminth parasites against breast cancer

Several studies have shown that hydatid cyst fluid has anti-tumor activity against breast cancer. In vitro study revealed that hydatid cyst fluid antigens, such as antigen B, glycolipid, glycoprotein, and 78 kDa fraction-induced apoptosis in mouse breast cancer cells (4T1 cell line) with the highest apoptotic percentage observed with 78 kDa fraction and glycoprotein fractions [ 179 ]. An in vivo study demonstrated that intraperitoneal hydatidosis in a rat model of Dimethyl Benzanthracene (DMBA) breast cancer reduced the development of breast cancer tumors by 50% [ 180 ]. In other studies, prophylactic immunization with the hydatid cyst wall protein bands (~ 27/28 kDa), that showed cross-reactivity with breast cancer patients’ sera, or crude hydatid cyst wall antigens (laminated layer) caused significant inhibition of 4T1 breast tumor growth, decrease of metastasis, and prolongation of the tumor-bearing mice survival time through a rise in the levels of IL-2, TNF-α, IFN-γ, and IL-4 [ 51 , 181 ]. Mass spectrometry analysis revealed that this ~ 27/28 kDa band has several proteins/polypeptides with a high degree of homology with cancer cell antigens, which are responsible for the cross-reactivity and anti-tumor immune response [ 51 ]. In the same line, similar findings were reported following immunization with hydatid cyst fluid and antigen B on 4T1 breast tumor cells in BALB/c mice. The anti-tumor activity of hydatid cyst fluid and antigen B may be related to the immune responses against these antigens with polarization of the Th1/Th2 ratio toward the Th1 pathway [ 182 ].

Parasites produce a variety of protease inhibitors with different functions primarily to evade their host [ 183 ]. For example, E . granulosus KI-1 (EgKI-1), a member of the Kunitz-type protease inhibitor family, is highly expressed by the oncosphere of E. granulosus . It is a powerful inhibitor of neutrophil elastase and chemotaxis [ 184 ] and was recently granted an international Patent Publication [ 185 ]. A study showed that EgKI-1 can penetrate tumors and effectively interact with and kill tumor cells. In vitro study demonstrated that recombinant EgKI-1 inhibited the growth and migration of breast cancer cells (MCF-7, T47D, and MDA-MB-231 cell lines) in a dose-dependent manner by disrupting the cell cycle and inducing apoptosis. Moreover, in a mouse model of triple-negative breast cancer (MDA-MB-231), rEgKI-1 treatment led to a significant reduction in tumor growth. This suggests that EgKI-1 has the potential to be a promising molecule for the development of anti-cancer therapeutics, as protease inhibitors are important in the treatment of cancer due to their association with carcinogenesis and cancer progression [ 186 ].

The anti-tumor activity of E. granulosus against breast cancer could be related to the mutual cross-reaction that exists between antigens of hydatid cyst and cancer cells. In vitro study demonstrated that hydatid cyst fluid antigens (Antigen B, glycolipid, glycoprotein, 78 kDa fractions cyst antigens, and excretory–secretory antigen of protoscolices) in particular the 78 kDa and glycoprotein fractions induced apoptosis on breast cancer cells (4T1 cell line) [ 179 ]. Additionally, rabbit antisera raised against hydatid cyst antigens (hydatid cyst fluid, germinal and laminated, protoscolex, and excretory–secretory) induced cell death of 4T1 breast cancer cell line [ 187 ]. Moreover, it has been shown using flow cytometry that rabbit antisera raised against hydatid cyst antigens (hydatid cyst wall, protoscolex, and cystic fluid antigens) reacted with breast cancer cells (4T1) [ 51 , 188 ]. Western immunoblotting demonstrated a considerable cross-reactivity between hydatid cyst wall antigens and breast cancer patients’ sera at a specific band (~ 27/28 kDa) [ 51 ]. Also, antisera raised against laminated and germinal layers of hydatid cyst reacted with excretory–secretory products of breast cancer cells. Moreover, a reaction was detected between hydatid cyst antigens (hydatid fluid, laminated and germinal layer antigens, and excretory–secretory antigens of protoscolices) and sera of patients with breast cancers [ 48 ].

Another study also observed cross-reactivity in S. equina parasite and MCF-7 human breast cancer using rabbit anti- S. equina extract and anti-diethylcarbamazine citrate polyclonal IgG antibodies, using indirect ELISA and western blotting. The results revealed the presence of cross-reactive proteins at molecular weights of 75 kDa and 70 kDa, which may correspond to G6PD and HSP70, respectively [ 89 , 126 ]. Further research is required to characterize, purify, and evaluate the efficacy of these shared proteins as potential vaccine candidates for breast cancer treatment.

In another in vitro study, recombinant T. solium calreticulin (rTsCRT) either alone or in combination with 5-fluorouracil inhibited the growth of the breast cancer cell line (MCF7) by interacting with scavenger receptors [ 75 ].

Trichinella spiralis parasite shifts the host immune response from a Th1 profile, characterized by pro-inflammatory cytokines, to a Th2 profile with the release of different cytokines with anti-inflammatory properties. Interestingly, T. spiralis infection successfully inhibited tumor growth and prolonged host survival. In 1970, Weatherly discovered the prolongation of survival rates and reduction of mortality of Swiss mice model of breast tumor when sublethally infected with T. spiralis muscle larvae [ 189 ]. Similar results were also demonstrated by Apanasevich and Britov who reported that T. spiralis infection inhibited the growth of chemically induced mammary gland cancer by 7,12-dimethylbenzo(a)anthracene [ 190 ].

Antineoplastic activity of protozoan parasites against breast cancer

Live attenuated parasites allow the host’s immune system to interact with a wide range of antigens that are important for the development of protective immunity without causing harm. In this context, a study by Caner et al. [ 191 ] demonstrated that intratumoral inoculation of attenuated Leishmania strains ( L. infantum and L. major ) regressed 4T1 breast cancer in BALB/c. This also led to the activation of an anti-tumor immune response, inducing M1 phenotype-macrophages and subsequently triggering the adaptive immune response [ 191 ].

Trypanosoma cruzi epimastigotes lysate showed a direct inhibitory effect on in vitro MCF-7 cells human breast cancer cells [ 192 ]. Studies in animal models have demonstrated that vaccination with T. cruzi epimastigote lysates strongly inhibited chemically induced mammary carcinoma. This vaccination-induced activation of both CD4 + and CD8 + T cells and higher splenocyte cytotoxic responses against tumors. This was associated with an increase in the number of CD11b/c + His48 − MHC II + cells corresponding to macrophages and/or DCs, which exhibited augmented NADPH-oxidase activity. Additionally, antibodies specific for mammary rat cancer cells were capable of mediating antibody-dependent cellular cytotoxicity. This anti-cancer effect was due to an integrated immune response involving both the cellular and humoral components. In the same study, anti- T. cruzi antibodies were cross-reacted with breast cancer cell lines, denoting the existence of shared epitopes between T. cruzi and breast cancer cells [ 52 ]. In other studies, T. cruzi calreticulin (rTcCRT) was documented to have anti-angiogenic and anti-tumor properties, inhibiting the growth of the murine mammary (TA3 MTXR tumor cell line) in vivo [ 193 , 194 ]. Similarly, a study demonstrated that T. cruzi infection and T. cruzi epimastigotes extract inhibited the growth of an aggressive murine mammary adenocarcinoma cell line (TA3-MTXR) in mice. That study concluded that translocated/externalized natural T. cruzi Calreticulin (nTcCRT) played a significant role in the anti-mammary tumor effect during experimental T. cruzi infection [ 195 ]. An in vitro study demonstrated that treating a murine mammary adenocarcinoma cells (TA3 cell line) with rTcCalr enhances phagocytosis and alters the expression of a variety of membrane molecules. This includes decreasing the membrane expression of MHC class II, m-Dectin-1, Galectin-9 and PD-L1, while increasing the expression of Rae-1γ, which is associated with increased tumor immunogenicity [ 196 ].

Interestingly, both the native and recombinant forms of T. cruzi calreticulin showed an anti-mammary tumor capacity in vivo. They were also found to be more effective than human calreticulin in their anti-angiogenic effect as well as in inhibiting endothelial cell migration and differentiation, thus suppressing tumor growth [ 194 , 195 ].

Trypanosoma cruzi P21 is a protein secreted by the parasite and its recombinant form rP21 has various biological properties. These include binding to CXCR4 receptors in macrophages, chemotactic activity of immune cells, and inhibiting angiogenesis [ 197 , 198 ]. A study reported the binding of T. cruzi rP21 to triple-negative breast cancer (MDA-MB-231 cells) cell membrane’s CXCR4 receptors and down-regulating CXCR4 gene expression. This was associated with a decrease in receptors in the cytoplasm of MDA-MB-231 cells, indicating CXCR4 internalization. This internalization probably explains the desensitization of the receptors in these cells. As a result, rP21 was found to reduce migration, invasion, and progression in MDA-MB-231 cells [ 197 ].

In another study, T. cruz i infection showed a high invasion and multiplication rate in the triple-negative breast cancer cell line (MDA-MB-231). This infection contributed to the perpetuation of a cycle of MDA-MB-231 cell proliferation, parasite cell invasion, infected cell lysis, and impaired host cell migration. These findings suggest that molecules from T. cruzi may hinder host cell migration with potential use to avoid metastasis [ 199 ].

The recombinant malarial protein VAR2–hemiasterlin Drug (KT886) Conjugate (VDC886) has shown strong anti-cancer activity in both in vitro and in vivo studies. In in vitro testing, results showed a strong cytotoxic effect on human breast cancer cells (MDA-MB-231 and 4T1 breast cancer cell lines). Moreover, in vivo testing in a highly aggressive syngeneic mouse model of bone metastatic murine breast cancer (4T1), administration of VDC886 resulted in a significant increase in mice survival time with no detectable metastases compared to control mice, all of which died with metastatic disease [ 90 ]. Also, infection with the non-lethal P. yoelii 17XNL strain significantly inhibited tumor growth, and increased the survival rate of mice with triple-negative breast cancer (4T1). These effects might be due to the induction of CD8 + T-cell-mediated anti-tumor immune responses [ 200 ]. A clinical trial of Plasmodium immunotherapy for advanced breast cancer [ NCT03474822 ] has been approved and is currently ongoing in China [ 36 ].

Several studies have shown that T. gondii and its antibodies have an inhibitory effect on the growth of breast cancer [ 187 , 201 , 202 ]. In vitro studies, live T. gondii tachyzoites had a significant dose-dependent inhibitory and cytotoxic effect on MCF-7 cells, a human breast cancer cell line [ 105 , 201 ]. Another study showed that these tachyzoites were able to effectively destroy Her2/Neu-expressing mammary cancer cell lines (TUBO cells) in a dose- and time-dependent manner [ 202 ]. Moreover, rabbit anti- T. gondii antisera also induced significant death of the 4T1 breast cancer cell line [ 187 ]. Additionally, it has been shown by flow cytometry that both rabbit and human anti- T. gondii antisera reacted strongly with breast cancer cells (4T1 and MCF7) [ 53 , 203 ], suggesting the existence of shared epitopes on the surface of cancer cells and Toxoplasma antigens. These findings highlight the potential use of these antibodies in targeted cancer immunotherapy. Similarly, T. gondii anti-cancer activity was reported in several animal studies. Chronic T. gondii infection led to significant resistance to mammary tumor development in C 3 H/ He mice [ 204 ]. Moreover, intratumoral inoculation of an attenuated uracil auxotroph strain of T. gondii directly into the 4T1 tumor stimulated anti-tumor immunity in mice, resulting in inhibition of tumor growth and metastasis, increased survival of the tumor-bearing mice, and increased secretion of IL-12 and IFN-γ in both the serum and tumor microenvironment [ 205 ]. In agreement with the previous results from animal studies, the protective effect of T. gondii infection in breast cancer patients was also reported. In a hospital-based cohort study, Ye et al. [ 206 ] demonstrated a favorable effect of high anti- T. gondii IgG on breast cancer survival, particularly in patients with systemic inflammation and high levels of IL-17 or IL-9. These results support the potential use of attenuated T. gondii in breast cancer immunotherapy [ 206 ].

Neospora caninum ( N. caninum ), an intracellular protozoan parasite, similar to T. gondii and is a major cause of reproductive failure in dairy cattle worldwide. In humans, it has not been shown to cause zoonotic disease, making it a potentially safe microbial anti-cancer therapy [ 207 ]. In an in vitro study, N. caninum was found to invade and multiply within human breast carcinoma cells (MCF-7) and destroy them [ 208 ].

Besnoitia jellisoni ( B. jellisoni ) is a rodent intracellular protozoan parasite closely related to other tissue-cyst-forming apicomplexan parasites such as T. gondii and N. caninum [ 209 ] . Similar to T. gondii infection, chronic infection with B. jellisoni induced significant resistance to mammary tumor development in C 3 H/ He mice [ 204 ].

Hematological malignancies

Table 5 a–d shows the in vitro and in vivo studies of the anti-neoplastic activity of different parasites against hematological malignancies (Leukemia, Lymphomas, Multiple Myeloma, and Mastocytoma).

Leukemia

Leukemia is a group of malignant hematologic disorders. The incidence of the disease is approximately 15 cases per 100,000 individuals. Current treatments for leukemia are not satisfactory, so new therapeutic strategies need to be developed [ 210 ].

Antineoplastic activity of helminth parasites against leukemia

Certain helminth parasites have been found to have anti-leukemia activity. Studies have shown that the recombinant Sj 16 (r Sj 16), a secreted protein from S. japonicum , has been found to significantly suppress the proliferation of murine myelomonocytic leukemia cell line (WEHI-3B JCS) cells in a dose- and time-dependent manner by inducing G1/G0 cell cycle arrest and apoptosis. This is achieved through the activation of the caspase-mediated mechanism by regulating the expression of the Bcl-2 family [ 38 , 211 ].

The protoscolex hydatid cyst somatic antigen showed a similar anti-leukemic effect in vitro by inducing programmed cell death in K562 cells (a human chronic myeloid leukemia cell line) in a dose and time-dependent manner [ 212 ].

Similarly, in other in vitro studies, crude T. spiralis antigen and T. gondii tachyzoites inhibited the proliferation and induced K562 cell apoptosis [ 104 , 213 ]. Interestingly, another study revealed that the excretory/secretory products from muscle larvae T. spiralis induced a dose-dependent proliferative response in U937 cells, an acute myeloid leukemia cell line, at 24 h and 48 h of treatment. However, after 72 h, significant cell death was observed, with a significantly higher apoptotic index than untreated cells [ 214 ]. In addition, peritoneal macrophages from T. spiralis -infected mice 1 week post-infection showed a strong cytotoxic effect on mouse R1 leukemia cells in vitro [ 215 ] .

The anti-leukemia activity was also demonstrated with the somatic antigen of Marshallagia marshalli ( M. marshalli ), a common gastrointestinal nematode worm that infects sheep. It inhibited proliferation and induced apoptosis in human chronic myeloid leukemia K562 cells [ 216 ].

Antineoplastic activity of protozoan parasites against leukemia

Interestingly, Eligio García et al. [ 217 ] demonstrated that the antigenic proteins of T. cruzi are shared with acute lymphoblastic leukemia. This was demonstrated by the reactivity of rabbit polyclonal antibodies against T. cruzi with protein extracts from acute lymphoblastic leukemia cells. This finding suggests an anti-parasitic immune response that also cross-reacts with cancer cells. Therefore, it is important to identify the antigens involved and determine their potential as target cells in cancer therapy [ 217 ].

As regards Plasmodium , a research study showed that VDC886, a hemiasterlin analog (KT886) conjugated to recombinant malaria protein VAR2 (rVAR2), as a drug carrier induced a strong in vitro cytotoxicity to myeloid leukemia cells (KG-1 cell line) [ 90 ].

In another study, infection of mice with the malaria parasite, P. yoelii significantly reduced the growth of WEHI-3 cells in mice. Additionally, there was a marked decrease in tumor cell infiltration in the liver and spleen. Plasmodium inhibited murine leukemia by boosting immune responses. It increased CD3 T-cell surface marker and CD19 B-cell surface marker while decreasing the surface markers of monocytes (CD11b) and macrophages (Mac-3). Additionally, it stimulated the secretion of IFN-γ and TNF-α and enhanced the activity of NK cells and macrophages [ 218 ].

Chronic infection with the intracellular protozoan parasites T. gondii and B. jellisoni induced significant resistance to the development of leukemia in AKR mice [ 204 ] .

Lymphomas

Lymphomas are a type of cancer that starts in the lymphatic system, which is part of the body’s immune system. They account for 3–4% of all cancers and are the seventh-most common form. In children, they are the third most common cancer. Lymphomas occur more frequently in developed countries than in developing countries [ 219 ]. There are two main types of lymphoma: non-Hodgkin, which makes up about 90% of cases, and Hodgkin lymphoma. Non-Hodgkin lymphoma has around 40 subtypes, each with different growth rates and responses to treatment [ 220 ]. Treatment options include chemotherapy, radiation therapy, and monoclonal antibodies. In some cases, stem cell transplant with strong chemotherapy may be necessary if the lymphoma has recurred or is likely to recur in the future [ 221 ].

Antineoplastic activity of helminth parasites against lymphomas

As regards helminth parasites’ anti-neoplastic activity against lymphoma, it has been demonstrated that macrophages from T. spiralis- infected mice had a powerful cytotoxic effect on syngeneic EL-4 lymphoma cells in vitro [ 222 ].

Antineoplastic activity of protozoan parasites against lymphomas

Protozoan parasites such as T. cruzi exhibited an anti-tumor activity against lymphoma. Infection of mice with T. cruzi CH4 strain resulted in the inhibition of growth and metastasis of solid L5178Y-R lymphoma transplanted to BALB/c mice. This effect was more pronounced when the tumor was transplanted during the sub-acute phase of T. cruzi infection, as opposed to the acute phase. The mechanism behind this anti-tumor activity appears to involve the production of cytotoxic/cytostatic substances and cross antibodies against both the parasite and the tumor antigens [ 223 ].

Regarding the Plasmodium parasite , VDC886, a complex formed by conjugating recombinant malaria protein rVAR2 with a hemiasterlin analog (KT886), induced in vitro strong cytotoxicity to MyLa2059 T-cell lymphoma and significantly inhibited the growth of non-Hodgkin’s lymphoma (Karpas 299) in the murine model [ 90 ].

The inhibitory effect of T. gondii on lymphoma growth has been demonstrated in cell culture and mouse models. As early as 1986, formalin-fixed Toxoplasma organisms were found to have a potent anti-tumor effect on EL4 lymphoma in mice, leading to a significant suppression of tumor growth and an increase in lifespan. This effect was more evident compared to Bacillus Calmette-Guerin denoting its powerful immunostimulant effect [ 224 ]. Another study reported that the in vivo treatment with Toxoplasma lysate antigen significantly enhanced the cytotoxicity of feline spleen cells against feline leukemia virus-producing lymphoma cells [ 225 ]. In the same line, T. gondii lysate antigen or its antigenic component, Toxoplasma lysate-Ig8 also demonstrated significant inhibition of tumor growth induced by 20-methylcholanthren in the murine models [ 226 – 228 ] and induced cytotoxic activity on the YAC-1 murine lymphoma cell line [ 226 ].

Additionally, both live T. gondii and Toxoplasma lysate antigen reduced the multidrug resistance of mouse lymphoma cell lines (Mdr L 5718 and Par 5718) making them more susceptible to cytostatic drugs by enhancing drug accumulation through reducing the activity of ATP-dependent efflux pump [ 107 ].

Multiple myeloma

Multiple myeloma is a type of hematological bone marrow malignancy. It arises from the clonal proliferation of defective plasma cells, and this causes harmful effects on multiple organs from the deposition of monoclonal paraproteins. It is currently viewed as a treatable but incurable condition [ 229 ]. First-line therapy usually involves proteasome inhibitors or immunomodulatory drugs. Because of side effects, these medications are usually used in combination with high-dose corticosteroids. Monoclonal antibody therapies are also now available but can also interfere with blood grouping. In fit patients, autologous stem cell transplantation is recommended to consolidate response to the first-line treatment [ 230 ]. Regarding helminth parasites’ anti-neoplastic activity against multiple myeloma, Tsocheva et al . [ 116 ] discovered that biologically active substances isolated from the tissues of F. hepatica had a slight inhibitory effect on myeloma cell culture proliferation.

Interestingly, myeloma-associated antigens have been detected in T. spiralis parasite. Cross-immune responses between antigens of the myeloma cell SP2/0 versus positive sera to T. spiralis , and antigens of T. spiralis versus positive sera to myeloma cell SP2/0 were detected using T. spiralis and myeloma-specific enzyme-linked immunosorbent assays (ELISA). The study identified that the main component of the myeloma-associated antigens was tropomyosin, which is a protein found in T. spiralis myofibrils. Tropomyosin is an acidic protein that is located on the surface and consists of 284 amino acids. Interestingly, when mice were immunized either with tropomyosin or crude antigen of T. spiralis , it resulted in an anti-tumor effect. This was demonstrated by a significant increase in CD4 + , CD8 + T lymphocytes, and CD19 + B lymphocytes. These findings suggest that tropomyosin may have a role in triggering cross-protective immunity [ 231 ]. Furthermore, immunoscreening of a T. spiralis cDNA expression library identified antigen genes responsible for the anti-tumor activity of T. spiralis . They discovered that the antisera raised against a novel gene product of T. spiralis cross-reacted with Sp2/0 myeloma cells. The sequencing analysis revealed that the fragment was 569 bp long and contained an open reading frame. It was predicted that the full-length gene encoded 136 amino acids. This gene known as TS2, had four potential N-Arg dibasic convertase (Nardilysin) cleavage sites, one peptide C-terminal amidation site, and one glycosaminoglycan attachment site. Bioinformatic analysis predicted six antibody epitopes [ 232 ]. Moreover, in another study using suppression-subtractive hybridization, researchers were able to identify genes that were expressed differently between tumor cells from T. spiralis -infected and non-infected mice. The results indicated that genes encoding RpL41, NKTR, Rbbp4, and ANXA2 were enriched and considered possible proteins responsible for the anti-tumor activity of T. spiralis [ 233 ]. Therefore, further investigations are needed to explore the potential use of these novel antigen genes as an anti-myeloma vaccine.

Mastocytoma

Mastocytoma is a rare tumor of mast cells, which are derived from myeloid stem cells and found in connective tissues, mainly in the skin and mucosal linings [ 234 ]. The clonal proliferation of neoplastic mast cells can cause localized and systemic manifestations, known as ‘mastocytosis’ and classified as a myeloproliferative disorder in the WHO classification of tumors of hematopoietic and lymphoid tissues [ 235 ]. In humans, advanced mast cell neoplasms are rare and have a poor prognosis, with limited treatment options available [ 236 ].

Antineoplastic activity of helminth parasites against mastocytoma

Activated macrophages from mice infected with T. spiralis inhibited allogeneic P815 tumor cells, a murine mastocytoma cell line [ 222 ].

Antineoplastic activity of protozoan parasites against mastocytoma

The protozoan parasite T. gondii induced an anti-neoplastic activity against mastocytoma. In an in vitro study, T. gondii lysate antigen demonstrated strong cytolytic activity on P-815 cells [ 226 ].

Connective tissue and bone cancers

Table 6 a, b shows the in vitro and in vivo studies of the anti-neoplastic activity of different parasites against connective tissue and bone tumors (sarcomas and bone tumors).

Sarcomas

Sarcomas are malignant connective tissue tumors. Fibrosarcoma is a type of soft tissue sarcoma that originates from fibroblasts and typically starts in the fascia and tendons of soft tissue but can also occur in bones. Fibrosarcomas can be divided into two types: infantile or congenital fibrosarcomas which rarely metastasize, and adult-type fibrosarcomas which are highly malignant. Treatment for fibrosarcoma usually involves a combination of surgery, chemotherapy, and radiation. However, fibrosarcoma is resistant to chemotherapy and has a high rate of recurrence [ 237 – 239 ]. Therefore, it is important to find new methods to improve the treatment of this tumor. Recent data suggest that immunotherapy may be effective in treating soft tissue sarcomas. This raises hope for novel treatments that target the tumor microenvironment [ 240 ].

Antineoplastic activity of helminth parasites against sarcomas

Both in vivo and in vitro studies have shown that certain helminth parasites can hinder sarcoma growth. For instance, in the murine model, S. mansoni infection-induced resistance against transplantable sarcoma 180 ascites tumor cells [ 241 ].

Live hydatid cyst protoscolices have been found to inhibit proliferation and induce cell death in WEHI-164 fibrosarcoma cells in vitro denoting their strong anti-cancer activity [ 242 ]. Similarly, T. spiralis crude antigens have demonstrated in vitro antiproliferative effect against a murine sarcoma cell line (S180) [ 104 ]. Moreover, in vivo testing has revealed that infection with T. spiralis or treatment of sarcoma-bearing mice with crude extracts of adult and newborn larvae of T. spiralis can inhibit tumor growth under selected conditions of larval dose and tumor challenge interval [ 104 , 243 , 244 ]. Additionally, T. canis egg antigen has been found to inhibit tumor growth in the WEHI-164 fibrosarcoma BALB/c mouse model [ 245 ].

Antineoplastic activity of protozoan parasites against sarcomas

Sphingolipids, a member of the lipid family, play a role in various cellular processes such as cell growth, adhesion, migration, senescence, and programmed cell death. They have shown potential for regulating cell growth and inducing apoptosis in cancer cells, making them a promising target for cancer therapy [ 246 ]. Studies have demonstrated that L. donovani sphingolipid-1, a component of sphingolipids has significant cytotoxic effects on murine sarcoma 180 cells in vitro . It altered mitochondrial homeostasis and activated caspases in a dose- and time-dependent manner [ 247 , 248 ]. In a sarcoma 180 murine model, it improved the survival rate of tumor-bearing mice and reduced tumor growth in a dose-dependent manner. It also inhibited angiogenesis and regulated the expression of matrix metalloproteinases and cytokines making it a potential therapeutic for sarcoma [ 248 ].

Several studies demonstrated the anti-sarcoma effect of T. gondii . Chronic infection with T. gondii significantly induced resistance to the development of sarcoma 180 in Swiss mice [ 204 ]. Similarly, T. gondii antigen has been found to inhibit WEHI-164 fibrosarcoma growth in BALB/c mice [ 245 ].

Interestingly, immunotherapy of fibrosarcoma-bearing mice was induced using DCs that were treated with protein components of T. gondii . Such treatment significantly inhibited tumor growth, improved the survival of the mice, and revealed that the protein components of Toxoplasma were able to increase the capability of DCs. This induced a significant increase in the activity of cytotoxic T cell-mediated anti-tumor response and the infiltration of CD8 + T cells into the tumor microenvironment [ 249 , 250 ]. Furthermore, treatment of mice bearing sarcoma-180 tumors model with T. gondii lysate antigen reduced tumor size and decreased the expression of CD31, an angiogenesis marker within the tumor tissue [ 251 ]. Surprisingly, in an in vitro experiment, three live protozoan parasites were examined for their anti-cancer effects on WEHI-164 fibrosarcoma cells. These parasites were T. gondii tachyzoites, T. vaginalis trophozoites, and L. major promastigotes. It was noticed that only T. gondii showed a decrease in fibrosarcoma cell proliferation and an increase in cell lysis in the cell culture medium. It is interesting to note that although both T. gondii and L. major are intracellular parasites, they have different effects on fibrosarcoma cells [ 252 ].

The anti-tumor activity of Eimeria spp . has been demonstrated in a murine model of sarcoma (S180). Both native and recombinant soluble protein extracts of E. tenella have shown potent immunostimulatory effects, significant anti-tumor activity, and potent IL-12-inducing properties. This was evidenced by a significant reduction in tumor size, increased mice survival, and cure rates of over 80%. Therefore, E. tenella protein could be considered a new type of innate immunity stimulator and may be more therapeutically beneficial than others due to its lack of toxicity even at very high doses [ 253 ]. Likewise, chronic infection with B. jellisoni also s ignificantly induced resistance to sarcoma 180 development in Swiss mice [ 204 ].

Bone tumors

Primary bone tumors are classified as either benign such as osteoma, osteochondroma, or giant cell tumor of bone among others, or malignant such as osteosarcoma, Ewing sarcoma, chondrosarcoma, fibrosarcomas, and others. Bone tumors are challenging to prevent and treat and current methods such as surgery, radiotherapy, and chemotherapy have severe side effects. This highlights the need for new approaches [ 254 , 255 ].

Interestingly, a study found that antigens from hydatid cysts, specifically the crude extract of the laminated layer antigens, reacted with the serum of different bone cancer patients. Two specific antigens, 43 kDa, and 70 kDa, were identified. This suggests that there may be a similarity in the immunogenic antigens between hydatid cysts and different bone cancers [ 256 ].

In another study, anti-TPD52 antiserum was developed against the cross-antigen gene tumor protein D52 (TPD52) found in human osteosarcoma and T. spiralis . This antiserum showed both in vitro and in vivo anti-osteosarcoma activity. It inhibited the proliferation of human osteosarcoma MG-63 cells and induced apoptosis in a dose-dependent manner. In a mouse model of osteosarcoma, the anti-TPD52 antiserum was more effective than the anti- T. spiralis antiserum and enhanced immunity as demonstrated by increased levels of IFN-γ, TNF-α, and IL-12 in the serum, without causing any histopathological damage. Thus, the anti-TPD52 antiserum significantly inhibited osteosarcoma growth by inducing apoptosis and enhancing immunity [ 54 ].

Skin cancers

Table 7 a, b shows the in vitro and in vivo studies of the anti-neoplastic activity of different parasites against skin cancers (Melanoma and Merkel Cell Carcinoma).

Melanoma

Melanoma, a deadly form of skin cancer, is caused by abnormal proliferation of melanocytes. It affects the deep layers of the skin and can easily spread to other tissues. The main cause of melanoma is believed to be exposure to ultraviolet radiation. Recent research has shown that melanoma is not a single disease but a group of diseases with different genetics, histopathological, and clinical characteristics [ 257 , 258 ]. One major challenge in treating melanoma is drug resistance [ 259 ]. However, there have been promising advancements in combined therapy regimens, particularly with the use of immunotherapy and new therapeutics [ 260 ].

Antineoplastic activity of helminth parasites against melanoma

Finding new therapeutic strategies for treating melanoma is an inspiring opportunity for research. According to numerous studies, certain worms and protozoa have shown anti-melanoma activity. For example, E. granulosus , a worm parasite contains compounds that have been found to exhibit anti-tumor activity. In a study, hydatid cyst fluid or excretory–secretory antigen of protoscolices of E. granulosus inhibited melanoma cancer growth in C57 black mice [ 261 ]. Similar results were obtained in the other studies, in which mice-bearing melanoma cancer were treated using live protoscolices, hydatid cyst fluid, or a fraction of cyst fluid. Significant inhibition of tumor growth was observed, along with differences in the levels of measured cytokines such as IL-2, TNF-α, IFN-γ, and IL-4 [ 262 , 263 ]. In vitro, studies demonstrated that hydatid cyst fluid and AgB from hydatid cyst fluid inhibited the proliferation and promoted apoptosis of the A375 human melanoma cancer cells and B16.F10 melanoma cancer cell line, respectively. This was achieved by increasing the mRNA expression of the pro-apoptotic gene BAX, Caspase-9, and Caspase-3, and decreasing the mRNA expression of the anti-apoptotic gene BCL2 [ 264 , 265 ]. Additionally, recombinant E. granulosus Kunitz-type protease inhibitor (EgKI-1) inhibited the growth and migration of melanoma cells (CJM) in a dose-dependent manner [ 186 ].

In another study, the synthetic T. crassiceps cysticerci-derived peptide GK1 showed anti-melanoma activity in a mouse melanoma model of B16-F10 melanoma cells. GK1 is an 18-amino acid peptide that boosts the immune response. The treatment with GK1 significantly prolonged the survival time of melanoma-bearing mice, slowed down tumor growth, and increased tumor necrosis. This suggests that GK1 could be used as a primary or adjuvant component for cancer treatment by stimulating pro-inflammatory cytokines [ 266 ]. Interestingly, when GK1 was combined with anti-programmed death ligand 1 therapy in the mouse melanoma model of B16-F10-luck melanoma cells, the survival time was even longer compared to each treatment alone. Additionally, the combination treatment led to a decrease in TNF-α, IL-4, IL-5, IL-6, and IL-10 serum levels, indicating the beneficial effects of GK1 [ 267 ].

Trichinella spiralis has been found to have an anti-cancer activity against melanoma. In a study, infection of B6D2F1/J mice with T. spiralis followed by its challenge with viable B-16 melanoma cells developed strong anti-neoplastic activity. None of the infected mice showed any signs of neoplasia or developed detectable tumors, while all of the control mice did [ 268 ]. In another study, oral infection of melanoma-bearing C57B1/6 with T. spiralis larvae showed a significant decrease in tumor growth and lung metastases. This was attributed to changes in cytokine regulation, specifically in the levels of CXCL9, CXCL10, and CXCL13 [ 269 ]. Similarly, chronic T. spiralis infection also induced an impressive reduction in tumor size with a longer tumor induction interval in a mouse melanoma model [ 270 , 271 ]. Moreover, the ESPs of the first larval stage of T. spiralis , which is released during the chronic stage of infection, inhibited the survival and induced mild apoptosis of mouse (B16) melanoma cells [ 270 ].

Antineoplastic activity of protozoan parasites against melanoma

In addition to worms, protozoan parasites like the pathogenic/free-living amoeba Acanthamoeba castellanii ( A. castellanii ), L. donovani , T. cruzi , Plasmodium spp., T. gondii , N. caninum , and Babesia microti ( B. microti ) have also shown anti-melanoma activity. An in vitro study demonstrated that Leishmania sphingolipid-1 (LSPL-1) has cytotoxic effects and induces apoptosis in murine and human melanoma cells (B16F10 and A375 cell lines) by regulating the mitochondrial death pathway and generating reactive oxygen species. LSPL-1 up-regulated the expression of p53, p21, NOXA, and PUMA which are involved in p53-mediated apoptosis and bind with Bcl-2 and Bax to induce apoptosis in a concentration- and time-dependent manner [ 247 , 272 , 273 ]. In a B16F10 cell-induced xenograft melanoma murine model, LSPL-1 improved survival time, elicited an immunostimulatory response, and significantly reduced tumor volume in a dose-dependent manner. It also reduced the metastatic flare of angiogenic factors such as VEGF, Ang-2, and CD34 without any deleterious effects on the murine model. Therefore, LSPL-1 can be considered a promising therapeutic of parasitic origin against melanoma and its metastatic properties [ 247 ].

Acanthamoeba castellanii is one of the most common protozoa found in the environment. In humans, it can cause diseases such as keratitis, which can lead to corneal ulceration or blindness, and granulomatous amoebic encephalitis which is often seen in immunosuppressed patients [ 274 ]. An in vitro study has shown that viable A. castellanii and its parasite lysates can induce extensive cytolysis of human melanoma (OCM-1) and murine melanoma (D5.1G4) cells. Additionally, intratumoral injection of viable parasites or parasite lysates into progressively growing subcutaneous melanomas in a mouse model resulted in 83% and 53% reductions, respectively, in tumor masses compared with untreated controls [ 275 ].

As regards T. cruzi , a recombinant protein named J18, which is based on T. cruzi surface molecule gp 82 fused to glutathione- S -transferase (GST) induced cell death and apoptosis in Tm5 melanoma cells in vitro. Moreover, melanoma-bearing C57BL/6 mice treated with J18 at the site of tumor cell inoculation developed smaller tumors and had longer survival compared to control mice [ 42 ].

In another study, immunization with a plasmid encoding survivin, a tumor-associated antigen, along with the administration of systemic recombinant T. cruzi Calreticulin (r Tc CRT), had a synergistic effect on inhibiting tumor growth and inducing humoral anti-r Tc CRT immunity in a B16-F10 melanoma murine model [ 276 ]. In the same line, a further study has shown that T. cruzi derived Toll-Like Receptor (TLR) agonists, such as glycoinositolphospholipids and CpGs oligodeoxynucleotides, are effective immunological adjuvants. They have been found to induce significant protective immunity and cause a significant delay in the growth of B16F10 melanoma cells expressing a cancer-testis antigen (NY-ESO-1) in a murine model. These agonists also stimulate the production of IFN-γ by CD4 + T cells. Additionally, CpGs oligodeoxynucleotides derived from the parasite but not glycoinositolphospholipids triggered a potent IFN-γ response by CD8 + T lymphocytes [ 277 ].

Interestingly, the use of recombinant non-pathogenic clone of T. cruzi as a vaccine vector expressing a cancer-testis antigen (NY-ESO-1), a cancer vaccine candidate, which resulted in strong and long-term T-cell-mediated immunity and solid protection against melanoma in mice [ 278 ]. Additionally, its combination with blockade of Cytotoxic T Lymphocyte Antigen 4 resulted in a significant therapeutic response. This combination enhanced the frequency of NY-ESO-1-specific effector CD8 + T cells producing IFN-γ and promoted lymphocyte migration to the tumor infiltrate, ultimately controlling the development of an established melanoma in the murine model [ 279 ].

Research studies on the anti-cancer effects of the Plasmodium parasite on melanoma have shown promising results. Animal studies have demonstrated that infection with the 17XL strain of P. yoelii significantly delayed the occurrence of tumors and inhibited the growth of melanoma in the B16F10 tumor cells melanoma model [ 280 ]. Additionally, VDC886, a hemiasterlin analog (KT886) conjugated with the refined malaria protein VAR2, has shown anti-cancer activity in various types of cancer, including strong cytotoxicity to C3 human and B16 murine melanoma cells [ 90 ]. Furthermore, malaria-mimicking erythrocyte nanoparticles (MMENPs), a lipid catcher-tag conjugation system for the functionalization of erythrocyte membrane-coated drug carriers with recombinant VAR2 CSA (rVAR2), loaded with the anti-cancer drug docetaxel (DTX) have been shown to specifically target and kill melanoma cells in vitro . They also demonstrate effective targeting and therapeutic efficacy in a xenografted melanoma animal model [ 281 ]. Similarly, a study developed a recombinant VAR2CSA peptide (rVAR2)-modified activated platelet-mimicking nanoparticles (rVAR2-PM/PLGA-ss-HA) by coating the surface of disulfide-containing biodegradable PLGA conjugate nanoparticles (PLGA-ss-HA) with an activated platelet membrane. Loading these nanoparticles with the chemotherapy drug, DTX, exhibited a significant synergistic and active tumor-targeting, anti-neoplastic effect against primary and lung metastasis in a mouse model of melanoma (B16F10). It significantly reduced the volume and weight of the primary tumor, decreased the number of lung metastasis nodules, and induced a high level of tumor cell apoptosis. This synergistic active targeting of tumor cells depends on the activated platelet membrane and chondroitin sulfate receptors on the tumor surface, regardless of their location. Once these nanoparticles are endocytosed and become inside the tumor cells, they release, DTX, resulting in the death of tumor cells. This study suggests that the rVAR2-decorated activated platelet-targeting nanoparticles with controlled drug release could be an effective strategy for treating both primary and metastatic cancer [ 282 ].

Several studies have shown that T. gondii effectively inhibits melanoma growth. Syngeneic C57BL/6 mice infected with T. gondii on the same day of B16.F10 melanoma cells implantation experienced a significant suppression of melanoma growth and strong systemic suppression of angiogenesis [ 283 ]. Similarly, treatment of B16 melanoma-bearing mice with T. gondii excretory–secretory antigens suppressed tumor growth and led to a decrease in CD4 + CD25 + Treg cells and an increase in NK cells [ 284 ]. Additionally, two protein fractions A1 and C14 of Toxoplasma tachyzoite antigens were identified as potent activators of DCs, with A1 proving to be more effective than C14 in inducing an immune response inducing slowing tumor growth and prolonged mice survival time [ 285 ].

The use of non-pathogenic live protozoan parasites as anti-cancer therapeutic approaches has gained global attention. Live organisms have been found to elicit a much stronger anti-tumor effect than dead ones. Several studies have shown that intratumoral injection with mutant T. gondii strain can enhance anti-tumor immunity. In one study, treatment of melanoma-bearing mice with the non-replicating uracil auxotroph strain of T. gondii (cps strain) effectively halted tumor growth and induced a systemic anti-tumor immune response, while also modifying the tumor microenvironment [ 286 ]. Similar results were obtained with intratumoral administration of attenuated T. gondii mutants lacking two lactate dehydrogenases (ME49 Δldh1–Δldh2 ), which repressed the growth of established tumors and inhibited lethal tumor development in a mouse melanoma model [ 287 ]. Furthermore, intratumoral injection of attenuated RH-ΔGRA17 mutant T. gondii tachyzoites boosted anti-tumor immunity and the effectiveness of checkpoint inhibition therapy. This significantly extended the survival of mice and suppressed tumor growth in both targeted and distal tumors in pre-clinical mouse models of melanoma tumors with better treatment outcomes compared with monotherapy with Toxoplasma [ 95 ].

Interestingly, a study investigated the reactivity of different antibodies with mouse melanoma cells using flow cytometry. Surprisingly, only anti- T. gondii antiserum reacted strongly with mouse melanoma cells, suggesting the possibility of shared antigens between Toxoplasma and melanoma cells. Antibodies against T. vaginalis , hydatid cyst fluid, and protoscolice antigens did not show significant reactivity with these cells [ 53 ].

For the other coccidian parasite, N. caninum , a study in a C57BL/6 mouse melanoma model showed that intratumoral and distal subcutaneous injections of parasite tachyzoites had a significant inhibitory effect on tumor growth, resulting in over 50% of tumor cells being dead. This treatment also increased the infiltration of CD8 + T cells and macrophages, as well as the mRNA expression levels of IL-12, IFN-γ, IL-2, IL-10, TNF-α, and PD-L1 in the tumor microenvironment. In the spleen of tumor-bearing mice, IL-12 and IFN-γ levels were also increased. Overall, N. caninum inhibits B16F10 melanoma by activating strong immune responses and directly destroying cancer cells [ 288 ].

Since 85% of advanced-stage melanoma patients have lung metastases, which is the leading cause of their death, a study was conducted to investigate the potential of intranasal administration of N. caninum or engineered N. caninum to secrete human interleukin IL-15/IL-15Rα in the microenvironment, in a syngeneic C57BL6 mouse model of B16-F10 melanoma lung metastases. The study demonstrated that the engineered N. caninum was more effective than wild N. caninum in preventing further progression of lung metastases. In mice treated with the engineered parasite, only 0.08% of the lung surface had metastases, compared to 4.4% in wild-type N. caninum treated mice and 36% in untreated mice. The control of tumor development was associated with a significant increase in NK cells, CD8 + T cells, and macrophages in the lung. Additionally, the macrophages showed polarization toward an anti-tumoral M1 phenotype. This study demonstrates the potential of engineered N. caninum as a safe and effective immunotherapeutic approach for the treatment of metastatic solid cancers, which currently have limited treatment options [ 289 ].

Babesia microti , an intraerythrocytic protozoan parasite, is transmitted through the bite of an infected Ixodes tick. It primarily infects small rodents but can also infect humans which are dead-end hosts. Most infections are asymptomatic and clinical recovery usually occurs [ 290 ]. It has been shown in an in vivo study that mice infection with B. microti inhibited the growth of melanoma in tumor-bearing mice and prolonged their survival time. Babesia microti stimulated the immune system and induced polarization of immunosuppressive M2 macrophages to pro-inflammatory M1 macrophages. This led to an increase in the number of macrophages, CD4 + T cells, the proportion of CD4 + T cells, and M1 macrophages as well as inhibition of angiogenesis in the tumor microenvironment [ 291 ].

Merkel-cell carcinoma (MCC)

Merkel-cell carcinoma is a rare and aggressive form of skin cancer that affects about three people per million in the population. This cancer affects the epidermis and often spreads to lymph nodes and organs. Risk factors for MCC include exposure to ultraviolet light, weakened immune system, age, and infection with the Merkel-cell polyomavirus. Surgical excision with a safety margin is the primary treatment for early cases, but it often recurs. Advanced MCC carcinoma may respond to chemotherapy, but the responses are usually temporary. Immunotherapies have shown promise in treating advanced-stage or chemotherapy-resistant MCC [ 292 , 293 ].

Neospora caninum displayed a highly effective and non-toxic anti-cancer activity against MCC. It could infect, multiply, and destroy human tumor Merkel cells [The WaGa (RRID:CVCL E998)]. In a model of NOD/SCID mice-bearing human MCC, intratumoral injection of N. caninum showed strong efficacy in destroying cancer cells and triggering potent anti-tumor immune responses, resulting in a threefold reduction in tumor size. This study highlights the potential clinical application of using N. caninum as an oncolytic protozoan in human medicine [ 294 ].

Miscellaneous cancers

Table 8 a–e shows the in vitro and in vivo studies of the anti-neoplastic activity of different parasites against miscellaneous cancer subtypes (Ovarian Cancer, Cervical Cancer, Prostate Cancer, Neuroglial and Neural Crest Cancers, Thymoma and Head and Neck Squamous Cell Carcinoma).

Gynecological cancers

Ovarian cancer Ovarian cancer is the leading cause of death among women with gynecological cancers and the fifth most common cause of death among women in general [ 295 ]. The standard treatment includes surgery and platinum-based chemotherapy, but there has been increasing use of anti-angiogenic Bevacizumab and Poly(ADP-ribose) polymerase (PARP) inhibitors in the past decade [ 296 ]. Unfortunately, most of the cases are diagnosed at an advanced stage, which leads to poor outcomes. Additionally, there is a high rate of recurrence after the initial treatment with these relapsed cases being less curable and more likely to experience treatment failures [ 297 , 298 ]. Therefore, there is a pressing need for new and effective treatment options based on a better understanding of the molecular characteristics of this cancer [ 299 ].

Antineoplastic activity of helminth parasites against ovarian cancer:

A research study has shown that helminth parasites, specifically recombinant T. solium Calreticulin (r Ts CRT), have demonstrated anti-cancer activity against ovarian cancer. An in vitro study has shown that r Ts CRT inhibits the growth of the ovarian cancer cell line (SKOV3) by interacting with scavenger receptors in a dose-dependent manner [ 75 ].

Antineoplastic activity of protozoan parasites against ovarian cancer:

For protozoan parasites, cps is an avirulent non-replicating uracil auxotroph strain of T. gondii that has shown promising anti-neoplastic activity. When administered intraperitoneally, cps triggers the rejection of established ID8-VegfA tumors, which is an aggressive xenograft model of ovarian carcinoma. Cps preferentially invades tumor-associated antigen-presenting cells in the ovarian carcinoma microenvironment and restores their ability to trigger potent anti-tumor CD8 + T-cell responses. The therapeutic benefit of cps treatment relies on the expression of IL-12, but it is unexpectedly independent of MyD88 signaling. Thus, applications of cps as an immunotherapeutic agent might be helpful to reawaken natural immunity in the immunosuppressive microenvironment of some solid tumors [ 300 ] . Additionally, secretion of rhoptry and dense granule effector proteins by the non-replicating T. gondii uracil auxotrophs activated anti-tumor immunity through host responses involving CD8α + DCs, the IL-12/IFN-γ Th 1 axis, as well as CD4 + and CD8 + T cells and reversed immune suppression in the tumor microenvironment [ 301 ].

Interestingly, in an in vitro experiment, extracts of T. gondii and L. major inhibited the proliferation of susceptible (A2780) and resistant (A2780-CP) ovarian cancer cell lines to cisplatin due to their complex excretion/secretion antigens [ 302 ].

Cervical cancer Worldwide, cervical cancer is both the fourth-most common type of cancer and a contributor to cancer-related deaths in women. Infection with helminths has been linked to an increase in human papillomavirus (HPV) prevalence, and persistent HPV infection is responsible for nearly all new cervical cancer cases [ 303 ].

Antineoplastic activity of helminth parasites against cervical cancer:

Despite the increased incidence of cervical cancer in helminth endemic areas, several in vitro and in vivo studies demonstrated the anti-neoplastic activity of certain helminths against cancer cervix. In vitro studies showed that both recombinant E. granulosus Kunitz-type protease inhibitor (EgKI-1) and recombinant T. solium Calreticulin (rTsCRT) either alone or in combination with 5-fluorouracil inhibited the growth and migration of cervical epithelial adenocarcinoma (HeLa) cells (HPV18-positive epithelial adenocarcinoma cells) in a dose-dependent manner. This was achieved through disruption of the cell cycle and triggering of apoptosis by EgKI-1 whereas, rTsCRT interacted with scavenger receptors [ 75 , 186 ]. Also, Nippostrongylus brasiliensis ( N. brasiliensis ) third-stage larvae (L3), a rodent hookworm parasite, reduced cell migration of HeLa, Ca Ski (HPV16 positive epithelial epidermoid carcinoma cells) and C33-A (HPV negative epithelial carcinoma cells) cervical cancer cell lines. N. brasiliensis L3 antigen decreased HPV type 16 (HPV16) pseudovirion internalization and reduced expression of vimentin and N-cadherin which are associated with the transition of epithelial cells to a more invasive and metastatic mesenchymal cell type. Moreover, in vivo testing revealed that infection with N. brasiliensis L3 can systemically alter genital tract mesenchymal markers in a manner that may impair cervical cancer cell progression. This was demonstrated by a significant reduction in vimentin expression within the female genital tract in a murine model [ 61 ].

As for the other helminth T. spiralis , biologically active substances isolated from the livers of T. spiralis -infected rats showed a mild inhibiting effect on the growth of human cervical carcinoma HeLa cells, although they had a strong inhibitory effect on Graffi myeloid tumor cells [ 304 ].

Antineoplastic activity of protozoan parasites against cervical cancer:

Numerous in vitro studies have demonstrated the anti-neoplastic activity of T. vaginalis on cervical cancer cell lines. In one study, the culture supernatant of T. vaginalis inhibited the growth of HeLa cervical cancer cells by inhibiting proliferation and promoting apoptosis [ 305 ]. In another study, live T. vaginalis isolate T016 and its excretory–secretory product induced apoptosis of human cervical cancer cells (SiHa cells), and vaginal epithelial cells (MS74 cells) in a parasite-dose-dependent manner through the induction of mitochondria-dependent apoptosis via the dissociation of Bcl-xL/Bim and Mcl-1/Bim complexes [ 306 ]. This is consistent with other studies that have implicated the involvement of the mitochondria-dependent intrinsic apoptotic pathway through an NF-κB-regulated, mitochondria-mediated pathway involving the activation of reactive oxygen species [ 307 , 308 ] and the promotion of endoplasmic reticulum stress-mediated mitochondrial apoptosis via the IRE1/ASK1/JNK/Bcl-2 family protein pathways [ 308 ].

Prostate cancer

Prostate cancer is a major health concern for men with poor prognosis for advanced castration-resistant prostate cancer. In the early stages, prostate cancer is symptomless. However, as the tumor grows, it can cause erectile dysfunction, blood in the urine or semen, and difficulty in urinating [ 309 , 310 ]. In some cases, prostate cancer can spread to other parts of the body, particularly the bones and lymph nodes causing severe pain, leg weakness, or paralysis, and eventually leading to death [ 311 ].

Research studies have shown that certain protozoan parasites, including T. vaginalis , Plasmodium , and T. gondii , can induce an outstanding anti-neoplastic activity against prostate cancer. In vitro experiments have demonstrated that the culture supernatant of T. vaginalis inhibited the proliferation and promoted apoptosis of PC-3 and DU145 prostate cancer cell lines cells, through up-regulation of the antiproliferative molecule p21 and down-regulation of the anti-apoptotic molecule Bcl-2 [ 312 ]. Similarly, the refined malaria protein rVAR2–drug conjugates, recombinant rVAR2-DT fusion protein [genetically fused the cytotoxic domain of Diphtheria toxin (DT388) to rVAR2], and VDC886 [hemiasterlin analog (KT886) conjugated to rVAR2] demonstrated strong cytotoxicity to human prostate cancer cells (PC-3). Additionally, it induced significant inhibition of the growth of the metastatic castration-resistant prostate cancer cell line, PC-3 in the mouse tumor xenograft model. Importantly, these conjugates were found to be safe with no signs of toxicity to the kidney or liver tissues in the murine animal model [ 90 ]. Also, T . gondii tachyzoites showed an inhibitory effect on DU-145 prostate cancer cell line proliferation [ 105 ].

Neuroglial and neural crest cancers

Table 8 c shows the in vitro and in vivo studies of the anti-neoplastic activity of different parasites against neuroglial and neural crest cancers (Gliomas, Medulloblastoma, Ependymoblastoma, and Neuroblastoma).

Gliomas

Gliomas are the most common type of primary brain tumor in adults, accounting for 40% of all central nervous system tumors. Treatment of gliomas requires a multidisciplinary approach involving surgery, radiotherapy, and chemotherapy. The choice of treatment modality depends on the type of glioma, which is determined by clinical-histological features, molecular evidence, and anticipated prognosis. However, progress in improving survival outcomes for gliomas is still limited and challenging. Therefore, it is important to explore novel therapies [ 313 , 314 ].

Antineoplastic activity of helminth parasites against gliomas:

The anti-cancer effects of T. spiralis have been studied in gliomas. Liu and colleagues demonstrated that T. spiralis infection had anti-neoplastic activity against glioma in BALB/C mice, and that effectiveness was dependent on the parasite load [ 315 ].

Antineoplastic activity of protozoan parasites against gliomas

A research group discovered that T. vaginalis purine nucleoside phosphorylase ( Tv PNP) improved the cleavage of F-araAMP or deoxyadenosine analogs used for cancer therapy. In a human glioma D54 xenograft murine model stably transduced with Tv PNP (D54- Tv PNP) showed significant anti-tumor effects when F-araAMP was administered systemically or intratumorally, with catalytical efficiency 25 times greater than Ec PNP [ 316 ].

In another study, VDC886, a refined malaria protein conjugated with a cytotoxic compound, exhibited strong cytotoxicity to glioma cells in vitro [ 90 ]. In orthotopic and subcutaneous models of mouse glioma (GL261), immunotherapy with the non-lethal P. yoelii , either alone or in combination with radiotherapy, induced synergistic anti-tumor effects. The combination therapy significantly slowed tumor growth and prolonged the life span of tumor-bearing mice more than monotherapy. This was achieved by up-regulating the perforin-expressing effector CD8 + T cells and down-regulating the myeloid-derived suppressor cells. Most importantly, the combination therapy was able to cure approximately 70% of gliomas. Therefore, it is important to consider introducing this combination therapy to clinical trials for the treatment of glioma [ 171 ].

Similarly, the T. gondii lysate antigen has been found to have anti-neoplastic activity against gliomas in both in vitro and in vivo studies. In the in vitro study, it was observed that the Toxoplasma lysate antigen suppressed the proliferation and invasion of two human glioma cells, U373MG and U87MG, in a dose-dependent manner. At high concentrations, Toxoplasma lysate antigen also induced apoptosis in the glioma cells. In the in vivo study, the Toxoplasma lysate antigen decreased tumor growth in athymic nude mice that were transplanted with human malignant glioma cells. Additionally, the addition of Quil-A to the Toxoplasma lysate antigen treatment significantly enhanced its anti-tumor effects [ 317 ].

Medulloblastoma

Medulloblastoma is the most common malignant brain tumor in children, originating from the cerebellum. Current treatment involves surgery, chemotherapy, and radiation therapy. This multimodal approach has improved long-term survival rates for 70%–80% of patients. However, approximately 30% of patients still do not survive, and those who do, often experience long-term side effects that affect their quality of life [ 318 ].

One of the challenges in treating medulloblastoma is the lack of T-cell infiltration and a supportive tumor microenvironment which hinders immunotherapy. However, a study by Nguyen et al. [ 319 ] showed that in a mouse model of medulloblastoma, T. gondii infection reduced tumor incidence. This infection attracted T cells to the brain tumors and transformed the non-supportive tumor microenvironment into a supportive one for T cells. The study also detected an increase in IFN-γ and IFN-γ-driven genes in the tumors indicating the presence of Th 1 immunity in the tumor microenvironment [ 319 ].

Ependymoblastoma

Ependymoblastoma is a rare and highly malignant brain tumor that primarily affects children and significantly impacts their quality of life. Most ependymoblastomas are located in the supratentorial region of the brain, followed by the infratentorial region. In rare cases, ependymoblastomas can be found outside the central nervous system, such as in the sacrococcygeal region, rectovaginal space, or ovaries. The prognosis for ependymoblastomas is very poor. Due to the limited number of case reports and original studies, there are no standardized therapeutic methods for treating ependymoblastoma [ 320 , 321 ].

Interestingly, in a C57BL/6J mouse model of ependymoblastoma, infection with T. gondii resulted in a significant reduction in tumor growth. The infected mice showed a strong inflammatory response surrounding the tumor growth with more necrosis per unit area compared to the control mice. Furthermore, peritoneal macrophages from Toxoplasma -infected mice were found to be cytotoxic to ependymoblastoma cells in vitro, while those from control mice were not [ 322 ].

Neuroblastoma

Neuroblastoma is the most frequently diagnosed cancer in children during the first year of life. It is an embryonic autonomic nervous system tumor usually found in the adrenal glands but can also occur in other areas, such as the head, chest, neck, abdomen, and spine. Treatment options include observation, surgery, radiation, chemotherapy, immunotherapy, or stem cell transplantation [ 323 , 324 ].

Several studies have shown that certain parasite derivatives can inhibit the growth of tumor cells by stimulating the immune response. Interestingly, Eligio García et al. [ 217 ] discovered the presence of antigenic proteins of T. cruzi shared with neuroblastoma cells. By confocal microscopy assay, the presence of antigenic proteins by immunodetection in neuroblastoma cells reacted with antibodies against T. cruzi suggesting, a cross-reactive immune response [ 217 ]. Such finding has valuable implications for the discovery of novel molecules of parasitic origin targeting oncogenic cells.

Thymoma

Thymoma is a rare neoplasm that develops from the epithelial cells of the thymus. It makes up 20% of tumors in the mediastinal and is the most common tumor in the anterior mediastinum. Although it usually has an indolent growth pattern, thymoma can invade nearby tissues with intrathoracic recurrences frequency. It is often linked to various immune and non-immune-related paraneoplastic syndromes. The main treatment for thymoma is surgery to completely remove the tumor. Inoperable patients receive chemotherapy first followed by reassessment for surgery, and radiation therapy may also be recommended. New treatment approaches are currently being explored [ 325 ].

Preliminary promising results from experimental studies have shown that N. caninum , a non-pathogenic protozoan parasite in humans, could be a promising candidate to enrich the repository of anti-cancer immunotherapies. In an in vitro study N. caninum (NC1 strain) tachyzoites successfully infected and multiplied inside murine thymoma cells (cell line EG7) and caused their lysis. In a mouse model wild-type murine thymoma EG7, treatment via subcutaneous injection of N. caninum tachyzoites either in or far from the tumor resulted in strong anti-tumor immunity and significant inhibition of tumor growth, often leading to complete eradication. Analysis of immune responses revealed that N. caninum could destroy infected cancer cells, reactivate the suppressed immune cells, and activate the systemic immune system by generating a protective anti-tumor response dependent on NK cells, CD8+ T cells and associated with strong IFN-γ secretion in the tumor microenvironment. Additionally, modifying N. caninum to secrete the IL-15/IL-15Rα in the microenvironment significantly enhanced its immunological properties.

In the same study, the authors compared the anti-tumor capacity of N. caninum to that of T. gondii (RH strain), a naturally infectious parasite of rodents and humans known to have anti-tumor activity. Intra-tumoral inoculation of T. gondii tachyzoites induced a strong inhibition of tumor development and complete eradication of tumors in some mice 25 days post-treatment. Therefore, both the apicomplexan protozoan parasites, N. caninum and T. gondii , have similar anti-tumor properties against murine thymoma EG7 tumor regardless of whether the mice are a natural or non-natural host of the parasite used. Interestingly, after 18 days post-treatment, N. caninum was completely cleared from the tumor, spleen, brain, and liver, indicating a natural clearance of N. caninum by the mouse immune system. In contrast, T. gondii was still detected in the tumor 25 days post-treatment, and its quantity was 200-fold the initial injected dose, indicating its high ability to multiply and persist compared to N. caninum , despite similar anti-tumor efficacy.

These results further support the potential of using a non-naturally infectious agent as a therapeutic due to its strong anti-tumor properties and natural clearance, highlighting its safety. Thus, N. caninum could be used as an oncolytic protozoan and engineered strains of N. caninum have the potential to be used to either secrete anti-tumor effectors or express proteins at its surface, expanding the potential clinical applications of N. caninum to a wide range of cancer therapies [ 294 ].

Head and neck squamous cell carcinoma

Head and neck squamous cell carcinoma refers to cancers that typically originate from the mucosal epithelium of the oral cavity, pharynx, and larynx. Risk factors for oral cavity and larynx cancers include tobacco use, alcohol abuse, or both, while pharynx cancers are increasingly linked to human papillomavirus (HPV) infection, particularly HPV-16. Treatment usually includes surgery, chemoradiotherapy, EGFR monoclonal antibody, and immune checkpoint inhibitors. Current efforts are focused on identifying more effective and less toxic therapies [ 326 ].

Interestingly, Parker and colleagues studied the effect of T. vaginalis purine nucleoside phosphorylase ( Tv PNP), an enzyme for the activation of deoxyadenosine analogs. In human head and neck squamous cell carcinoma, (FaDu) xenografts expressing Tv PNP (FaDu- Tv PNP) in nude mice, exhibited robust tumor regressions. Tv PNP was found to be more efficient than Ec PNP for activating deoxyadenosine analogs [ 316 ].

Therefore, parasites should be thoroughly explored as the upcoming era of anti-neoplastic agents. Advancements in technology can help address challenges, such as standardizing parasite components, optimizing their delivery methods, and elucidating their mechanisms of action. Assessment of the safety profiles of these novel therapies and advancing promising candidates to clinical trials is a noteworthy step in developing novel, nature-based cancer therapeutics that can revive hope for cancer therapy.

Conclusion

The aforementioned data highlight the promising anti-neoplastic activity of certain parasites and their derivatives against various cancers. Parasites hold promise to contribute to the development of advanced cancer treatments, including immunotherapeutics as highly immunogenic cancer vaccines, therapeutic antibodies, and immunomodulators, among others. They also offer opportunities for gene therapy, targeted therapy, synergistic combination therapies, and combating drug resistance. Thus, funding agencies must support multidisciplinary research projects involving different scientific disciplines in collaboration with the pharmaceutical industry to accelerate this process to fight cancer.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author contributions

M.M. E., A. E. S., N. E.S.: the authors contributed equally to all aspects of the article.

Funding

Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB). This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The authors declare that no funds, grants, or other supports were received during the preparation of this manuscript.

Availability of data and materials

No datasets were generated or analyzed during the current study.

Declarations

Competing interests

The authors declare no competing interests.

References

1. Sung H Ferlay J Siegel RL Laversanne M Soerjomataram I Jemal A Bray F Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 2021 71 209 249 10.3322/caac.21660 33538338 Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. 33538338 10.3322/caac.21660

2. PAHO-WHO. World cancer day 2023: close the care gap. 2023.

3. Schirrmacher V From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment Int J Oncol 2019 54 2 407 419 10.3892/ijo.2018.4661 30570109 PMC6317661 Schirrmacher V. From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment. Int J Oncol. 2019;54(2):407–19. 10.3892/ijo.2018.4661. 30570109 10.3892/ijo.2018.4661 PMC6317661

4. Kozakiewicz P Grzybowska-Szatkowska L Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma Oncol Lett 2018 15 7497 7505 10.3892/ol.2018.8300 29725456 PMC5920345 Kozakiewicz P, Grzybowska-Szatkowska L. Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma. Oncol Lett. 2018;15:7497–505. 10.3892/ol.2018.8300. 29725456 10.3892/ol.2018.8300 PMC5920345

5. Nagase H Kato T Yoshimoto T State-of-the-art cancer immunotherapies Int J Mol Sci 2024 25 5 2532 10.3390/ijms25052532 38473780 PMC10931254 Nagase H, Kato T, Yoshimoto T. State-of-the-art cancer immunotherapies. Int J Mol Sci. 2024;25(5):2532. 10.3390/ijms25052532. 38473780 10.3390/ijms25052532 PMC10931254

6. Roy R Singh SK Misra S Advancements in cancer immunotherapies Vaccines 2022 11 1 59 10.3390/vaccines11010059 36679904 PMC9861770 Roy R, Singh SK, Misra S. Advancements in cancer immunotherapies. Vaccines. 2022;11(1):59. 10.3390/vaccines11010059. 36679904 10.3390/vaccines11010059 PMC9861770

7. Zhang Y Zhang Z The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications Cell Mol Immunol 2020 17 807 821 10.1038/s41423-020-0488-6 32612154 PMC7395159 Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17:807–21. 10.1038/s41423-020-0488-6. 32612154 10.1038/s41423-020-0488-6 PMC7395159

8. Stiemsma LT Reynolds LA Turvey SE Finlay BB The hygiene hypothesis: current perspectives and future therapies ImmunoTargets Ther 2015 4 143 157 10.2147/itt.s61528 27471720 PMC4918254 Stiemsma LT, Reynolds LA, Turvey SE, Finlay BB. The hygiene hypothesis: current perspectives and future therapies. ImmunoTargets Ther. 2015;4:143–57. 10.2147/itt.s61528. 27471720 10.2147/ITT.S61528 PMC4918254

9. Bakhshani A Parande Shirvan S Sadr S Maleki M Haghparast A Borji H Evaluating the Toxocara cati extract as a therapeutic agent for allergic airway inflammation Immun Inflamm Dis 2024 12 6 e1307 10.1002/iid3.1307 38860753 PMC11165684 Bakhshani A, Parande Shirvan S, Sadr S, Maleki M, Haghparast A, Borji H. Evaluating the Toxocara cati extract as a therapeutic agent for allergic airway inflammation. Immun Inflamm Dis. 2024;12(6): e1307. 10.1002/iid3.1307. 38860753 10.1002/iid3.1307 PMC11165684

10. Conti M Repurposing infectious pathogen vaccines in cancer immunotherapy Drug repurposing 2020 London IntechOpen 1 14 Conti M. Repurposing infectious pathogen vaccines in cancer immunotherapy. In: Drug repurposing. London: IntechOpen; 2020. p. 1–14.

11. Waldman AD Fritz JM Lenardo MJ A guide to cancer immunotherapy: from T cell basic science to clinical practice Nat Rev Immunol 2020 20 1 18 10.1038/s41577-020-0306-5 32433532 PMC7238960 Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20:1–18. 10.1038/s41577-020-0306-5. 32433532 10.1038/s41577-020-0306-5 PMC7238960

12. Riccardo F Bolli E Macagno M Arigoni M Cavallo F Quaglino E Chimeric DNA vaccines: an effective way to overcome immune tolerance Cancer vaccines 2017 Cham Springer 99 122 10.1007/82_2014_426 25294003 Riccardo F, Bolli E, Macagno M, Arigoni M, Cavallo F, Quaglino E. Chimeric DNA vaccines: an effective way to overcome immune tolerance. In: Cancer vaccines. Cham: Springer; 2017. p. 99–122. 10.1007/82_2014_426. 10.1007/82_2014_426 25294003

13. Mellman I Coukos G Dranoff G Cancer immunotherapy comes of age Nature 2011 480 7378 480 489 10.1038/nature10673 22193102 PMC3967235 Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480–9. 22193102 10.1038/nature10673 PMC3967235

14. Darani HY Yousefi M Parasites and cancers: parasite antigens as possible targets for cancer immunotherapy Future Oncol 2012 8 12 1529 1535 10.2217/fon.12.155 23231515 Darani HY, Yousefi M. Parasites and cancers: parasite antigens as possible targets for cancer immunotherapy. Future Oncol. 2012;8(12):1529–35. 10.2217/fon.12.155. 23231515 10.2217/fon.12.155

15. Bhatla N Aoki D Sharma DN Sankaranarayanan R Cancer of the cervix uteri Int J Gynecol Obstet 2018 143 22 36 10.1002/ijgo.13865 30306584 Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. Int J Gynecol Obstet. 2018;143:22–36. 10.1002/ijgo.13865. 10.1002/ijgo.12611 30306584

16. Kao J-H Hepatitis B vaccination and prevention of hepatocellular carcinoma Best Pract Res Clin Gastroenterol 2015 29 6 907 917 10.1016/j.bpg.2015.09.011 26651252 Kao J-H. Hepatitis B vaccination and prevention of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 2015;29(6):907–17. 26651252 10.1016/j.bpg.2015.09.011

17. Kidner TB Morton DL Lee DJ Hoban M Foshag LJ Turner RR Combined intralesional Bacille Calmette–Guérin (BCG) and topical imiquimod for in-transit melanoma J Immunother 2012 35 9 716 10.1097/cji.0b013e31827457bd 23090081 PMC3674843 Kidner TB, Morton DL, Lee DJ, Hoban M, Foshag LJ, Turner RR, et al. Combined intralesional Bacille Calmette–Guérin (BCG) and topical imiquimod for in-transit melanoma. J Immunother. 2012;35(9):716. 10.1097/cji.0b013e31827457bd. 23090081 10.1097/CJI.0b013e31827457bd PMC3674843

18. Fasihi-Karami M Afrisham R Karami S Beigzadeh E Kazemi F Association between some helminths and tumorigenesis through immunological and biochemical factors Curr Cancer Ther Rev 2023 19 2 96 102 10.2174/1573394718666220915114659 Fasihi-Karami M, Afrisham R, Karami S, Beigzadeh E, Kazemi F. Association between some helminths and tumorigenesis through immunological and biochemical factors. Curr Cancer Ther Rev. 2023;19(2):96–102. 10.2174/1573394718666220915114659.

19. Callejas BE Martinez-Saucedo D Terrazas LI Parasites as negative regulators of cancer Biosci Rep 2018 38 1 8 10.1042/BSR20180935 PMC6200699 30266743 Callejas BE, Martinez-Saucedo D, Terrazas LI. Parasites as negative regulators of cancer. Biosci Rep. 2018;38:1–8. 10.1042/BSR20180935. 10.1042/BSR20180935 PMC6200699 30266743

20. Eissa MMMD Ghazy AA El Azzouni MZ Boulos LM Younis LK Anti-arthritic activity of Schistosoma mansoni and Trichinella spiralis derived-antigens in adjuvant arthritis in rats: Role of Foxp3+ Treg cells PLoS ONE 2016 11 11 1 20 10.1371/journal.pone.0165916 PMC5089557 27802332 Eissa MMMD, Ghazy AA, El Azzouni MZ, Boulos LM, Younis LK. Anti-arthritic activity of Schistosoma mansoni and Trichinella spiralis derived-antigens in adjuvant arthritis in rats: Role of Foxp3+ Treg cells. PLoS ONE. 2016;11(11):1–20. 10.1371/journal.pone.0165916. 10.1371/journal.pone.0165916 PMC5089557 27802332

21. Sun SLH Yuan Y Wang L He W Xie H Gao S Cheng R Qian H Jiang H Wang X Zhan B Fang Q Yang X Preventive and therapeutic effects of Trichinella spiralis adult extracts on allergic inflammation in an experimental asthma mouse model Parasites Vectors 2019 12 1 10 10.1186/s13071-019-3561-1 31253164 PMC6599242 Sun SLH, Yuan Y, Wang L, He W, Xie H, Gao S, Cheng R, Qian H, Jiang H, Wang X, Zhan B, Fang Q, Yang X. Preventive and therapeutic effects of Trichinella spiralis adult extracts on allergic inflammation in an experimental asthma mouse model. Parasites Vectors. 2019;12:1–10. 10.1186/s13071-019-3561-1. 31253164 10.1186/s13071-019-3561-1 PMC6599242

22. Summers RW Elliott DE Urban JF Jr Thompson RA Weinstock JV Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial Gastroenterology 2005 128 4 825 832 10.1053/j.gastro.2005.01.005 15825065 Summers RW, Elliott DE, Urban JF Jr, Thompson RA, Weinstock JV. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology. 2005;128(4):825–32. 10.1053/j.gastro.2005.01.005. 15825065 10.1053/j.gastro.2005.01.005

23. Hasseldam H Hansen C Johansen F Immunomodulatory effects of helminths and protozoa in multiple sclerosis and experimental autoimmune encephalomyelitis Parasite Immunol 2013 35 3–4 103 108 10.1111/pim.12023 23227936 Hasseldam H, Hansen C, Johansen F. Immunomodulatory effects of helminths and protozoa in multiple sclerosis and experimental autoimmune encephalomyelitis. Parasite Immunol. 2013;35(3–4):103–8. 10.1111/pim.12023. 23227936 10.1111/pim.12023

24. Pham K Mertelsmann A Mages K Kingery JR Mazigo HD Jaka H Effects of helminths and anthelmintic treatment on cardiometabolic diseases and risk factors: a systematic review PLOS Negl Trop Dis 2023 17 2 e0011022 10.1371/journal.pntd.0011022 36827239 PMC9956023 Pham K, Mertelsmann A, Mages K, Kingery JR, Mazigo HD, Jaka H, et al. Effects of helminths and anthelmintic treatment on cardiometabolic diseases and risk factors: a systematic review. PLOS Negl Trop Dis. 2023;17(2): e0011022. 10.1371/journal.pntd.0011022. 36827239 10.1371/journal.pntd.0011022 PMC9956023

25. Akgül H Tez M Ünal AE Keşkek M Sayek İ Özçelik T Echinococcus against cancer: why not? Cancer 2003 98 9 1998 1999 10.1002/cncr.11752 14584087 Akgül H, Tez M, Ünal AE, Keşkek M, Sayek İ, Özçelik T. Echinococcus against cancer: why not? Cancer. 2003;98(9):1998–9. 10.1002/cncr.11752. 10.1002/cncr.11752 14584087

26. Garcia SB Aranha AL Garcia FRB Basile FV Pinto APM Oliveira ECD A retrospective study of histopathological findings in 894 cases of megacolon: what is the relationship between megacolon and colonic cancer? Rev Inst Med Trop São Paulo 2003 45 91 93 10.1590/S0036-46652003000200007 12754574 Garcia SB, Aranha AL, Garcia FRB, Basile FV, Pinto APM, Oliveira ECD, et al. A retrospective study of histopathological findings in 894 cases of megacolon: what is the relationship between megacolon and colonic cancer? Rev Inst Med Trop São Paulo. 2003;45:91–3. 12754574 10.1590/s0036-46652003000200007

27. Qin L Chen C Chen L Xue R Ou-Yang M Zhou C Worldwide malaria incidence and cancer mortality are inversely associated Infect Agents Cancer 2017 12 1 1 8 10.1186/s13027-017-0117-x PMC5307699 28228842 Qin L, Chen C, Chen L, Xue R, Ou-Yang M, Zhou C, et al. Worldwide malaria incidence and cancer mortality are inversely associated. Infect Agents Cancer. 2017;12(1):1–8. 10.1186/s13027-017-0117-x PMC5307699 28228842

28. Seyedeh MS Nahid S Nahid M Shima DP Morteza Y Hossein YD Low titer of antibody against Toxoplasma gondii may be related to resistant to cancer J Cancer Res Ther 2015 11 2 305 307 10.4103/0973-1482.144638 26148590 Seyedeh MS, Nahid S, Nahid M, Shima DP, Morteza Y, Hossein YD. Low titer of antibody against Toxoplasma gondii may be related to resistant to cancer. J Cancer Res Ther. 2015;11(2):305–7. 10.4103/0973-1482.144638. 26148590 10.4103/0973-1482.144638

29. Bo R Yasen A Shao Y Zhang W Lin R Jiang T Co-existence of hepatocellular carcinoma and cystic echinococcosis Infect Agents Cancer 2020 15 1 1 8 10.1186/s13027-020-0275-0 PMC6988235 32010203 Bo R, Yasen A, Shao Y, Zhang W, Lin R, Jiang T, et al. Co-existence of hepatocellular carcinoma and cystic echinococcosis. Infect Agents Cancer. 2020;15(1):1–8. 10.1186/s13027-020-0275-0. 10.1186/s13027-020-0275-0 PMC6988235 32010203

30. Plumelle Y Gonin C Edouard A Bucher BJ Thomas L Brebion A Effect of Strongyloides stercoralis infection and eosinophilia on age at onset and prognosis of adult T-cell leukemia Am J Clin Pathol 1997 107 1 81 87 10.1093/ajcp/107.1.81 8980372 Plumelle Y, Gonin C, Edouard A, Bucher BJ, Thomas L, Brebion A, et al. Effect of Strongyloides stercoralis infection and eosinophilia on age at onset and prognosis of adult T-cell leukemia. Am J Clin Pathol. 1997;107(1):81–7. 10.1093/ajcp/107.1.81. 8980372 10.1093/ajcp/107.1.81

31. Asghari A Nourmohammadi H Majidiani H Shariatzadeh SA Anvari D Shamsinia S Promising effects of parasite-derived compounds on tumor regression: a systematic review of in vitro and in vivo studies Environ Sci Pollut Res Int 2022 29 22 32383 32396 10.1007/s11356-021-17090-5 35146610 Asghari A, Nourmohammadi H, Majidiani H, Shariatzadeh SA, Anvari D, Shamsinia S, et al. Promising effects of parasite-derived compounds on tumor regression: a systematic review of in vitro and in vivo studies. Environ Sci Pollut Res Int. 2022;29(22):32383–96. 10.1007/s11356-021-17090-5. 35146610 10.1007/s11356-021-17090-5

32. Ding H Wu S Jin Z Zheng B Hu Y He K Anti-tumor effect of parasitic protozoans Bioengineering 2022 9 1 16 10.3390/bioengineering9080395 PMC9405343 36004920 Ding H, Wu S, Jin Z, Zheng B, Hu Y, He K, et al. Anti-tumor effect of parasitic protozoans. Bioengineering. 2022;9:1–16. 10.3390/bioengineering9080395. 10.3390/bioengineering9080395 PMC9405343 36004920

33. El Skhawy N Eissa MM Shedding light on a mysterious link between Toxoplasma gondii and cancer: a review Exp Parasitol 2023 250 1 8 10.1016/j.exppara.2023.108544 37149210 El Skhawy N, Eissa MM. Shedding light on a mysterious link between Toxoplasma gondii and cancer: a review. Exp Parasitol. 2023;250:1–8. 10.1016/j.exppara.2023.108544. 10.1016/j.exppara.2023.108544 37149210

34. Sadr S Ghiassi S Lotfalizadeh N Simab PA Hajjafari A Borji H Antitumor mechanisms of molecules secreted by Trypanosoma cruzi in colon and breast cancer: a review Anticancer Agents Med Chem 2023 23 15 1710 1721 10.2174/1871520623666230529141544 37254546 Sadr S, Ghiassi S, Lotfalizadeh N, Simab PA, Hajjafari A, Borji H. Antitumor mechanisms of molecules secreted by Trypanosoma cruzi in colon and breast cancer: a review. Anticancer Agents Med Chem. 2023;23(15):1710–21. 10.2174/1871520623666230529141544. 37254546 10.2174/1871520623666230529141544

35. Yousefi M Akbari M Hadipour M Dehkordi AB Farahbakhsh Z Darani HY Parasites as potential targets for cancer immunotherapy J Cancer Res Clin Oncol 2023 149 8027 8038 10.1007/s00432-023-04694-2 36949175 PMC11797331 Yousefi M, Akbari M, Hadipour M, Dehkordi AB, Farahbakhsh Z, Darani HY. Parasites as potential targets for cancer immunotherapy. J Cancer Res Clin Oncol. 2023;149:8027–38. 10.1007/s00432-023-04694-2. 36949175 10.1007/s00432-023-04694-2 PMC11797331

36. Chen X Qin L Hu W Adah D The mechanisms of action of Plasmodium infection against cancer Cell Commun Signal 2021 19 1 1 9 10.1186/s12964-021-00748-5 34243757 PMC8268363 Chen X, Qin L, Hu W, Adah D. The mechanisms of action of Plasmodium infection against cancer. Cell Commun Signal. 2021;19(1):1–9. 10.1186/s12964-021-00748-5. 34243757 10.1186/s12964-021-00748-5 PMC8268363

37. Chen J Liao W Peng H Toxoplasma gondii infection possibly reverses host immunosuppression to restrain tumor growth Front Cell Infect Microbiol 2022 12 1 11 10.3389/fcimb.2022.959300 PMC9470863 36118042 Chen J, Liao W, Peng H. Toxoplasma gondii infection possibly reverses host immunosuppression to restrain tumor growth. Front Cell Infect Microbiol. 2022;12:1–11. 10.3389/fcimb.2022.959300. 10.3389/fcimb.2022.959300 PMC9470863 36118042

38. Yang F Sun X Shen J Yu LP Liang JY Zheng HQ A recombined protein (rSj16) derived from Schistosoma japonicum induces cell cycle arrest and apoptosis of murine myeloid leukemia cells Parasitol Res 2013 112 3 1261 1272 10.1007/s00436-012-3260-8 23319265 Yang F, Sun X, Shen J, Yu LP, Liang JY, Zheng HQ, et al. A recombined protein (rSj16) derived from Schistosoma japonicum induces cell cycle arrest and apoptosis of murine myeloid leukemia cells. Parasitol Res. 2013;112(3):1261–72. 10.1007/s00436-012-3260-8. 23319265 10.1007/s00436-012-3260-8

39. Eissa MM Gaafar MR Younis LK Ismail CA El Skhawy N Prophylactic anti-neoplastic activity of Toxoplasma gondii RH derived antigen against Ehrlich solid carcinoma with evidence of shared antigens by comparative immunoblotting Infect Agents Cancer 2023 18 21 1 13 10.1186/s13027-023-00500-3 PMC10082516 37029378 Eissa MM, Gaafar MR, Younis LK, Ismail CA, El Skhawy N. Prophylactic anti-neoplastic activity of Toxoplasma gondii RH derived antigen against Ehrlich solid carcinoma with evidence of shared antigens by comparative immunoblotting. Infect Agents Cancer. 2023;18(21):1–13. 10.1186/s13027-023-00500-3. 10.1186/s13027-023-00500-3 PMC10082516 37029378

40. Ismail CA Eissa MM Gaafar MR Younis LK El Skhawy N Toxoplasma gondii -derived antigen modifies tumor microenvironment of Ehrlich solid carcinoma murine model and enhances immunotherapeutic activity of cyclophosphamide Med Oncol 2023 40 1 13 10.1007/s12032-023-01994-y PMC10073061 37014499 Ismail CA, Eissa MM, Gaafar MR, Younis LK, El Skhawy N. Toxoplasma gondii -derived antigen modifies tumor microenvironment of Ehrlich solid carcinoma murine model and enhances immunotherapeutic activity of cyclophosphamide. Med Oncol. 2023;40:1–13. 10.1007/s12032-023-01994-y. 10.1007/s12032-023-01994-y PMC10073061 37014499

41. Shojaeian A, Barati N, Motavallihaghi S. Investigating the inhibitory effects of hydatid cyst fluid and its antigens on cancer progression; a review. Preprint. 2023:1–9. 10.20944/preprints202307.2141.v1.

42. Atayde VD Jasiulionis MG Cortez M Yoshida N A recombinant protein based on Trypanosoma cruzi surface molecule Gp82 induces apoptotic cell death in melanoma cells Melanoma Res 2008 18 3 172 183 10.1097/cmr.0b013e3282feeaab 18477891 Atayde VD, Jasiulionis MG, Cortez M, Yoshida N. A recombinant protein based on Trypanosoma cruzi surface molecule Gp82 induces apoptotic cell death in melanoma cells. Melanoma Res. 2008;18(3):172–83. 10.1097/cmr.0b013e3282feeaab. 18477891 10.1097/CMR.0b013e3282feeaab

43. Bruschi F Ashour DS Othman AA Trichinella -induced immunomodulation: another tale of helminth success Food Waterborne Parasitol 2022 27 1 19 10.1016/j.fawpar.2022.e00164 PMC9125654 35615625 Bruschi F, Ashour DS, Othman AA. Trichinella -induced immunomodulation: another tale of helminth success. Food Waterborne Parasitol. 2022;27:1–19. 10.1016/j.fawpar.2022.e00164. 10.1016/j.fawpar.2022.e00164 PMC9125654 35615625

44. Sadr S Yousefsani Z Simab PA Alizadeh HJR Lotfalizadeh A Borji H Trichinella spiralis as a potential anti-tumor agent: an update World Vet J 2023 13 65 74 10.54203/scil.2023.wvj7 Sadr S, Yousefsani Z, Simab PA, Alizadeh HJR, Lotfalizadeh A, Borji H. Trichinella spiralis as a potential anti-tumor agent: an update. World Vet J. 2023;13:65–74. 10.54203/scil.2023.wvj7.

45. Caner A Toxoplasma gondii could have a possible role in the cancer mechanism by modulating the host’s cell response Acta Trop 2021 220 1 11 10.1016/j.actatropica.2021.105966 34023305 Caner A. Toxoplasma gondii could have a possible role in the cancer mechanism by modulating the host’s cell response. Acta Trop. 2021;220:1–11. 10.1016/j.actatropica.2021.105966. 10.1016/j.actatropica.2021.105966 34023305

46. Lopes-Coelho F Martins F Pereira SA Serpa J Anti-angiogenic therapy: current challenges and future perspectives Int J Mol Sci 2021 22 7 1 26 10.3390/ijms22073765 PMC8038573 33916438 Lopes-Coelho F, Martins F, Pereira SA, Serpa J. Anti-angiogenic therapy: current challenges and future perspectives. Int J Mol Sci. 2021;22(7):1–26. 10.3390/ijms22073765. 10.3390/ijms22073765 PMC8038573 33916438

47. Oikonomopoulou K Brinc D Kyriacou K Diamandis EP Infection and cancer: revaluation of the hygiene hypothesis Clin Cancer Res 2013 19 11 2834 2841 10.1158/1078-0432.CCR-12-3661 23536438 Oikonomopoulou K, Brinc D, Kyriacou K, Diamandis EP. Infection and cancer: revaluation of the hygiene hypothesis. Clin Cancer Res. 2013;19(11):2834–41. 10.1158/1078-0432.CCR-12-3661. 23536438 10.1158/1078-0432.CCR-12-3661

48. Daneshpour S Bahadoran M Hejazi SH Eskandarian AA Mahmoudzadeh M Darani HY Common antigens between hydatid cyst and cancers Adv Biomed Res 2016 5 99 105 10.4103/2277-9175.175242 26962511 PMC4770709 Daneshpour S, Bahadoran M, Hejazi SH, Eskandarian AA, Mahmoudzadeh M, Darani HY. Common antigens between hydatid cyst and cancers. Adv Biomed Res. 2016;5:99–105. 10.4103/2277-9175.175242. 26962511 10.4103/2277-9175.175242 PMC4770709

49. Osinaga E Expression of cancer-associated simple mucin-type O-glycosylated antigens in parasites IUBMB Life 2007 59 269 273 10.1080/15216540601188553 17505964 Osinaga E. Expression of cancer-associated simple mucin-type O-glycosylated antigens in parasites. IUBMB Life. 2007;59:269–73. 10.1080/15216540601188553. 17505964 10.1080/15216540601188553

50. Zenina AV Kravtsov EG Tsetsegsaikhan B Yashina NV Dalin MV Karpenko LP The study of immunological component in anti-tumor effect of Trypanosoma cruzi Bull Exp Biol Med 2008 145 3 352 354 10.1007/s10517-008-0089-3 19039942 Zenina AV, Kravtsov EG, Tsetsegsaikhan B, Yashina NV, Dalin MV, Karpenko LP, et al. The study of immunological component in anti-tumor effect of Trypanosoma cruzi . Bull Exp Biol Med. 2008;145(3):352–4. 10.1007/s10517-008-0089-3. 19039942 10.1007/s10517-008-0089-3

51. Shakibapour M Kefayat A Reza Mofid M Shojaie B Mohamadi F Maryam Sharafi S Anti-cancer immunoprotective effects of immunization with hydatid cyst wall antigens in a non-immunogenic and metastatic triple-negative murine mammary carcinoma model Int Immunopharmacol 2021 99 1 9 10.1016/j.intimp.2021.107955 34247052 Shakibapour M, Kefayat A, Reza Mofid M, Shojaie B, Mohamadi F, Maryam Sharafi S, et al. Anti-cancer immunoprotective effects of immunization with hydatid cyst wall antigens in a non-immunogenic and metastatic triple-negative murine mammary carcinoma model. Int Immunopharmacol. 2021;99:1–9. 10.1016/j.intimp.2021.107955. 10.1016/j.intimp.2021.107955 34247052

52. Ubillos L Freire T Berriel E Chiribao ML Chiale C Festari MF Trypanosoma cruzi extracts elicit protective immune response against chemically induced colon and mammary cancers Int J Cancer 2016 138 7 1719 1731 10.1002/ijc.29910 26519949 Ubillos L, Freire T, Berriel E, Chiribao ML, Chiale C, Festari MF, et al. Trypanosoma cruzi extracts elicit protective immune response against chemically induced colon and mammary cancers. Int J Cancer. 2016;138(7):1719–31. 10.1002/ijc.29910. 26519949 10.1002/ijc.29910

53. Mohamadi F Shakibapour M Sharafi SM Reza AA Tolouei S Darani HY Anti- Toxoplasma gondii antibodies attach to mouse cancer cell lines but not normal mouse lymphocytes Biomed Rep 2019 10 3 183 188 10.3892/br.2019.1186 30906547 PMC6403471 Mohamadi F, Shakibapour M, Sharafi SM, Reza AA, Tolouei S, Darani HY. Anti- Toxoplasma gondii antibodies attach to mouse cancer cell lines but not normal mouse lymphocytes. Biomed Rep. 2019;10(3):183–8. 10.3892/br.2019.1186. 30906547 10.3892/br.2019.1186 PMC6403471

54. Yue T-T Zhang N Li J-H Lu X-Y Wang X-C Li X Anti-osteosarcoma effect of antiserum against cross antigen TPD52 between osteosarcoma and Trichinella spiralis Parasites Vectors 2021 14 1 13 10.1186/s13071-021-05008-6 34565443 PMC8474799 Yue T-T, Zhang N, Li J-H, Lu X-Y, Wang X-C, Li X, et al. Anti-osteosarcoma effect of antiserum against cross antigen TPD52 between osteosarcoma and Trichinella spiralis . Parasites Vectors. 2021;14:1–13. 10.1186/s13071-021-05008-6. 34565443 10.1186/s13071-021-05008-6 PMC8474799

55. Eissa MM Ismail CA El-Azzouni MZ Ghazy AA Hadi MA Immuno-therapeutic potential of Schistosoma mansoni and Trichinella spiralis antigens in a murine model of colon cancer Invest New Drugs 2019 37 1 47 56 10.1007/s10637-018-0609-6 29808307 Eissa MM, Ismail CA, El-Azzouni MZ, Ghazy AA, Hadi MA. Immuno-therapeutic potential of Schistosoma mansoni and Trichinella spiralis antigens in a murine model of colon cancer. Invest New Drugs. 2019;37(1):47–56. 10.1007/s10637-018-0609-6. 29808307 10.1007/s10637-018-0609-6

56. International Agency for Research on Cancer. Globocan; cancer fact sheets—colorectal cancer. 2018. https://gco.iarc.who.int/media/globocan/factsheets/cancers/8-colon-fact-sheet.pdf .

57. Mougiakakos D Regulatory T cells in colorectal cancer: from biology to prognostic relevance Cancers 2011 3 2 1708 1731 10.3390/cancers3021708 24212779 PMC3757386 Mougiakakos D. Regulatory T cells in colorectal cancer: from biology to prognostic relevance. Cancers. 2011;3(2):1708–31. 10.3390/cancers3021708. 24212779 10.3390/cancers3021708 PMC3757386

58. Hotez PJ Brindley PJ Bethony JM King CH Pearce EJ Jacobson J Helminth infections: the great neglected tropical diseases J Clin Invest 2008 118 4 1311 1321 10.1172/jci34261 18382743 PMC2276811 Hotez PJ, Brindley PJ, Bethony JM, King CH, Pearce EJ, Jacobson J. Helminth infections: the great neglected tropical diseases. J Clin Invest. 2008;118(4):1311–21. 10.1172/jci34261. 18382743 10.1172/JCI34261 PMC2276811

59. Salim OE Hamid HK Mekki SO Suleiman SH Ibrahim SZ Colorectal carcinoma associated with schistosomiasis: a possible causal relationship World J Surg Oncol 2010 8 1 6 10.1186/1477-7819-8-68 20704754 PMC2928231 Salim OE, Hamid HK, Mekki SO, Suleiman SH, Ibrahim SZ. Colorectal carcinoma associated with schistosomiasis: a possible causal relationship. World J Surg Oncol. 2010;8:1–6. 10.1186/1477-7819-8-68. 20704754 10.1186/1477-7819-8-68 PMC2928231

60. Elliott DE Li J Blum A Metwali A Qadir K Urban JF Jr Exposure to schistosome eggs protects mice from TNBS-induced colitis Am J Physiol Gastrointest Liver Physiol 2003 284 3 385 391 10.1152/ajpgi.00049.2002 12431903 Elliott DE, Li J, Blum A, Metwali A, Qadir K, Urban JF Jr, et al. Exposure to schistosome eggs protects mice from TNBS-induced colitis. Am J Physiol Gastrointest Liver Physiol. 2003;284(3):385–91. 10.1152/ajpgi.00049.2002 12431903

61. Jacobs B-A Prince S Smith KA Gastrointestinal nematode-derived antigens alter colorectal cancer cell proliferation and migration through regulation of cell cycle and epithelial–mesenchymal transition proteins Int J Mol Sci 2020 21 21 7845 10.3390/ijms21217845 33105843 PMC7660063 Jacobs B-A, Prince S, Smith KA. Gastrointestinal nematode-derived antigens alter colorectal cancer cell proliferation and migration through regulation of cell cycle and epithelial–mesenchymal transition proteins. Int J Mol Sci. 2020;21(21):7845. 10.3390/ijms21217845. 33105843 10.3390/ijms21217845 PMC7660063

62. Loures MA Andrade A Peralta JM Local response in mouse tumor treated with Schistosoma mansoni antigen Mem Inst Oswaldo Cruz 1991 86 127 128 10.1590/s0074-02761991000700027 1668995 Loures MA, Andrade A, Peralta JM. Local response in mouse tumor treated with Schistosoma mansoni antigen. Mem Inst Oswaldo Cruz. 1991;86:127–8. 10.1590/s0074-02761991000700027. 10.1590/s0074-02761991000700027 1668995

63. Eissa MM Allam S El Azzouni M Baddour N Autoclaved cercarial vaccine: a new hope against schistosomiasis: parasitologic, histopathologic and immunologic studies J Egypt Soc Parasitol 1998 28 2 461 479 9707675 Eissa MM, Allam S, El Azzouni M, Baddour N. Autoclaved cercarial vaccine: a new hope against schistosomiasis: parasitologic, histopathologic and immunologic studies. J Egypt Soc Parasitol. 1998;28(2):461–79. 9707675

64. Eissa MM El-Azzouni MZ Baddour NM Boulos LM Vaccination trial against experimental trichinellosis using autoclaved Trichinella spiralis larvae vaccine (ATSLV) J Egypt Soc Parasitol 2003 33 1 219 228 12739813 Eissa MM, El-Azzouni MZ, Baddour NM, Boulos LM. Vaccination trial against experimental trichinellosis using autoclaved Trichinella spiralis larvae vaccine (ATSLV). J Egypt Soc Parasitol. 2003;33(1):219–28. 12739813

65. Eissa MM El-Azzouni MZ Mady RF Fathy FM Baddour NM Initial characterization of an autoclaved Toxoplasma vaccine in mice Exp Parasitol 2012 131 3 310 316 10.1016/j.exppara.2012.05.001 22595548 Eissa MM, El-Azzouni MZ, Mady RF, Fathy FM, Baddour NM. Initial characterization of an autoclaved Toxoplasma vaccine in mice. Exp Parasitol. 2012;131(3):310–6. 10.1016/j.exppara.2012.05.001. 22595548 10.1016/j.exppara.2012.05.001

66. Tosyali OA Allahverdiyev A Bagirova M Abamor ES Aydogdu M Dinparvar S Nano-co-delivery of lipophosphoglycan with soluble and autoclaved Leishmania antigens into PLGA nanoparticles: evaluation of in vitro and in vivo immunostimulatory effects against visceral leishmaniasis Mater Sci Eng C 2021 120 111684 10.1016/j.msec.2020.111684 33545846 Tosyali OA, Allahverdiyev A, Bagirova M, Abamor ES, Aydogdu M, Dinparvar S, et al. Nano-co-delivery of lipophosphoglycan with soluble and autoclaved Leishmania antigens into PLGA nanoparticles: evaluation of in vitro and in vivo immunostimulatory effects against visceral leishmaniasis. Mater Sci Eng C. 2021;120: 111684. 10.1016/j.msec.2020.111684. 10.1016/j.msec.2020.111684 33545846

67. Eissa MM Allam SR El-Azzouni MZ Maged HR Dessouky IS Further studies on autoclaved cercarial vaccine against schistosomiasis: safety, longevity and stability J Egypt Soc Parasitol 2003 33 2 541 560 14964666 Eissa MM, Allam SR, El-Azzouni MZ, Maged HR, Dessouky IS. Further studies on autoclaved cercarial vaccine against schistosomiasis: safety, longevity and stability. J Egypt Soc Parasitol. 2003;33(2):541–60. 14964666

68. Khalil EAG Musa AM Modabber F El-Hassan AM Safety and immunogenicity of a candidate vaccine for visceral leishmaniasis (Alum-precipitated autoclaved Leishmania major + BCG) in children: an extended phase II study Ann Trop Paediatr 2006 26 4 357 361 10.1179/146532806X152890 17132302 Khalil EAG, Musa AM, Modabber F, El-Hassan AM. Safety and immunogenicity of a candidate vaccine for visceral leishmaniasis (Alum-precipitated autoclaved Leishmania major + BCG) in children: an extended phase II study. Ann Trop Paediatr. 2006;26(4):357–61. 17132302 10.1179/146532806X152890

69. Moro P Schantz PM Echinococcosis: a review Int J Infect Dis 2009 13 2 125 133 10.1016/j.ijid.2008.03.037 18938096 Moro P, Schantz PM. Echinococcosis: a review. Int J Infect Dis. 2009;13(2):125–33. 10.1016/j.ijid.2008.03.037. 18938096 10.1016/j.ijid.2008.03.037

70. Sadr S, Charbgoo A, Borji H. Interactions between innate immunity system and Echinococcus granulosus : permission for vaccine development. Ser Med Sci. 2022;3.

71. Motavallihaghi S Tanzadehpanah H Soleimani Asl S Shojaeian A Yousefimashouf M Barati N In vitro anti-cancer activity of hydatid cyst fluid on colon cancer cell line (C26) Egypt J Med Hum Genet 2023 24 1 15 10.1186/s43042-023-00394-1 Motavallihaghi S, Tanzadehpanah H, Soleimani Asl S, Shojaeian A, Yousefimashouf M, Barati N. In vitro anti-cancer activity of hydatid cyst fluid on colon cancer cell line (C26). Egypt J Med Hum Genet. 2023;24(1):15.

72. Berriel E Russo S Monin L Festari MF Berois N Fernández G Antitumor activity of human hydatid cyst fluid in a murine model of colon cancer Sci World J 2013 10.1155/2013/230176 PMC3759250 24023528 Berriel E, Russo S, Monin L, Festari MF, Berois N, Fernández G, et al. Antitumor activity of human hydatid cyst fluid in a murine model of colon cancer. Sci World J. 2013. 10.1155/2013/230176. 10.1155/2013/230176 PMC3759250 24023528

73. Rostamirad S Daneshpour S Mofid MR Andalib A Eskandariyan A Mousavi S Inhibition of mouse colon cancer growth following immunotherapy with a fraction of hydatid cyst fluid Exp Parasitol 2023 249 108501 10.1016/j.exppara.2023.108501 36931383 Rostamirad S, Daneshpour S, Mofid MR, Andalib A, Eskandariyan A, Mousavi S, et al. Inhibition of mouse colon cancer growth following immunotherapy with a fraction of hydatid cyst fluid. Exp Parasitol. 2023;249: 108501. 10.1016/j.exppara.2023.108501. 36931383 10.1016/j.exppara.2023.108501

74. Garcia HH Rodriguez S Friedland JS Peru CWGI Immunology of Taenia solium taeniasis and human cysticercosis Parasite Immunol 2014 36 8 388 396 10.1111/pim.12126 24962350 PMC5761726 Garcia HH, Rodriguez S, Friedland JS, Peru CWGI. Immunology of Taenia solium taeniasis and human cysticercosis. Parasite Immunol. 2014;36(8):388–96. 24962350 10.1111/pim.12126 PMC5761726

75. Schcolnik-Cabrera A Juárez M Oldak B Cruz-Rivera M Flisser A Dueñas-González A In vitro employment of recombinant Taenia solium calreticulin as a novel strategy against breast and ovarian cancer stem-like cells Arch Med Res 2020 51 1 65 75 10.1016/j.arcmed.2019.12.003 32097797 Schcolnik-Cabrera A, Juárez M, Oldak B, Cruz-Rivera M, Flisser A, Dueñas-González A, et al. In vitro employment of recombinant Taenia solium calreticulin as a novel strategy against breast and ovarian cancer stem-like cells. Arch Med Res. 2020;51(1):65–75. 32097797 10.1016/j.arcmed.2019.12.003

76. Kielbik M Szulc-Kielbik I Klink M Calreticulin—multifunctional chaperone in immunogenic cell death: potential significance as a prognostic biomarker in ovarian cancer patients Cells 2021 10 1 130 10.3390/cells10010130 33440842 PMC7827772 Kielbik M, Szulc-Kielbik I, Klink M. Calreticulin—multifunctional chaperone in immunogenic cell death: potential significance as a prognostic biomarker in ovarian cancer patients. Cells. 2021;10(1):130. 10.3390/cells10010130. 33440842 10.3390/cells10010130 PMC7827772

77. Heldwein K Biedermann H-G Hamperl W-D Bretzel G Löscher T Laregina D Subcutaneous Taenia crassiceps infection in a patient with non-Hodgkin’s lymphoma Am J Trop Med Hyg 2006 75 1 108 111 10.4269/ajtmh.2006.75.108 16837716 Heldwein K, Biedermann H-G, Hamperl W-D, Bretzel G, Löscher T, Laregina D, et al. Subcutaneous Taenia crassiceps infection in a patient with non-Hodgkin’s lymphoma. Am J Trop Med Hyg. 2006;75(1):108–11. 10.4269/ajtmh.2006.75.108. 16837716

78. León-Cabrera S Callejas BE Ledesma-Soto Y Coronel J Pérez-Plasencia C Gutiérrez-Cirlos EB Extraintestinal helminth infection reduces the development of colitis-associated tumorigenesis Int J Biol Sci 2014 10 9 948 10.7150/ijbs.9033 25210492 PMC4159685 León-Cabrera S, Callejas BE, Ledesma-Soto Y, Coronel J, Pérez-Plasencia C, Gutiérrez-Cirlos EB, et al. Extraintestinal helminth infection reduces the development of colitis-associated tumorigenesis. Int J Biol Sci. 2014;10(9):948. 10.7150/ijbs.9033. 25210492 10.7150/ijbs.9033 PMC4159685

79. Ren HN Guo KX Zhang Y Sun GG Liu RD Jiang P Molecular characterization of a 31 kDa protein from Trichinella spiralis and its induced immune protection in BALB/c mice Parasites Vectors 2018 11 1 1 12 10.1186/s13071-018-3198-5 30518426 PMC6282284 Ren HN, Guo KX, Zhang Y, Sun GG, Liu RD, Jiang P, et al. Molecular characterization of a 31 kDa protein from Trichinella spiralis and its induced immune protection in BALB/c mice. Parasites Vectors. 2018;11(1):1–12. 10.1186/s13071-018-3198-5. 30518426 10.1186/s13071-018-3198-5 PMC6282284

80. Li X Zhang G Zhang X Li J Yang J Gong P Effect of Trichinella on growth of human colorectal carcinoma HCT-8 cells in BALB/c mice Chin J Biol 2008 4 285 287 Li X, Zhang G, Zhang X, Li J, Yang J, Gong P, et al. Effect of Trichinella on growth of human colorectal carcinoma HCT-8 cells in BALB/c mice. Chin J Biol. 2008;4:285–7.

81. Ma G Holland CV Wang T Hofmann A Fan C-K Maizels RM Human toxocariasis Lancet Infect Dis 2018 18 1 e14 e24 10.1016/S1473-3099(17)30331-6 28781085 Ma G, Holland CV, Wang T, Hofmann A, Fan C-K, Maizels RM, et al. Human toxocariasis. Lancet Infect Dis. 2018;18(1):e14–24. 10.1016/S1473-3099(17)30331-6. 28781085 10.1016/S1473-3099(17)30331-6

82. Bahadory S Sadraei J Zibaei M Pirestani M Dalimi A In vitro anti-gastrointestinal cancer activity of Toxocara canis -derived peptide: analyzing the expression level of factors related to cell proliferation and tumor growth Front Pharmacol 2022 13 878724 10.3389/fphar.2022.878724 36204226 PMC9530354 Bahadory S, Sadraei J, Zibaei M, Pirestani M, Dalimi A. In vitro anti-gastrointestinal cancer activity of Toxocara canis -derived peptide: analyzing the expression level of factors related to cell proliferation and tumor growth. Front Pharmacol. 2022;13: 878724. 10.3389/fphar.2022.878724. 36204226 10.3389/fphar.2022.878724 PMC9530354

83. Roskin G Exempliarskaia E Protozoeninfektion und experimenteller Krebs: I. Mitteilung Z Krebsforsch 1931 34 628 645 10.1007/BF01625403 Roskin G, Exempliarskaia E. Protozoeninfektion und experimenteller Krebs: I. Mitteilung. Z Krebsforsch. 1931;34:628–45.

84. Hauschka T Saxe LH Jr Blair M Trypanosoma cruzi in treatment of mouse tumors J Natl Cancer Inst 1947 7 189 20240431 Hauschka T, Saxe LH Jr, Blair M. Trypanosoma cruzi in treatment of mouse tumors. J Natl Cancer Inst. 1947;7:189. 20240431

85. Malisoff WM The action of the endotoxin of Trypanosoma cruzi (KR) on malignant mouse tumors Science 1947 106 2763 591 594 10.1126/science.106.2763.591.b 17821395 Malisoff WM. The action of the endotoxin of Trypanosoma cruzi (KR) on malignant mouse tumors. Science. 1947;106(2763):591–4. 10.1126/science.106.2763.591-a 17821395

86. Jedeloo G Lignac G Ligtenberg A Van Thiel P The biotherapeutic action of Trypanosoma cruzi on tar carcinoma in mice J Natl Cancer Inst 1950 10 4 809 813 15415724 Jedeloo G, Lignac G, Ligtenberg A, Van Thiel P. The biotherapeutic action of Trypanosoma cruzi on tar carcinoma in mice. J Natl Cancer Inst. 1950;10(4):809–13. 15415724

87. Oliveira E Leite M Miranda J Andrade A Garcia SB Luquetti A Chronic Trypanosoma cruzi infection associated with low incidence of 1, 2-dimethylhydrazine-induced colon cancer in rats Carcinogenesis 2001 22 5 737 740 10.1093/carcin/22.5.737 11323392 Oliveira E, Leite M, Miranda J, Andrade A, Garcia SB, Luquetti A, et al. Chronic Trypanosoma cruzi infection associated with low incidence of 1, 2-dimethylhydrazine-induced colon cancer in rats. Carcinogenesis. 2001;22(5):737–40. 10.1093/carcin/22.5.737. 11323392 10.1093/carcin/22.5.737

88. Freire T Robello C Soulé S Ferreira F Osinaga E Sialyl-Tn antigen expression and O-linked GalNAc-Thr synthesis by Trypanosoma cruzi Biochem Biophys Res Commun 2003 312 4 1309 1316 10.1016/j.bbrc.2003.11.060 14652017 Freire T, Robello C, Soulé S, Ferreira F, Osinaga E. Sialyl-Tn antigen expression and O-linked GalNAc-Thr synthesis by Trypanosoma cruzi . Biochem Biophys Res Commun. 2003;312(4):1309–16. 10.1016/j.bbrc.2003.11.060. 14652017 10.1016/j.bbrc.2003.11.060

89. Yao X Cao Y Lu L Xu Y Chen H Liu C Plasmodium infection suppresses colon cancer growth by inhibiting proliferation and promoting apoptosis associated with disrupting mitochondrial biogenesis and mitophagy in mice Parasites Vectors 2022 15 1 1 12 10.1186/s13071-022-05291- 35668501 PMC9169289 Yao X, Cao Y, Lu L, Xu Y, Chen H, Liu C, et al. Plasmodium infection suppresses colon cancer growth by inhibiting proliferation and promoting apoptosis associated with disrupting mitochondrial biogenesis and mitophagy in mice. Parasites Vectors. 2022;15(1):1–12. 10.1186/s13071-022-05291-. 35668501 10.1186/s13071-022-05291-x PMC9169289

90. Salanti A Clausen TM Agerbæk MØ Al Nakouzi N Dahlbäck M Oo HZ Targeting human cancer by a glycosaminoglycan binding malaria protein Cancer Cell 2015 28 4 500 514 10.1016/j.ccell.2015.09.003 26461094 PMC4790448 Salanti A, Clausen TM, Agerbæk MØ, Al Nakouzi N, Dahlbäck M, Oo HZ, et al. Targeting human cancer by a glycosaminoglycan binding malaria protein. Cancer Cell. 2015;28(4):500–14. 10.1016/j.ccell.2015.09.003. 26461094 10.1016/j.ccell.2015.09.003 PMC4790448

91. Ding Y Huang X Liu T Fu Y Tan Z Zheng H The Plasmodium circumsporozoite protein, a novel NF-κB inhibitor, suppresses the growth of SW480 Pathol Oncol Res 2012 18 895 902 10.1007/s12253-012-9519-7 22678765 Ding Y, Huang X, Liu T, Fu Y, Tan Z, Zheng H, et al. The Plasmodium circumsporozoite protein, a novel NF-κB inhibitor, suppresses the growth of SW480. Pathol Oncol Res. 2012;18:895–902. 10.1007/s12253-012-9519-7. 22678765 10.1007/s12253-012-9519-7

92. Elsheikha HM Marra CM Zhu X-Q Epidemiology, pathophysiology, diagnosis, and management of cerebral toxoplasmosis Clin Microbiol Rev 2020 34 1 10 128 10.1128/CMR.00115-19 PMC7690944 33239310 Elsheikha HM, Marra CM, Zhu X-Q. Epidemiology, pathophysiology, diagnosis, and management of cerebral toxoplasmosis. Clin Microbiol Rev. 2020;34(1):10–128. 10.1128/CMR.00115-19. 10.1128/CMR.00115-19 PMC7690944 33239310

93. Seo S-H Shin J-H Ham D-W Shin E-H PTEN/AKT signaling pathway related to hTERT downregulation and telomere shortening induced in Toxoplasma GRA16-expressing colorectal cancer cells Biomed Pharmacother 2022 153 113366 10.1016/j.biopha.2022.113366 35810694 Seo S-H, Shin J-H, Ham D-W, Shin E-H. PTEN/AKT signaling pathway related to hTERT downregulation and telomere shortening induced in Toxoplasma GRA16-expressing colorectal cancer cells. Biomed Pharmacother. 2022;153: 113366. 10.1016/j.biopha.2022.113366. 35810694 10.1016/j.biopha.2022.113366

94. Kim J-S Lee D Kim D Mun S-J Cho E Son W Toxoplasma gondii GRA8-derived peptide immunotherapy improves tumor targeting of colorectal cancer Oncotarget 2020 11 1 62 10.18632/oncotarget.27417 32002124 PMC6967779 Kim J-S, Lee D, Kim D, Mun S-J, Cho E, Son W, et al. Toxoplasma gondii GRA8-derived peptide immunotherapy improves tumor targeting of colorectal cancer. Oncotarget. 2020;11(1):62. 10.18632/oncotarget.27417. 32002124 10.18632/oncotarget.27417 PMC6967779

95. Zhu Y-C Elsheikha HM Wang J-H Fang S He J-J Zhu X-Q Synergy between Toxoplasma gondii type I ΔGRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors J Immunother Cancer 2021 9 11 e002970 10.1136/jitc-2021-002970 34725213 PMC8562526 Zhu Y-C, Elsheikha HM, Wang J-H, Fang S, He J-J, Zhu X-Q, et al. Synergy between Toxoplasma gondii type I ΔGRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors. J Immunother Cancer. 2021;9(11): e002970. 10.1136/jitc-2021-002970. 34725213 10.1136/jitc-2021-002970 PMC8562526

96. Pyo K-H Jung B-K Xin C-F Lee Y-W Chai J-Y Shin E-H Prominent IL-12 production and tumor reduction in athymic nude mice after Toxoplasma gondii lysate antigen treatment Korean J Parasitol 2014 52 6 605 10.3347/kjp.2014.52.6.605 25548411 PMC4277022 Pyo K-H, Jung B-K, Xin C-F, Lee Y-W, Chai J-Y, Shin E-H. Prominent IL-12 production and tumor reduction in athymic nude mice after Toxoplasma gondii lysate antigen treatment. Korean J Parasitol. 2014;52(6):605. 10.3347/kjp.2014.52.6.605. 25548411 10.3347/kjp.2014.52.6.605 PMC4277022

97. Pyo K-H Lee Y-W Lim SM Shin E-H Immune adjuvant effect of a Toxoplasma gondii profilin-like protein in autologous whole-tumor-cell vaccination in mice Oncotarget 2016 7 45 74107 10.18632/oncotarget.12316 27687589 PMC5342039 Pyo K-H, Lee Y-W, Lim SM, Shin E-H. Immune adjuvant effect of a Toxoplasma gondii profilin-like protein in autologous whole-tumor-cell vaccination in mice. Oncotarget. 2016;7(45):74107. 10.18632/oncotarget.12316. 27687589 10.18632/oncotarget.12316 PMC5342039

98. Mani R Martin CG Balu KE Wang Q Rychahou P Izumi T A novel protozoa parasite-derived protein adjuvant is effective in immunization with cancer cells to activate the cancer-specific protective immunity and inhibit the cancer growth in a murine model of colorectal cancer Cells 2024 13 2 111 10.3390/cells13020111 38247803 PMC10814441 Mani R, Martin CG, Balu KE, Wang Q, Rychahou P, Izumi T, et al. A novel protozoa parasite-derived protein adjuvant is effective in immunization with cancer cells to activate the cancer-specific protective immunity and inhibit the cancer growth in a murine model of colorectal cancer. Cells. 2024;13(2):111. 38247803 10.3390/cells13020111 PMC10814441

99. Lu J Wei N Zhu S Chen X Gong H Mi R Exosomes derived from dendritic cells infected with Toxoplasma gondii show anti-tumoral activity in a mouse model of colorectal cancer Front Oncol 2022 12 899737 10.3389/fonc.2022.899737 35600363 PMC9114749 Lu J, Wei N, Zhu S, Chen X, Gong H, Mi R, et al. Exosomes derived from dendritic cells infected with Toxoplasma gondii show anti-tumoral activity in a mouse model of colorectal cancer. Front Oncol. 2022;12: 899737. 10.3389/fonc.2022.899737. 35600363 10.3389/fonc.2022.899737 PMC9114749

100. Zhu S Lu J Lin Z Abuzeid AM Chen X Zhuang T Anti-tumoral effect and action mechanism of exosomes derived from Toxoplasma gondii -infected dendritic cells in mice colorectal cancer Front Oncol 2022 12 870528 10.3389/fonc.2022.870528 35600340 PMC9118538 Zhu S, Lu J, Lin Z, Abuzeid AM, Chen X, Zhuang T, et al. Anti-tumoral effect and action mechanism of exosomes derived from Toxoplasma gondii -infected dendritic cells in mice colorectal cancer. Front Oncol. 2022;12: 870528. 10.3389/fonc.2022.870528. 35600340 10.3389/fonc.2022.870528 PMC9118538

101. Juckett DA Aylsworth CF Quensen JM Intestinal protozoa are hypothesized to stimulate immunosurveillance against colon cancer Med Hypotheses 2008 71 1 104 110 10.1016/j.mehy.2008.01.024 18343044 Juckett DA, Aylsworth CF, Quensen JM. Intestinal protozoa are hypothesized to stimulate immunosurveillance against colon cancer. Med Hypotheses. 2008;71(1):104–10. 10.1016/j.mehy.2008.01.024. 18343044 10.1016/j.mehy.2008.01.024

102. Huang H Yang W Hu J Jiang Y Wang J Shi C Antitumour metastasis and the antiangiogenic and antitumour effects of a Eimeria stiedae soluble protein Parasite Immunol 2021 43 6 e12825 10.1111/pim.12825 33507547 Huang H, Yang W, Hu J, Jiang Y, Wang J, Shi C, et al. Antitumour metastasis and the antiangiogenic and antitumour effects of a Eimeria stiedae soluble protein. Parasite Immunol. 2021;43(6): e12825. 10.1111/pim.12825. 33507547 10.1111/pim.12825

103. Gallo A Cha C Updates on esophageal and gastric cancers World J Gastroenterol 2006 10.3748/wjg.v12.i20.3237 PMC4087968 16718845 Gallo A, Cha C. Updates on esophageal and gastric cancers. World J Gastroenterol. 2006. 10.3748/wjg.v12.i20.3237. 10.3748/wjg.v12.i20.3237 PMC4087968 16718845

104. Wang X Fu B Yang S Wu X Cui G Liu M Trichinella spiralis —a potential anti-tumor agent Vet Parasitol 2009 159 3–4 249 252 10.1016/j.vetpar.2008.10.052 19041180 Wang X, Fu B, Yang S, Wu X, Cui G, Liu M, et al. Trichinella spiralis —a potential anti-tumor agent. Vet Parasitol. 2009;159(3–4):249–52. 10.1016/j.vetpar.2008.10.052. 19041180 10.1016/j.vetpar.2008.10.052

105. Xin W Li S Li Z Zheng-Quan L Jiang L Lin-Xi Z Impact of Toxoplasma gondii on the proliferation and apoptosis of tumor cell lines Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi (CJPPD) 2012 30 2 17 22908820 Xin W, Li S, Li Z, Zheng-Quan L, Jiang L, Lin-Xi Z. Impact of Toxoplasma gondii on the proliferation and apoptosis of tumor cell lines. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi (CJPPD). 2012;30(2):17. 22908820

106. Luo Q Sun L Tian Q-Q Ren H Liu H Yang C-J Effect of culture supernatant of Toxoplasma gondii on the proliferation and apoptosis of BGC-823 cells Chin J Parasitol Parasit Dis 2014 32 2 123 127 25065211 Luo Q, Sun L, Tian Q-Q, Ren H, Liu H, Yang C-J, et al. Effect of culture supernatant of Toxoplasma gondii on the proliferation and apoptosis of BGC-823 cells. Chin J Parasitol Parasit Dis. 2014;32(2):123–7. 25065211

107. Varga A Sokolowska-Kohler W Presber W Von Baehr V Von Baehr R Lucius R Toxoplasma infection and cell free extract of the parasites are able to reverse multidrug resistance of mouse lymphoma and human gastric cancer cells in vitro Anticancer Res 1999 19 2A 1317 1324 10368693 Varga A, Sokolowska-Kohler W, Presber W, Von Baehr V, Von Baehr R, Lucius R, et al. Toxoplasma infection and cell free extract of the parasites are able to reverse multidrug resistance of mouse lymphoma and human gastric cancer cells in vitro. Anticancer Res. 1999;19(2A):1317–24. 10368693

108. Kulik L El-Serag HB Epidemiology and management of hepatocellular carcinoma Gastroenterology 2019 156 2 477 491 10.1053/j.gastro.2018.08.065 30367835 PMC6340716 Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156(2):477–91. 10.1053/j.gastro.2018.08.065. 30367835 10.1053/j.gastro.2018.08.065 PMC6340716

109. Berry A Iriart X Fillaux J Magnaval JF Urinary schistosomiasis and cancer Bull Soc Pathol Exot 2017 110 1 68 75 10.1007/s13149-017-0547-4 28185084 Berry A, Iriart X, Fillaux J, Magnaval JF. Urinary schistosomiasis and cancer. Bull Soc Pathol Exot. 2017;110(1):68–75. 10.1007/s13149-017-0547-4. 28185084 10.1007/s13149-017-0547-4

110. Berindan-Neagoe I Monroig PDC Pasculli B Calin GA MicroRNAome genome: a treasure for cancer diagnosis and therapy CA Cancer J Clin 2014 64 5 311 336 10.3322/caac.21244 25104502 PMC4461198 Berindan-Neagoe I, Monroig PDC, Pasculli B, Calin GA. MicroRNAome genome: a treasure for cancer diagnosis and therapy. CA Cancer J Clin. 2014;64(5):311–36. 10.3322/caac.21244. 25104502 10.3322/caac.21244 PMC4461198

111. Hu C Zhu S Wang J Lin Y Ma L Zhu L Schistosoma japonicum MiRNA-7-5p inhibits the growth and migration of hepatoma cells via cross-species regulation of S-phase kinase-associated protein 2 Front Oncol 2019 9 175 10.3389/fonc.2019.00175 30967999 PMC6443022 Hu C, Zhu S, Wang J, Lin Y, Ma L, Zhu L, et al. Schistosoma japonicum MiRNA-7-5p inhibits the growth and migration of hepatoma cells via cross-species regulation of S-phase kinase-associated protein 2. Front Oncol. 2019;9:175. 10.3389/fonc.2019.00175. 30967999 10.3389/fonc.2019.00175 PMC6443022

112. Lin Y Zhu S Hu C Wang J Jiang P Zhu L Cross-species suppression of hepatoma cell growth and migration by a Schistosoma japonicum microRNA Mol Ther Nucleic Acids 2019 18 400 412 10.1016/j.omtn.2019.09.006 31655260 PMC6831938 Lin Y, Zhu S, Hu C, Wang J, Jiang P, Zhu L, et al. Cross-species suppression of hepatoma cell growth and migration by a Schistosoma japonicum microRNA. Mol Ther Nucleic Acids. 2019;18:400–12. 10.1016/j.omtn.2019.09.006. 31655260 10.1016/j.omtn.2019.09.006 PMC6831938

113. Hu C Li Y Pan D Wang J Zhu L Lin Y A Schistosoma japonicum microRNA exerts anti-tumor effects through inhibition of both cell migration and angiogenesis by targeting PGAM1 Front Oncol 2021 11 652395 10.3389/fonc.2021.652395 34221971 PMC8242254 Hu C, Li Y, Pan D, Wang J, Zhu L, Lin Y, et al. A Schistosoma japonicum microRNA exerts anti-tumor effects through inhibition of both cell migration and angiogenesis by targeting PGAM1. Front Oncol. 2021;11: 652395. 10.3389/fonc.2021.652395. 34221971 10.3389/fonc.2021.652395 PMC8242254

114. Jiang P Wang J Zhu S Hu C Lin Y Pan W Identification of a Schistosoma japonicum microRNA that suppresses hepatoma cell growth and migration by targeting host FZD4 gene Front Cell Infect Microbiol 2022 12 31 10.3389/fcimb.2022.786543 PMC8842725 35174106 Jiang P, Wang J, Zhu S, Hu C, Lin Y, Pan W. Identification of a Schistosoma japonicum microRNA that suppresses hepatoma cell growth and migration by targeting host FZD4 gene. Front Cell Infect Microbiol. 2022;12:31. 10.3389/fcimb.2022.786543. 10.3389/fcimb.2022.786543 PMC8842725 35174106

115. Mas-Coma S Bargues M Valero M Human fascioliasis infection sources, their diversity, incidence factors, analytical methods and prevention measures Parasitology 2018 145 13 1665 1699 10.1017/s0031182018000914 29991363 Mas-Coma S, Bargues M, Valero M. Human fascioliasis infection sources, their diversity, incidence factors, analytical methods and prevention measures. Parasitology. 2018;145(13):1665–99. 10.1017/s0031182018000914. 29991363 10.1017/S0031182018000914

116. Tsocheva N Toshikova R Filchev A Inhibition of proliferation of tumour cell cultures by biologically active substances isolated from the tissues of Fasciola hepatica and Fasciola hepatica -infected rat liver Folia Parasitol 1992 39 387 390 1291455 Tsocheva N, Toshikova R, Filchev A. Inhibition of proliferation of tumour cell cultures by biologically active substances isolated from the tissues of Fasciola hepatica and Fasciola hepatica -infected rat liver. Folia Parasitol. 1992;39:387–90. 1291455

117. Ding J Tang B Liu X Bai X Wang Y Li S Excretory-secretory product of Trichinella spiralis inhibits tumor cell growth by regulating the immune response and inducing apoptosis Acta Trop 2022 225 106172 10.1016/j.actatropica.2021.106172 34627760 Ding J, Tang B, Liu X, Bai X, Wang Y, Li S, et al. Excretory-secretory product of Trichinella spiralis inhibits tumor cell growth by regulating the immune response and inducing apoptosis. Acta Trop. 2022;225: 106172. 10.1016/j.actatropica.2021.106172. 34627760 10.1016/j.actatropica.2021.106172

118. Wang X Liu M Sun S Liu X Yu L Wang X An anti-tumor protein produced by Trichinella spiralis induces apoptosis in human hepatoma H7402 cells Vet Parasitol 2013 194 2–4 186 188 10.1016/j.vetpar.2013.01.052 23433602 Wang X, Liu M, Sun S, Liu X, Yu L, Wang X, et al. An anti-tumor protein produced by Trichinella spiralis induces apoptosis in human hepatoma H7402 cells. Vet Parasitol. 2013;194(2–4):186–8. 10.1016/j.vetpar.2013.01.052. 23433602 10.1016/j.vetpar.2013.01.052

119. Ruenchit P Reamtong O Khowawisetsut L Adisakwattana P Chulanetra M Kulkeaw K Peptide of Trichinella spiralis infective larval extract that harnesses growth of human hepatoma cells Front Cell Infect Microbiol 2022 12 882608 10.3389/fcimb.2022.882608 35558100 PMC9086976 Ruenchit P, Reamtong O, Khowawisetsut L, Adisakwattana P, Chulanetra M, Kulkeaw K, et al. Peptide of Trichinella spiralis infective larval extract that harnesses growth of human hepatoma cells. Front Cell Infect Microbiol. 2022;12: 882608. 10.3389/fcimb.2022.882608. 35558100 10.3389/fcimb.2022.882608 PMC9086976

120. Zhang Y Gong P Zhang X Li J Ju Y Zhang G Anti-tumoral effect of Trichinella spirialis on Hepa 1–6 hepatoma carcinoma cell in the C57BL/6 mice J Pathogen Biol 2009 4 1 24 26 Zhang Y, Gong P, Zhang X, Li J, Ju Y, Zhang G. Anti-tumoral effect of Trichinella spirialis on Hepa 1–6 hepatoma carcinoma cell in the C57BL/6 mice. J Pathogen Biol. 2009;4(1):24–6.

121. Elhasawy FA Ashour DS ElSaka AM Ismail HI The apoptotic effect of Trichinella spiralis infection against experimentally induced hepatocellular carcinoma Asian Pac J Cancer Prev 2021 22 3 935 10.31557/apjcp.2021.22.3.935 33773560 PMC8286675 Elhasawy FA, Ashour DS, ElSaka AM, Ismail HI. The apoptotic effect of Trichinella spiralis infection against experimentally induced hepatocellular carcinoma. Asian Pac J Cancer Prev. 2021;22(3):935. 10.31557/apjcp.2021.22.3.935. 33773560 10.31557/APJCP.2021.22.3.935 PMC8286675

122. Baheti N Sreedharan M Krishnamoorthy T Nair M Radhakrishnan K Eosinophilic meningitis and an ocular worm in a patient from Kerala, South India BMJ Case Rep 2008 79 3 271 276 10.1136/bcr.2007.122093 PMC3106000 21687288 Baheti N, Sreedharan M, Krishnamoorthy T, Nair M, Radhakrishnan K. Eosinophilic meningitis and an ocular worm in a patient from Kerala, South India. BMJ Case Rep. 2008;79(3):271–6. 10.1136/bcr.2007.122093. 10.1136/bcr.2007.122093 PMC3106000 21687288

123. Lu Y Yang Y Yang S Xia Q Immunomodulatory action of excretory–secretory products of Angiostrongylus cantonensis in a mouse tumour model Parasitol Res 2020 119 3705 3718 10.1007/s00436-020-06872-4 32901341 Lu Y, Yang Y, Yang S, Xia Q. Immunomodulatory action of excretory–secretory products of Angiostrongylus cantonensis in a mouse tumour model. Parasitol Res. 2020;119:3705–18. 10.1007/s00436-020-06872-4. 32901341 10.1007/s00436-020-06872-4

124. Abdel-Latif M Sakran T El-Shahawi G El-Fayoumi H El-Mallah A-M Effect of diethylcarbamazine citrate and Setaria equina excretory–secretory material on rat hepatocellular carcinoma Arch Immunol Ther Exp 2014 62 511 520 10.1007/s00005-014-0292-z 24879096 Abdel-Latif M, Sakran T, El-Shahawi G, El-Fayoumi H, El-Mallah A-M. Effect of diethylcarbamazine citrate and Setaria equina excretory–secretory material on rat hepatocellular carcinoma. Arch Immunol Ther Exp. 2014;62:511–20. 10.1007/s00005-014-0292-z. 10.1007/s00005-014-0292-z 24879096

125. Abdel-Latif M Sakran T El-Shahawi G El-Fayoumi H El-Mallah A-M Immunomodulatory effect of diethylcarbamazine citrate plus filarial excretory–secretory product on rat hepatocarcinogenesis Int Immunopharmacol 2015 24 2 173 181 10.1016/j.intimp.2014.12.004 25499729 Abdel-Latif M, Sakran T, El-Shahawi G, El-Fayoumi H, El-Mallah A-M. Immunomodulatory effect of diethylcarbamazine citrate plus filarial excretory–secretory product on rat hepatocarcinogenesis. Int Immunopharmacol. 2015;24(2):173–81. 10.1016/j.intimp.2014.12.004. 25499729 10.1016/j.intimp.2014.12.004

126. Abdel-Latif M Sakran T Detection for cross-reactive proteins in filarial worm Setaria equina , MCF-7 human breast cancer, and Huh-7 hepatoma cells J Immunoassay Immunochem 2016 37 6 572 584 10.1080/15321819.2016.1179644 27093573 Abdel-Latif M, Sakran T. Detection for cross-reactive proteins in filarial worm Setaria equina , MCF-7 human breast cancer, and Huh-7 hepatoma cells. J Immunoassay Immunochem. 2016;37(6):572–84. 10.1080/15321819.2016.1179644. 27093573 10.1080/15321819.2016.1179644

127. Stevenson MM Riley EM Innate immunity to malaria Nat Rev Immunol 2004 4 3 169 180 10.1038/nri1311 15039754 Stevenson MM, Riley EM. Innate immunity to malaria. Nat Rev Immunol. 2004;4(3):169–80. 10.1038/nri1311. 15039754 10.1038/nri1311

128. Angsubhakorn S Bhamarapravati N Sahaphong S Sathiropas P Reducing effects of rodent malaria on hepatic carcinogenesis induced by dietary Aflatoxin B1 Int J Cancer 1988 41 1 69 73 10.1002/ijc.2910410114 3121525 Angsubhakorn S, Bhamarapravati N, Sahaphong S, Sathiropas P. Reducing effects of rodent malaria on hepatic carcinogenesis induced by dietary Aflatoxin B1. Int J Cancer. 1988;41(1):69–73. 10.1002/ijc.2910410114. 3121525 10.1002/ijc.2910410114

129. Wang B Li Q Wang J Zhao S Nashun B Qin L Plasmodium infection inhibits tumor angiogenesis through effects on tumor-associated macrophages in a murine implanted hepatoma model Cell Commun Signal 2020 18 1 17 10.1186/s12964-020-00570-5 32972437 PMC7513281 Wang B, Li Q, Wang J, Zhao S, Nashun B, Qin L, et al. Plasmodium infection inhibits tumor angiogenesis through effects on tumor-associated macrophages in a murine implanted hepatoma model. Cell Commun Signal. 2020;18:1–17. 10.1186/s12964-020-00570-5. 32972437 10.1186/s12964-020-00570-5 PMC7513281

130. Masson V De La Ballina LR Munaut C Wielockx B Jost M Maillard C Contribution of host MMP-2 and MMP-9 to promote tumor vascularization and invasion of malignant keratinocytes FASEB J 2005 19 2 234 10.1096/fj.04-2140fje 15550552 PMC2771171 Masson V, De La Ballina LR, Munaut C, Wielockx B, Jost M, Maillard C, et al. Contribution of host MMP-2 and MMP-9 to promote tumor vascularization and invasion of malignant keratinocytes. FASEB J. 2005;19(2):234. 15550552 10.1096/fj.04-2140fje PMC2771171

131. Liu Q Yang Y Tan X Tao Z Adah D Yu S Plasmodium parasite as an effective hepatocellular carcinoma antigen glypican-3 delivery vector Oncotarget 2017 8 15 24785 10.18632/oncotarget.15806 28445973 PMC5421888 Liu Q, Yang Y, Tan X, Tao Z, Adah D, Yu S, et al. Plasmodium parasite as an effective hepatocellular carcinoma antigen glypican-3 delivery vector. Oncotarget. 2017;8(15):24785. 10.18632/oncotarget.15806. 28445973 10.18632/oncotarget.15806 PMC5421888

132. Liang Y Chen X Tao Z Ma M Adah D Li X Plasmodium infection prevents recurrence and metastasis of hepatocellular carcinoma possibly via inhibition of the epithelial–mesenchymal transition Mol Med Rep 2021 23 6 1 10 10.3892/mmr.2021.12057 PMC8025467 33846776 Liang Y, Chen X, Tao Z, Ma M, Adah D, Li X, et al. Plasmodium infection prevents recurrence and metastasis of hepatocellular carcinoma possibly via inhibition of the epithelial–mesenchymal transition. Mol Med Rep. 2021;23(6):1–10. 10.3892/mmr.2021.12057. 10.3892/mmr.2021.12057 PMC8025467 33846776

133. Wang G Gao M Influence of Toxoplasma gondii on in vitro proliferation and apoptosis of hepatoma carcinoma H7402 cell Asian Pac J Trop Med 2016 9 1 63 66 10.1016/j.apjtm.2015.12.013 26851789 Wang G, Gao M. Influence of Toxoplasma gondii on in vitro proliferation and apoptosis of hepatoma carcinoma H7402 cell. Asian Pac J Trop Med. 2016;9(1):63–6. 10.1016/j.apjtm.2015.12.013. 26851789 10.1016/j.apjtm.2015.12.013

134. Kim SG Seo SH Shin JH Yang JP Lee SH Shin EH Increase in the nuclear localization of PTEN by the Toxoplasma GRA16 protein and subsequent induction of p53-dependent apoptosis and anti-cancer effect J Cell Mol Med 2019 23 5 3234 3245 10.1111/jcmm.14207 30834688 PMC6484329 Kim SG, Seo SH, Shin JH, Yang JP, Lee SH, Shin EH. Increase in the nuclear localization of PTEN by the Toxoplasma GRA16 protein and subsequent induction of p53-dependent apoptosis and anti-cancer effect. J Cell Mol Med. 2019;23(5):3234–45. 10.1111/jcmm.14207. 30834688 10.1111/jcmm.14207 PMC6484329

135. Li Y Poppoe F Chen J Yu L Deng F Luo Q Macrophages polarized by expression of Toxo GRA15II inhibit growth of hepatic carcinoma Front Immunol 2017 8 137 10.3389/fimmu.2017.00137 28243242 PMC5303709 Li Y, Poppoe F, Chen J, Yu L, Deng F, Luo Q, et al. Macrophages polarized by expression of Toxo GRA15II inhibit growth of hepatic carcinoma. Front Immunol. 2017;8:137. 10.3389/fimmu.2017.00137. 28243242 10.3389/fimmu.2017.00137 PMC5303709

136. Fitzgerald AA Wang S Agarwal V Marcisak EF Zuo A Jablonski SA DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma J Immunother Cancer 2021 9 11 e002837 10.1136/jitc-2021-002837 34737215 PMC8578994 Fitzgerald AA, Wang S, Agarwal V, Marcisak EF, Zuo A, Jablonski SA, et al. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma. J Immunother Cancer. 2021;9(11): e002837. 10.1136/jitc-2021-002837. 34737215 10.1136/jitc-2021-002837 PMC8578994

137. Mayo SC Nathan H Cameron JL Olino K Edil BH Herman JM Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent Cancer 2012 118 10 2674 2681 10.1002/cncr.26553 21935914 PMC3578343 Mayo SC, Nathan H, Cameron JL, Olino K, Edil BH, Herman JM, et al. Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. Cancer. 2012;118(10):2674–81. 21935914 10.1002/cncr.26553 PMC3578343

138. Doğan S Çakir M Kartal A Öztaş H Oltulu P Can Echinococcus granulosus infestation prevent pancreatic cancer? An in vivo experimental study Asian Pac J Cancer Prev 2023 24 4 1307 1312 10.31557/apjcp.2023.24.4.1307 37116153 PMC10352762 Doğan S, Çakir M, Kartal A, Öztaş H, Oltulu P. Can Echinococcus granulosus infestation prevent pancreatic cancer? An in vivo experimental study. Asian Pac J Cancer Prev. 2023;24(4):1307–12. 10.31557/apjcp.2023.24.4.1307. 37116153 10.31557/APJCP.2023.24.4.1307 PMC10352762

139. Fox BA Sanders KL Chen S Bzik DJ Targeting tumors with nonreplicating Toxoplasma gondii uracil auxotroph vaccines Trends Parasitol 2013 29 9 431 437 10.1016/j.pt.2013.07.001 23928100 PMC3777737 Fox BA, Sanders KL, Chen S, Bzik DJ. Targeting tumors with nonreplicating Toxoplasma gondii uracil auxotroph vaccines. Trends Parasitol. 2013;29(9):431–7. 10.1016/j.pt.2013.07.001. 23928100 10.1016/j.pt.2013.07.001 PMC3777737

140. Sanders KL Fox BA Bzik DJ Attenuated Toxoplasma gondii stimulates immunity to pancreatic cancer by manipulation of myeloid cell populations Cancer Immunol Res 2015 3 8 891 901 10.1158/2326-6066 25804437 PMC4526316 Sanders KL, Fox BA, Bzik DJ. Attenuated Toxoplasma gondii stimulates immunity to pancreatic cancer by manipulation of myeloid cell populations. Cancer Immunol Res. 2015;3(8):891–901. 10.1158/2326-6066. 25804437 10.1158/2326-6066.CIR-14-0235 PMC4526316

141. Sanders KL Fox BA Bzik DJ Attenuated Toxoplasma gondii therapy of disseminated pancreatic cancer generates long-lasting immunity to pancreatic cancer Oncoimmunology 2016 5 4 e1104447 10.1080/2162402X.2015 27141388 PMC4839330 Sanders KL, Fox BA, Bzik DJ. Attenuated Toxoplasma gondii therapy of disseminated pancreatic cancer generates long-lasting immunity to pancreatic cancer. Oncoimmunology. 2016;5(4): e1104447. 10.1080/2162402X.2015. 27141388 10.1080/2162402X.2015.1104447 PMC4839330

142. Bahwal SA Chen JJ Lilin E Hao T Chen J Carruthers VB Attenuated Toxoplasma gondii enhances the anti-tumor efficacy of anti-PD1 antibody by altering the tumor microenvironment in a pancreatic cancer mouse model J Cancer Res Clin Oncol 2022 148 10 2743 2757 10.1007/s00432-022-04036-8 35556163 PMC11800998 Bahwal SA, Chen JJ, Lilin E, Hao T, Chen J, Carruthers VB, et al. Attenuated Toxoplasma gondii enhances the anti-tumor efficacy of anti-PD1 antibody by altering the tumor microenvironment in a pancreatic cancer mouse model. J Cancer Res Clin Oncol. 2022;148(10):2743–57. 10.1007/s00432-022-04036-8. 35556163 10.1007/s00432-022-04036-8 PMC11800998

143. Payne SN Emmerich PB Davis NM Deming DA Knoll LJ Novel murine pancreatic tumor model demonstrates immunotherapeutic control of tumor progression by a Toxoplasma gondii protein Infect Immun 2021 10.1128/IAI.00508-21 PMC8594601 34543124 Payne SN, Emmerich PB, Davis NM, Deming DA, Knoll LJ. Novel murine pancreatic tumor model demonstrates immunotherapeutic control of tumor progression by a Toxoplasma gondii protein. Infect Immun. 2021. 10.1128/IAI.00508-21. 10.1128/IAI.00508-21 PMC8594601 34543124

144. Siegel RL Miller KD Fuchs HE Jemal A Cancer statistics, 2021 CA Cancer J Clin 2021 71 1 7 33 10.3322/caac.21654 33433946 Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. 33433946 10.3322/caac.21654

145. Doroshow DB Sanmamed MF Hastings K Politi K Rimm DL Chen L Immunotherapy in non-small cell lung cancer: facts and hopes Clin Cancer Res 2019 25 15 4592 4602 10.1158/1078-0432.ccr-18-1538 30824587 PMC6679805 Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, et al. Immunotherapy in non-small cell lung cancer: facts and hopes. Clin Cancer Res. 2019;25(15):4592–602. 10.1158/1078-0432.ccr-18-1538. 30824587 10.1158/1078-0432.CCR-18-1538 PMC6679805

146. Collins LG Haines C Perkel R Enck RE Lung cancer: diagnosis and management AFP 2007 75 1 56 63 17225705 Collins LG, Haines C, Perkel R, Enck RE. Lung cancer: diagnosis and management. AFP. 2007;75(1):56–63. 17225705

147. Berriel E Freire T Chiale C Rodríguez E Morón G Fernandez-Grana G Human hydatid cyst fluid-induced therapeutic anti-cancer immune responses via NK1. 1+ cell activation in mice Cancer Immunol Immunother 2021 70 12 3617 3627 10.1007/s00262-021-02948-x 33944981 PMC10992520 Berriel E, Freire T, Chiale C, Rodríguez E, Morón G, Fernandez-Grana G, et al. Human hydatid cyst fluid-induced therapeutic anti-cancer immune responses via NK1. 1+ cell activation in mice. Cancer Immunol Immunother. 2021;70(12):3617–27. 10.1007/s00262-021-02948-x. 33944981 10.1007/s00262-021-02948-x PMC10992520

148. Yong W Heath D Savage T Possible antigenic similarity between pulmonary carcinoma and cysts of Echinococcus granulosus BMJ 1979 1 6176 1463 10.1136/bmj.1.6176.1463-a PMC1599112 466062 Yong W, Heath D, Savage T. Possible antigenic similarity between pulmonary carcinoma and cysts of Echinococcus granulosus . BMJ. 1979;1(6176):1463. 10.1136/bmj.1.6176.1463-a. 10.1136/bmj.1.6176.1463-a PMC1599112 466062

149. Karadayi S Arslan S Sumer Z Turan M Sumer H Karadayi K Does hydatid disease have protective effects against lung cancer? Mol Biol Rep 2013 40 4701 4704 10.1007/s11033-013-2565-8 23645038 Karadayi S, Arslan S, Sumer Z, Turan M, Sumer H, Karadayi K. Does hydatid disease have protective effects against lung cancer? Mol Biol Rep. 2013;40:4701–4. 10.1007/s11033-013-2565-8. 23645038 10.1007/s11033-013-2565-8

150. Gong P Zhang X Li J Zhang G Yang J Cao L Observation of anti-tumer effect of Trichinella spirialis in mice on A549 lung cancer cell J Pathogen Biol 2008 3 200 202 Gong P, Zhang X, Li J, Zhang G, Yang J, Cao L, et al. Observation of anti-tumer effect of Trichinella spirialis in mice on A549 lung cancer cell. J Pathogen Biol. 2008;3:200–2.

151. Luo J Yu L Xie G Li D Su M Zhao X Study on the mitochondrial apoptosis pathways of small cell lung cancer H446 cells induced by Trichinella spiralis muscle larvae ESPs Parasitology 2017 144 6 793 800 10.1017/S0031182016002535 28073393 Luo J, Yu L, Xie G, Li D, Su M, Zhao X, et al. Study on the mitochondrial apoptosis pathways of small cell lung cancer H446 cells induced by Trichinella spiralis muscle larvae ESPs. Parasitology. 2017;144(6):793–800. 10.1017/S0031182016002535. 28073393 10.1017/S0031182016002535

152. Wu H Li M Shao X An Z Du J Yin H Trichinella spiralis muscle larvae excretory/secretory products trigger apoptosis and S-phase arrest of the non-small-cell lung cancer line A549 Exp Parasitol 2020 218 107983 10.1016/j.exppara.2020.107983 32861680 Wu H, Li M, Shao X, An Z, Du J, Yin H, et al. Trichinella spiralis muscle larvae excretory/secretory products trigger apoptosis and S-phase arrest of the non-small-cell lung cancer line A549. Exp Parasitol. 2020;218: 107983. 10.1016/j.exppara.2020.107983. 32861680 10.1016/j.exppara.2020.107983

153. Wang H Zhu Y Li M Pan J Li D Guo W-P Transcriptome profiling of A549 non-small cell lung cancer cells in response to Trichinella spiralis muscle larvae excretory/secretory products Front Vet Sci 2023 10.3389/fvets.2023.1208538 PMC10433203 37601754 Wang H, Zhu Y, Li M, Pan J, Li D, Guo W-P, et al. Transcriptome profiling of A549 non-small cell lung cancer cells in response to Trichinella spiralis muscle larvae excretory/secretory products. Front Vet Sci. 2023. 10.3389/fvets.2023.1208538. 10.3389/fvets.2023.1208538 PMC10433203 37601754

154. Lu X Zhang X Li S Zhang H Gong P Li J Prokaryotic expression and identification of sHSP genes for antigens associated with Lewis lung cancer (LLC) cells and Trichinella spiralis J Pathogen Biol 2019 14 4 409 412 Lu X, Zhang X, Li S, Zhang H, Gong P, Li J, et al. Prokaryotic expression and identification of sHSP genes for antigens associated with Lewis lung cancer (LLC) cells and Trichinella spiralis . J Pathogen Biol. 2019;14(4):409–12.

155. Yue T Zhang X Gong P Li J Wang X Li X Antitumor effect of invasive Lactobacillus plantarum delivering associated antigen gene sHSP between Trichinella spiralis and Lewis lung cancer cells Int Immunopharmacol 2023 115 109708 10.1016/j.intimp.2023.109708 36638662 Yue T, Zhang X, Gong P, Li J, Wang X, Li X, et al. Antitumor effect of invasive Lactobacillus plantarum delivering associated antigen gene sHSP between Trichinella spiralis and Lewis lung cancer cells. Int Immunopharmacol. 2023;115: 109708. 10.1016/j.intimp.2023.109708. 36638662 10.1016/j.intimp.2023.109708

156. Zheng Z Lu X Zhou D Deng X-F Liu Q-X Liu X-B A novel enemy of cancer: recent investigations into protozoan anti-tumor properties Front Cell Infect Microbiol 2024 13 1325144 10.3389/fcimb.2023.1325144 38274735 PMC10808745 Zheng Z, Lu X, Zhou D, Deng X-F, Liu Q-X, Liu X-B, et al. A novel enemy of cancer: recent investigations into protozoan anti-tumor properties. Front Cell Infect Microbiol. 2024;13:1325144. 10.3389/fcimb.2023.1325144. 38274735 10.3389/fcimb.2023.1325144 PMC10808745

157. Freire T Landeira M Giacomini C Festari MF Pittini Á Cardozo V Trypanosoma cruzi -derived molecules induce anti-tumour protection by favouring both innate and adaptive immune responses Int J Mol Sci 2022 23 23 15032 10.3390/ijms232315032 36499361 PMC9739173 Freire T, Landeira M, Giacomini C, Festari MF, Pittini Á, Cardozo V, et al. Trypanosoma cruzi -derived molecules induce anti-tumour protection by favouring both innate and adaptive immune responses. Int J Mol Sci. 2022;23(23):15032. 10.3390/ijms232315032. 36499361 10.3390/ijms232315032 PMC9739173

158. Salvador-Membreve DMC Jacinto SD Rivera WL Trichomonas vaginalis induces cytopathic effect on human lung alveolar basal carcinoma epithelial cell line A549 Exp Parasitol 2014 147 33 40 10.1016/j.exppara.2014.10.003 25307688 Salvador-Membreve DMC, Jacinto SD, Rivera WL. Trichomonas vaginalis induces cytopathic effect on human lung alveolar basal carcinoma epithelial cell line A549. Exp Parasitol. 2014;147:33–40. 10.1016/j.exppara.2014.10.003. 25307688 10.1016/j.exppara.2014.10.003

159. Suzuki Y Kobayashi A Antitumor effect of intralesional injection with formalin-fixed Toxoplasma gondii organisms on Lewis lung carcinoma in Toxoplasma -infected mice Cancer Lett 1985 25 3 247 254 10.1016/s0304-3835(15)30003-3 3971344 Suzuki Y, Kobayashi A. Antitumor effect of intralesional injection with formalin-fixed Toxoplasma gondii organisms on Lewis lung carcinoma in Toxoplasma -infected mice. Cancer Lett. 1985;25(3):247–54. 10.1016/s0304-3835(15)30003-3. 3971344 10.1016/s0304-3835(15)30003-3

160. Yang Y Liu Q Lu J Adah D Yu S Zhao S Exosomes from Plasmodium -infected hosts inhibit tumor angiogenesis in a murine Lewis lung cancer model Oncogenesis 2017 6 6 e351 10.1038/oncsis.2017.52 28650446 PMC5519199 Yang Y, Liu Q, Lu J, Adah D, Yu S, Zhao S, et al. Exosomes from Plasmodium -infected hosts inhibit tumor angiogenesis in a murine Lewis lung cancer model. Oncogenesis. 2017;6(6): e351. 10.1038/oncsis.2017.52. 28650446 10.1038/oncsis.2017.52 PMC5519199

161. Caini S Gandini S Dudas M Bremer V Severi E Gherasim A Sexually transmitted infections and prostate cancer risk: a systematic review and meta-analysis Cancer Epidemiol 2014 38 4 329 338 10.1016/j.canep.2014.06.002 24986642 Caini S, Gandini S, Dudas M, Bremer V, Severi E, Gherasim A. Sexually transmitted infections and prostate cancer risk: a systematic review and meta-analysis. Cancer Epidemiol. 2014;38(4):329–38. 10.1016/j.canep.2014.06.002. 24986642 10.1016/j.canep.2014.06.002

162. Carter JE Whithaus KC Neonatal respiratory tract involvement by Trichomonas vaginalis : a case report and review of the literature Am J Trop Med Hyg 2008 78 1 17 19 10.4269/ajtmh.2008.78.17 18187779 Carter JE, Whithaus KC. Neonatal respiratory tract involvement by Trichomonas vaginalis : a case report and review of the literature. Am J Trop Med Hyg. 2008;78(1):17–9. 18187779

163. Trudeau C Yuan S Galipeau J Benlimame N Alaoui-Jamali MA Batist G A novel parasite-derived suicide gene for cancer gene therapy with specificity for lung cancer cells Hum Gene Ther 2001 12 13 1673 1680 10.1089/10430340152528165 11535170 Trudeau C, Yuan S, Galipeau J, Benlimame N, Alaoui-Jamali MA, Batist G. A novel parasite-derived suicide gene for cancer gene therapy with specificity for lung cancer cells. Hum Gene Ther. 2001;12(13):1673–80. 10.1089/10430340152528165. 11535170 10.1089/10430340152528165

164. Chen L He Z Qin L Li Q Shi X Zhao S Antitumor effect of malaria parasite infection in a murine Lewis lung cancer model through induction of innate and adaptive immunity PLoS ONE 2011 6 9 e24407 10.1371/journal.pone.0024407 21931708 PMC3170332 Chen L, He Z, Qin L, Li Q, Shi X, Zhao S, et al. Antitumor effect of malaria parasite infection in a murine Lewis lung cancer model through induction of innate and adaptive immunity. PLoS ONE. 2011;6(9): e24407. 10.1371/journal.pone.0024407. 21931708 10.1371/journal.pone.0024407 PMC3170332

165. Adah D Yang Y Liu Q Gadidasu K Tao Z Yu S Plasmodium infection inhibits the expansion and activation of MDSCs and Tregs in the tumor microenvironment in a murine Lewis lung cancer model Cell Commun Signal 2019 17 1 12 10.1186/s12964-019-0342-6 30979375 PMC6461823 Adah D, Yang Y, Liu Q, Gadidasu K, Tao Z, Yu S, et al. Plasmodium infection inhibits the expansion and activation of MDSCs and Tregs in the tumor microenvironment in a murine Lewis lung cancer model. Cell Commun Signal. 2019;17:1–12. 10.1186/s12964-019-0342-6. 30979375 10.1186/s12964-019-0342-6 PMC6461823

166. Deng X Zheng H Zhou D Liu Q Ding Y Xu W Antitumor effect of intravenous immunization with malaria genetically attenuated sporozoites through induction of innate and adaptive immunity Int J Clin Exp Pathol 2016 9 2 978 986 Deng X, Zheng H, Zhou D, Liu Q, Ding Y, Xu W, et al. Antitumor effect of intravenous immunization with malaria genetically attenuated sporozoites through induction of innate and adaptive immunity. Int J Clin Exp Pathol. 2016;9(2):978–86.

167. Zhou D Zheng H Liu Q Lu X Deng X Jiang L Attenuated Plasmodium sporozoite expressing MAGE-A3 induces antigen-specific CD8+ T cell response against lung cancer in mice Cancer Biol Med 2019 16 2 288 10.20892/j.issn.2095-3941.2018.0309 31516749 PMC6713645 Zhou D, Zheng H, Liu Q, Lu X, Deng X, Jiang L, et al. Attenuated Plasmodium sporozoite expressing MAGE-A3 induces antigen-specific CD8+ T cell response against lung cancer in mice. Cancer Biol Med. 2019;16(2):288. 10.20892/j.issn.2095-3941.2018.0309. 31516749 10.20892/j.issn.2095-3941.2018.0309 PMC6713645

168. Lu X Zhang J Li Y-Q Liu Q-X Zhou D Deng X-F Plasmodium circumsporozoite protein enhances the efficacy of gefitinib in lung adenocarcinoma cells by inhibiting autophagy via proteasomal degradation of LC3B Front Cell Dev Biol 2022 10 830046 10.3389/fcell.2022.830046 35186935 PMC8851824 Lu X, Zhang J, Li Y-Q, Liu Q-X, Zhou D, Deng X-F, et al. Plasmodium circumsporozoite protein enhances the efficacy of gefitinib in lung adenocarcinoma cells by inhibiting autophagy via proteasomal degradation of LC3B. Front Cell Dev Biol. 2022;10: 830046. 10.3389/fcell.2022.830046. 35186935 10.3389/fcell.2022.830046 PMC8851824

169. Deng XF Zhou D Liu QX Zheng H Ding Y Xu WY Plasmodium circumsporozoite protein suppresses the growth of A549 cells via inhibiting nuclear transcription factor κB Oncol Lett 2018 15 5 6585 6591 10.3892/ol.2018.8115 29616122 PMC5876457 Deng XF, Zhou D, Liu QX, Zheng H, Ding Y, Xu WY, et al. Plasmodium circumsporozoite protein suppresses the growth of A549 cells via inhibiting nuclear transcription factor κB. Oncol Lett. 2018;15(5):6585–91. 10.3892/ol.2018.8115. 29616122 10.3892/ol.2018.8115 PMC5876457

170. Qin L Zhong M Adah D Qin L Chen X Ma C A novel tumour suppressor lncRNA F630028O10Rik inhibits lung cancer angiogenesis by regulating miR-223-3p J Cell Mol Med 2020 24 6 3549 3559 10.1111/jcmm.15044 32052546 PMC7131933 Qin L, Zhong M, Adah D, Qin L, Chen X, Ma C, et al. A novel tumour suppressor lncRNA F630028O10Rik inhibits lung cancer angiogenesis by regulating miR-223-3p. J Cell Mol Med. 2020;24(6):3549–59. 10.1111/jcmm.15044. 32052546 10.1111/jcmm.15044 PMC7131933

171. Tao Z Ding W Cheng Z Feng Y Kang Z Qiu R Preclinical study of Plasmodium immunotherapy combined with radiotherapy for solid tumors Cells 2022 11 22 3600 10.3390/cells11223600 36429033 PMC9688403 Tao Z, Ding W, Cheng Z, Feng Y, Kang Z, Qiu R, et al. Preclinical study of Plasmodium immunotherapy combined with radiotherapy for solid tumors. Cells. 2022;11(22):3600. 10.3390/cells11223600. 36429033 10.3390/cells11223600 PMC9688403

172. Chen X Tao Z Liang Y Ma M Adah D Ding W Plasmodium immunotherapy combined with gemcitabine has a synergistic inhibitory effect on tumor growth and metastasis in murine Lewis lung cancer models Front Oncol 2023 13 1181176 10.3389/fonc.2023.1181176 37916167 PMC10618005 Chen X, Tao Z, Liang Y, Ma M, Adah D, Ding W, et al. Plasmodium immunotherapy combined with gemcitabine has a synergistic inhibitory effect on tumor growth and metastasis in murine Lewis lung cancer models. Front Oncol. 2023;13:1181176. 10.3389/fonc.2023.1181176. 37916167 10.3389/fonc.2023.1181176 PMC10618005

173. Clinical study of Plasmodium immunotherapy for advanced non-small cell lung. Cancer.Clinicaltrials.gov/ct2/show/ NCT02786589 . Laboratory of respiratory disease.

174. Kim J-O Jung S-S Kim S-Y Kim TY Shin D-W Lee J-H Inhibition of Lewis lung carcinoma growth by Toxoplasma gondii through induction of Th1 immune responses and inhibition of angiogenesis J Korean Med Sci 2007 22 Suppl S38 S46 10.3346/jkms.2007.22.S.S38 17923753 PMC2694397 Kim J-O, Jung S-S, Kim S-Y, Kim TY, Shin D-W, Lee J-H, et al. Inhibition of Lewis lung carcinoma growth by Toxoplasma gondii through induction of Th1 immune responses and inhibition of angiogenesis. J Korean Med Sci. 2007;22(Suppl):S38–46. 17923753 10.3346/jkms.2007.22.S.S38 PMC2694397

175. Yu-Meng J Zhi-Yong T Yu-Jian C Chun-Xiang L Hui X Xue-Mei W Inhibition of Toxoplasma gondii excretory–secretory antigens on growth of murine Lewis lung carcinoma Chin J Schisto Control 2019 31 4 400 10.16250/j.32.1374.2018269 31612675 Yu-Meng J, Zhi-Yong T, Yu-Jian C, Chun-Xiang L, Hui X, Xue-Mei W, et al. Inhibition of Toxoplasma gondii excretory–secretory antigens on growth of murine Lewis lung carcinoma. Chin J Schisto Control. 2019;31(4):400. 10.16250/j.32.1374.2018269. 10.16250/j.32.1374.2018269 31612675

176. Seo S-H Kim S-G Shin J-H Ham D-W Shin E-H Toxoplasma gra16 inhibits nf-κb activation through pp 2a-b55 upregulation in non-small-cell lung carcinoma cells Int J Mol Sci 2020 21 18 6642 10.3390/ijms21186642 32927892 PMC7554801 Seo S-H, Kim S-G, Shin J-H, Ham D-W, Shin E-H. Toxoplasma GRA16 inhibits NF-κB activation through PP2A-B55 upregulation in non-small-cell lung carcinoma cells. Int J Mol Sci. 2020;21(18):6642. 10.3390/ijms21186642. 32927892 10.3390/ijms21186642 PMC7554801

177. Nolan E Lindeman GJ Visvader JE Deciphering breast cancer: from biology to the clinic Cell 2023 10.1016/j.cell.2023.01.040 36931265 Nolan E, Lindeman GJ, Visvader JE. Deciphering breast cancer: from biology to the clinic. Cell. 2023. 10.1016/j.cell.2023.01.040. 10.1016/j.cell.2023.01.040 36931265

178. Tzeng YDT Hsiao J-H Tseng L-M Hou M-F Li C-J Breast cancer organoids derived from patients: a platform for tailored drug screening Biochem Pharmacol 2023 217 115803 10.1016/j.bcp.2023.115803 37709150 Tzeng YDT, Hsiao J-H, Tseng L-M, Hou M-F, Li C-J. Breast cancer organoids derived from patients: a platform for tailored drug screening. Biochem Pharmacol. 2023;217: 115803. 10.1016/j.bcp.2023.115803. 37709150 10.1016/j.bcp.2023.115803

179. Daneshpour S Kefayat AH Mofid MR Rad SR Darani HY Effect of hydatid cyst fluid antigens on induction of apoptosis on breast cancer cells Adv Biomed Res 2019 8 27 10.4103/abr.abr_220_18 31123670 PMC6477833 Daneshpour S, Kefayat AH, Mofid MR, Rad SR, Darani HY. Effect of hydatid cyst fluid antigens on induction of apoptosis on breast cancer cells. Adv Biomed Res. 2019;8:27. 10.4103/abr.abr_220_18. 31123670 10.4103/abr.abr_220_18 PMC6477833

180. Altun A Saraydın SÜ Soylu S İnan DŞ Yastı Ç Özdenkaya Y Chemopreventive effects of hydatid disease on experimental breast cancer Asian Pac J Cancer Prev 2015 10.7314/apjcp.2015.16.4.1391 25743804 Altun A, Saraydın SÜ, Soylu S, İnan DŞ, Yastı Ç, Özdenkaya Y, et al. Chemopreventive effects of hydatid disease on experimental breast cancer. Asian Pac J Cancer Prev. 2015. 10.7314/apjcp.2015.16.4.1391. 10.7314/apjcp.2015.16.4.1391 25743804

181. Shakibapour M Shojaie B Darani HY Immunization with hydatid cyst wall antigens can inhibit breast cancer through changes in serum levels of Th1/Th2 cytokines Int J Prev Med 2020 11 189 10.4103/ijpvm 33815713 PMC8000162 Shakibapour M, Shojaie B, Darani HY. Immunization with hydatid cyst wall antigens can inhibit breast cancer through changes in serum levels of Th1/Th2 cytokines. Int J Prev Med. 2020;11:189. 10.4103/ijpvm. 33815713 10.4103/ijpvm.IJPVM_311_19 PMC8000162

182. Eslahi AV Ghaffarifar F Hassan ZM Dalimi A Anticancer activity of hydatid cyst fluid along with antigen B on tumors induced by 4T1 breast cancer cell in a balb/c mice model Iran J Parasitol 2022 17 2 240 10.18502/ijpa.v17i2.9542 36032740 PMC9363258 Eslahi AV, Ghaffarifar F, Hassan ZM, Dalimi A. Anticancer activity of hydatid cyst fluid along with antigen B on tumors induced by 4T1 breast cancer cell in a balb/c mice model. Iran J Parasitol. 2022;17(2):240. 10.18502/ijpa.v17i2.9542. 36032740 10.18502/ijpa.v17i2.9542 PMC9363258

183. Hewitson JP Grainger JR Maizels RM Helminth immunoregulation: the role of parasite secreted proteins in modulating host immunity Mol Biochem Parasitol 2009 167 1 1 11 10.1016/j.molbiopara.2009.04.008 19406170 PMC2706953 Hewitson JP, Grainger JR, Maizels RM. Helminth immunoregulation: the role of parasite secreted proteins in modulating host immunity. Mol Biochem Parasitol. 2009;167(1):1–11. 10.1016/j.molbiopara.2009.04.008. 19406170 10.1016/j.molbiopara.2009.04.008 PMC2706953

184. Ranasinghe SL Fischer K Zhang W Gobert GN McManus DP Cloning and characterization of two potent Kunitz type protease inhibitors from Echinococcus granulosus PLOS Negl Trop Dis 2015 9 12 e0004268 10.1371/journal.pntd.0004268 26645974 PMC4672886 Ranasinghe SL, Fischer K, Zhang W, Gobert GN, McManus DP. Cloning and characterization of two potent Kunitz type protease inhibitors from Echinococcus granulosus . PLOS Negl Trop Dis. 2015;9(12): e0004268. 10.1371/journal.pntd.0004268. 26645974 10.1371/journal.pntd.0004268 PMC4672886

185. Ranasinghe S, Mcmanus D, Zhang W, Fischer K. Treatment of inflammation and/or cancer. Google Patents. 2016.

186. Ranasinghe SL Boyle GM Fischer K Potriquet J Mulvenna JP McManus DP Kunitz type protease inhibitor EgKI-1 from the canine tapeworm Echinococcus granulosus as a promising therapeutic against breast cancer PLoS One 2018 13 8 e0200433 10.1371/journal.pone.0200433 30169534 PMC6118354 Ranasinghe SL, Boyle GM, Fischer K, Potriquet J, Mulvenna JP, McManus DP. Kunitz type protease inhibitor EgKI-1 from the canine tapeworm Echinococcus granulosus as a promising therapeutic against breast cancer. PLoS One 2018;13(8):e0200433. 10.1371/journal.pone.0200433. 30169534 10.1371/journal.pone.0200433 PMC6118354

187. Darani HY Sharafi SM Effect of hydatid cyst antigens polyspecific antisera on breast cancer cells (4T1) growth in cell culture medium Int J Environ Health Eng 2022 11 1 15 10.4103/ijehe.ijehe_13_21 Darani HY, Sharafi SM. Effect of hydatid cyst antigens polyspecific antisera on breast cancer cells (4T1) growth in cell culture medium. Int J Environ Health Eng. 2022;11(1):15. 10.4103/ijehe.ijehe_13_21.

188. Mohamadi F Shakibapour M Sharafi SM Andalib AR Tolouei S Yousofi-Darani H Investigating the reaction of antisera against hydatid cyst antigens with the surface of breast cancer (4t1), melanoma (b16f10), and normal spleen cells using flow cytometry technique IUMS 2018 36 499 1191 1196 Mohamadi F, Shakibapour M, Sharafi SM, Andalib AR, Tolouei S, Yousofi-Darani H. Investigating the reaction of antisera against hydatid cyst antigens with the surface of breast cancer (4t1), melanoma (b16f10), and normal spleen cells using flow cytometry technique. IUMS. 2018;36(499):1191–6.

189. Weatherly NF Increased survival of Swiss mice given sublethal infections of Trichinella spiralis J Parasitol 1970 56 748 752 10.2307/3277722 5460510 Weatherly NF. Increased survival of Swiss mice given sublethal infections of Trichinella spiralis . J Parasitol. 1970;56:748–52. 5460510

190. Apanasevich V Britov V Antitumor cross-resistance of trichinosis Vopr Onkol 2002 48 2 223 226 12227073 Apanasevich V, Britov V. Antitumor cross-resistance of trichinosis. Vopr Onkol. 2002;48(2):223–6. 12227073

191. Caner A Sadıqova A Erdoğan A Namlıses D Nalbantsoy A Oltulu F Targeting of anti-tumor ımmune responses with live-attenuated Leishmania strains in breast cancer model Breast Cancer 2020 27 1082 1095 10.1007/s12282-020-01112-0 32472473 Caner A, Sadıqova A, Erdoğan A, Namlıses D, Nalbantsoy A, Oltulu F, et al. Targeting of anti-tumor ımmune responses with live-attenuated Leishmania strains in breast cancer model. Breast Cancer. 2020;27:1082–95. 10.1007/s12282-020-01112-0. 32472473 10.1007/s12282-020-01112-0

192. Sheklakova L Kallinikova V Karpenko L Genetic heterogeneity of Trypanosoma cruzi and its direct anti-cancer effect in cultured human tumor cells Bull Exp Biol Med 2003 135 1 89 10.1023/a:1023466517225 12717523 Sheklakova L, Kallinikova V, Karpenko L. Genetic heterogeneity of Trypanosoma cruzi and its direct anti-cancer effect in cultured human tumor cells. Bull Exp Biol Med. 2003;135(1):89. 10.1023/a:1023466517225. 12717523 10.1023/a:1023466517225

193. Molina MC Ferreira V Valck C Aguilar L Orellana J Rojas A An in viv o role for Trypanosoma cruzi calreticulin in antiangiogenesis Mol Biochem Parasitol 2005 140 2 133 140 10.1016/j.molbiopara.2004.12.014 15760653 Molina MC, Ferreira V, Valck C, Aguilar L, Orellana J, Rojas A, et al. An in viv o role for Trypanosoma cruzi calreticulin in antiangiogenesis. Mol Biochem Parasitol. 2005;140(2):133–40. 15760653 10.1016/j.molbiopara.2004.12.014

194. López NC Valck C Ramírez G Rodríguez M Ribeiro C Orellana J Antiangiogenic and anti-tumor effects of Trypanosoma cruzi calreticulin PLOS Negl Trop Dis 2010 4 7 e730 10.1371/journal.pntd.0000730 20625551 PMC2897838 López NC, Valck C, Ramírez G, Rodríguez M, Ribeiro C, Orellana J, et al. Antiangiogenic and anti-tumor effects of Trypanosoma cruzi calreticulin. PLOS Negl Trop Dis. 2010;4(7): e730. 10.1371/journal.pntd.0000730. 20625551 10.1371/journal.pntd.0000730 PMC2897838

195. Abello-Cáceres P Pizarro-Bauerle J Rosas C Maldonado I Aguilar-Guzmán L González C Does native Trypanosoma cruzi calreticulin mediate growth inhibition of a mammary tumor during infection? BMC Cancer 2016 16 1 12 10.1186/s12885-016-2764-5 PMC5020520 27619675 Abello-Cáceres P, Pizarro-Bauerle J, Rosas C, Maldonado I, Aguilar-Guzmán L, González C, et al. Does native Trypanosoma cruzi calreticulin mediate growth inhibition of a mammary tumor during infection? BMC Cancer. 2016;16:1–12. 10.1186/s12885-016-2764-5. 10.1186/s12885-016-2764-5 PMC5020520 27619675

196. Sosoniuk-Roche E Cruz P Maldonado I Duaso L Pesce B Michalak M In vitro treatment of a murine mammary adenocarcinoma cell line with recombinant Trypanosoma cruzi calreticulin promotes immunogenicity and phagocytosis Mol Immunol 2020 124 51 60 10.1016/j.molimm.2020.05.013 32526557 Sosoniuk-Roche E, Cruz P, Maldonado I, Duaso L, Pesce B, Michalak M, et al. In vitro treatment of a murine mammary adenocarcinoma cell line with recombinant Trypanosoma cruzi calreticulin promotes immunogenicity and phagocytosis. Mol Immunol. 2020;124:51–60. 10.1016/j.molimm.2020.05.013. 32526557 10.1016/j.molimm.2020.05.013

197. Borges BC Uehara IA Dos Santos MA Martins FA De Souza FC Junior ÁF The recombinant protein based on Trypanosoma cruzi P21 interacts with CXCR4 receptor and abrogates the invasive phenotype of human breast cancer cells Front Cell Dev Biol 2020 8 569729 10.3389/fcell.2020.569729 33195200 PMC7604327 Borges BC, Uehara IA, Dos Santos MA, Martins FA, De Souza FC, Junior ÁF, et al. The recombinant protein based on Trypanosoma cruzi P21 interacts with CXCR4 receptor and abrogates the invasive phenotype of human breast cancer cells. Front Cell Dev Biol. 2020;8: 569729. 10.3389/fcell.2020.569729. 33195200 10.3389/fcell.2020.569729 PMC7604327

198. Teixeira SC Lopes DS Gimenes SNC Teixeira TL da Silva MS Brígido RTES Mechanistic insights into the anti-angiogenic activity of Trypanosoma cruzi protein 21 and its potential impact on the onset of chagasic cardiomyopathy Sci Rep 2017 7 1 44978 10.1038/srep44978 28322302 PMC5359584 Teixeira SC, Lopes DS, Gimenes SNC, Teixeira TL, da Silva MS, Brígido RTES, et al. Mechanistic insights into the anti-angiogenic activity of Trypanosoma cruzi protein 21 and its potential impact on the onset of chagasic cardiomyopathy. Sci Rep. 2017;7(1):44978. 10.1038/srep44978. 28322302 10.1038/srep44978 PMC5359584

199. Silveira ACA de Oliveira RC Rodrigues CC Teixeira SC Borges BC da Silva CV Trypanosoma cruzi infection induces proliferation and impairs migration of a human breast cancer cell line Exp Parasitol 2023 245 108443 10.1016/j.exppara.2022.108443 36526003 Silveira ACA, de Oliveira RC, Rodrigues CC, Teixeira SC, Borges BC, da Silva CV. Trypanosoma cruzi infection induces proliferation and impairs migration of a human breast cancer cell line. Exp Parasitol. 2023;245: 108443. 10.1016/j.exppara.2022.108443. 36526003 10.1016/j.exppara.2022.108443

200. Pan J Ma M Qin L Kang Z Adah D Tao Z Plasmodium infection inhibits triple negative 4T1 breast cancer potentially through induction of CD8+ T cell-mediated anti-tumor responses in mice Biomed Pharmacother 2021 138 111406 10.1016/j.biopha.2021.111406 33676307 Pan J, Ma M, Qin L, Kang Z, Adah D, Tao Z, et al. Plasmodium infection inhibits triple negative 4T1 breast cancer potentially through induction of CD8+ T cell-mediated anti-tumor responses in mice. Biomed Pharmacother. 2021;138: 111406. 10.1016/j.biopha.2021.111406. 33676307 10.1016/j.biopha.2021.111406

201. Eissa MM Gaafar MR Younis LK Ismail CA El Skhawy N Evaluation of cytotoxic activity of live Toxoplasma gondii tachyzoites and toxoplasma antigen on MCF-7 human breast cancer cell line EUREKA Life Sci 2022 2 45 50 10.21303/2504-5695.2022.002409 Eissa MM, Gaafar MR, Younis LK, Ismail CA, El Skhawy N. Evaluation of cytotoxic activity of live Toxoplasma gondii tachyzoites and toxoplasma antigen on MCF-7 human breast cancer cell line. EUREKA Life Sci. 2022;2:45–50. 10.21303/2504-5695.2022.002409.

202. Şahar EA Döşkaya M Karakavuk M Can H Gül A Gürüz AY Toxoplasma gondii destroys Her2/Neu-expressing mammary cancer cells in vitro using a continuous feed medium approach J Infect Dev Ctries 2020 14 10 1204 1209 10.3855/jidc.12820 33175718 Şahar EA, Döşkaya M, Karakavuk M, Can H, Gül A, Gürüz AY, et al. Toxoplasma gondii destroys Her2/Neu-expressing mammary cancer cells in vitro using a continuous feed medium approach. J Infect Dev Ctries. 2020;14(10):1204–9. 33175718 10.3855/jidc.12820

203. Hosseini F Farahbakhsh Z Balouti A Kalantari R Pourshahbazi G Mobarakeh SM Human anti- Toxoplasma antibodies attach strongly to breast cancer cells Int J Cancer Manag 2023 10.3892/br.2019.1186 Hosseini F, Farahbakhsh Z, Balouti A, Kalantari R, Pourshahbazi G, Mobarakeh SM, et al. Human anti- Toxoplasma antibodies attach strongly to breast cancer cells. Int J Cancer Manag. 2023. 10.3892/br.2019.1186. ( In Press ).

204. Hibbs JB Jr Lambert LH Jr Remington JS Resistance to murine tumors conferred by chronic infection with intracellular protozoa, Toxoplasma gondii and Besnoitia jellisoni J Infect Dis 1971 124 6 587 592 10.1093/infdis/124.6.587 5127071 Hibbs JB Jr, Lambert LH Jr, Remington JS. Resistance to murine tumors conferred by chronic infection with intracellular protozoa, Toxoplasma gondii and Besnoitia jellisoni . J Infect Dis. 1971;124(6):587–92. 10.1093/infdis/124.6.587. 5127071 10.1093/infdis/124.6.587

205. Xu L-Q Yao L-J Jiang D Zhou L-J Chen M Liao W-Z A uracil auxotroph Toxoplasma gondii exerting immunomodulation to inhibit breast cancer growth and metastasis Parasites Vectors 2021 14 1 601 10.1186/s13071-021-05032-6 34895326 PMC8665513 Xu L-Q, Yao L-J, Jiang D, Zhou L-J, Chen M, Liao W-Z, et al. A uracil auxotroph Toxoplasma gondii exerting immunomodulation to inhibit breast cancer growth and metastasis. Parasites Vectors. 2021;14(1):601. 10.1186/s13071-021-05032-6. 34895326 10.1186/s13071-021-05032-6 PMC8665513

206. Ye H-M Lu M-J Liu Q Lin Y Tang L-Y Ren Z-F Beneficial effect of Toxoplasma gondii infection on the prognosis of breast cancer was modified by cytokines Clin Epidemiol 2023 15 469 481 10.2147/clep.s408182 37122480 PMC10145453 Ye H-M, Lu M-J, Liu Q, Lin Y, Tang L-Y, Ren Z-F. Beneficial effect of Toxoplasma gondii infection on the prognosis of breast cancer was modified by cytokines. Clin Epidemiol. 2023;15:469–81. 10.2147/clep.s408182. 37122480 10.2147/CLEP.S408182 PMC10145453

207. Fereig RM Nishikawa Y From signaling pathways to distinct immune responses: key factors for establishing or combating Neospora caninum infection in different susceptible hosts Pathogens 2020 9 5 384 10.3390/pathogens9050384 32429367 PMC7281608 Fereig RM, Nishikawa Y. From signaling pathways to distinct immune responses: key factors for establishing or combating Neospora caninum infection in different susceptible hosts. Pathogens. 2020;9(5):384. 10.3390/pathogens9050384. 32429367 10.3390/pathogens9050384 PMC7281608

208. Lv Q Li J Gong P Xing S Zhang X Neospora caninum : in vitro culture of tachyzoites in MCF-7 human breast carcinoma cells Exp Parasitol 2010 126 4 536 539 10.1016/j.exppara.2010.06.006 20566363 Lv Q, Li J, Gong P, Xing S, Zhang X. Neospora caninum : in vitro culture of tachyzoites in MCF-7 human breast carcinoma cells. Exp Parasitol. 2010;126(4):536–9. 20566363 10.1016/j.exppara.2010.06.006

209. Malatji MP Tembe D Mukaratirwa S An update on epidemiology and clinical aspects of besnoitiosis in livestock and wildlife in sub-Saharan Africa: a systematic review Parasite Epidemiol Control 2023 21 e00284 10.1016/j.parepi.2023.e00284 36793766 PMC9922981 Malatji MP, Tembe D, Mukaratirwa S. An update on epidemiology and clinical aspects of besnoitiosis in livestock and wildlife in sub-Saharan Africa: a systematic review. Parasite Epidemiol Control. 2023;21: e00284. 10.1016/j.parepi.2023.e00284. 36793766 10.1016/j.parepi.2023.e00284 PMC9922981

210. Han J Liu J-E Zheng X-L Ma Y-H Xiao Q Ding Y-M Caring in nursing: investigating the meaning of caring from the perspective of Chinese children living with leukemia Int J Nurs Sci 2014 1 1 34 41 Han J, Liu J-E, Zheng X-L, Ma Y-H, Xiao Q, Ding Y-M. Caring in nursing: investigating the meaning of caring from the perspective of Chinese children living with leukemia. Int J Nurs Sci. 2014;1(1):34–41.

211. Hu S Yang L Wu Z Mak NK Leung KN Fung MC Anti-inflammatory protein of Schistosoma japonicum directs the differentiation of the WEHI-3B JCS cells and mouse bone marrow cells to macrophages J Biomed Biotechnol 2010 2010 1 13 10.1155/2010/867368 PMC2831513 20204135 Hu S, Yang L, Wu Z, Mak NK, Leung KN, Fung MC. Anti-inflammatory protein of Schistosoma japonicum directs the differentiation of the WEHI-3B JCS cells and mouse bone marrow cells to macrophages. J Biomed Biotechnol. 2010;2010:1–13. 10.1155/2010/867368 PMC2831513 20204135

212. Asouli A Sadr S Mohebalian H Borji H Anti-tumor effect of protoscolex hydatid cyst somatic antigen on inhibition cell growth of K562 Acta Parasitol 2023 68 1 8 10.1007/s11686-023-00680-3 36991291 Asouli A, Sadr S, Mohebalian H, Borji H. Anti-tumor effect of protoscolex hydatid cyst somatic antigen on inhibition cell growth of K562. Acta Parasitol. 2023;68:1–8. 10.1007/s11686-023-00680-3. 36991291 10.1007/s11686-023-00680-3

213. Zhang X Cai N Sun L Luo Q An F Apoptosis of human leukemia K562 cell in vitro induced by Toxoplasma gondii Chin J Parasitol Parasit Dis 2007 25 3 185 188 18038773 Zhang X, Cai N, Sun L, Luo Q, An F. Apoptosis of human leukemia K562 cell in vitro induced by Toxoplasma gondii . Chin J Parasitol Parasit Dis. 2007;25(3):185–8. 18038773

214. Piaggi S Salvetti A Gomez-Morales MA Pinto B Bruschi F Glutathione- S -transferase omega 1 and nurse cell formation during experimental Trichinella infection Vet Parasitol 2021 297 109114 10.1016/j.vetpar.2020.109114 32386865 Piaggi S, Salvetti A, Gomez-Morales MA, Pinto B, Bruschi F. Glutathione- S -transferase omega 1 and nurse cell formation during experimental Trichinella infection. Vet Parasitol. 2021;297: 109114. 10.1016/j.vetpar.2020.109114. 32386865 10.1016/j.vetpar.2020.109114

215. Meerovitch E Bomford R Macrophage potentiation by Trichinella spiralis Ann Trop Med Parasitol 1977 71 2 245 247 10.1080/00034983.1977.11687187 869616 Meerovitch E, Bomford R. Macrophage potentiation by Trichinella spiralis . Ann Trop Med Parasitol. 1977;71(2):245–7. 869616 10.1080/00034983.1977.11687187

216. Raisnia R Mohebalian H Sabzevar AS Borji H Anti-tumor effect of Marshallagia marshalli somatic antigen on inhibition cell growth of K562 Iran J Parasitol 2022 17 1 28 10.18502/ijpa.v17i1.9013 36046565 PMC9375725 Raisnia R, Mohebalian H, Sabzevar AS, Borji H. Anti-tumor effect of Marshallagia marshalli somatic antigen on inhibition cell growth of K562. Iran J Parasitol. 2022;17(1):28. 10.18502/ijpa.v17i1.9013. 36046565 10.18502/ijpa.v17i1.9013 PMC9375725

217. Eligio García L Crisóstomo Vázquez MDP Maravelez Acosta VA Soria Guerrero M Cortés Campos A Jiménez Cardoso E Trypanosoma cruzi antigenic proteins shared with acute lymphoblastic leukemia and neuroblastoma Pharmaceuticals 2022 15 11 1421 10.3390/ph15111421 36422551 PMC9693088 Eligio García L, Crisóstomo Vázquez MDP, Maravelez Acosta VA, Soria Guerrero M, Cortés Campos A, Jiménez Cardoso E. Trypanosoma cruzi antigenic proteins shared with acute lymphoblastic leukemia and neuroblastoma. Pharmaceuticals. 2022;15(11):1421. 10.3390/ph15111421. 36422551 10.3390/ph15111421 PMC9693088

218. Tong Z-Z Fang Z-M Zhang Q Zhan Y Zhang Y Jiang W-F Plasmodium yoelii infection inhibits murine leukaemia WEHI-3 cell proliferation in vivo by promoting immune responses Infect Dis Poverty 2018 7 1 1 8 10.1186/s40249-018-0433-4 29764519 PMC5954458 Tong Z-Z, Fang Z-M, Zhang Q, Zhan Y, Zhang Y, Jiang W-F, et al. Plasmodium yoelii infection inhibits murine leukaemia WEHI-3 cell proliferation in vivo by promoting immune responses. Infect Dis Poverty. 2018;7(1):1–8. 10.1186/s40249-018-0433-4. 29764519 10.1186/s40249-018-0433-4 PMC5954458

219. Mugnaini EN Ghosh N Lymphoma Prim Care Clin Off Pract 2016 43 4 661 675 10.1016/j.pop.2016.07.012 27866584 Mugnaini EN, Ghosh N. Lymphoma. Prim Care Clin Off Pract. 2016;43(4):661–75. 10.1016/j.pop.2016.07.012 27866584

220. Swerdlow SH Campo E Pileri SA Harris NL Stein H Siebert R The 2016 revision of the World Health Organization classification of lymphoid neoplasms Am J Hematol 2016 127 20 2375 2390 10.1182/blood-2016-01-643569 PMC4874220 26980727 Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Am J Hematol. 2016;127(20):2375–90. 10.1182/blood-2016-01-643569 PMC4874220 26980727

221. Matasar MJ Zelenetz AD Overview of lymphoma diagnosis and management Radiol Clin North Am 2008 46 2 175 198 10.1016/j.rcl.2008.03.005 18619375 Matasar MJ, Zelenetz AD. Overview of lymphoma diagnosis and management. Radiol Clin North Am. 2008;46(2):175–98. 18619375 10.1016/j.rcl.2008.03.005

222. Wing E Krahenbuhl J Remington J Studies of macrophage function during Trichinella spiralis infection in mice Immunology 1979 36 3 479 437839 PMC1457586 Wing E, Krahenbuhl J, Remington J. Studies of macrophage function during Trichinella spiralis infection in mice. Immunology. 1979;36(3):479. 437839 PMC1457586

223. Mel’nikov V Fierro Velasko F Dobrovinskaya O Suppression of growth and metastasizing of T-cell lymphoma in mice infected with American trypanosomiasis at different stages of experimental infection Bull Exp Biol Med 2004 137 475 478 10.1023/B:BEBM.0000038157.69208.27 15455122 Mel’nikov V, Fierro Velasko F, Dobrovinskaya O. Suppression of growth and metastasizing of T-cell lymphoma in mice infected with American trypanosomiasis at different stages of experimental infection. Bull Exp Biol Med. 2004;137:475–8. 15455122 10.1023/b:bebm.0000038157.69208.27

224. Suzuki Y Muto M Kobayashi A Antitumor effect of formalin-fixed Toxoplasma gondii organisms on EL4 lymphoma in Toxoplasma -infected mice J Biol Response Mod 1986 5 4 288 293 3734844 Suzuki Y, Muto M, Kobayashi A. Antitumor effect of formalin-fixed Toxoplasma gondii organisms on EL4 lymphoma in Toxoplasma -infected mice. J Biol Response Mod. 1986;5(4):288–93. 3734844

225. Yang MP Goitsuka R Ono K Suzuki N Hasegawa A Effect of Toxoplasma lysate antigen (TLA) on feline cytotoxicity against FeLV positive lymphoma cells Nihon Juigaku Zasshi 1990 52 4 735 742 10.1292/jvms1939.52.735 2167995 Yang MP, Goitsuka R, Ono K, Suzuki N, Hasegawa A. Effect of Toxoplasma lysate antigen (TLA) on feline cytotoxicity against FeLV positive lymphoma cells. Nihon Juigaku Zasshi. 1990;52(4):735–42. 10.1292/jvms1939.52.735. 2167995 10.1292/jvms1939.52.735

226. Miyahara K Honda U Tose S Sakurai H Igarashi I Saito A Therapeutic effects of Toxoplasma lysate antigen on 20-methylcholanthrene-induced BALB/c mouse tumors J Vet Med Sci 1992 54 1 7 12 10.1292/jvms.54.7 1558892 Miyahara K, Honda U, Tose S, Sakurai H, Igarashi I, Saito A, et al. Therapeutic effects of Toxoplasma lysate antigen on 20-methylcholanthrene-induced BALB/c mouse tumors. J Vet Med Sci. 1992;54(1):7–12. 10.1292/jvms.54.7. 1558892 10.1292/jvms.54.7

227. Miyahara K Yokoo N Sakurai H Igarashi I Sakata Y Yoshida Y Antitumor activity of Toxoplasma lysate antigen against methylcholanthrene-induced tumor-bearing rats J Vet Med Sci 1992 54 2 221 228 10.1292/jvms.54.221 1606251 Miyahara K, Yokoo N, Sakurai H, Igarashi I, Sakata Y, Yoshida Y, et al. Antitumor activity of Toxoplasma lysate antigen against methylcholanthrene-induced tumor-bearing rats. J Vet Med Sci. 1992;54(2):221–8. 10.1292/jvms.54.221. 1606251 10.1292/jvms.54.221

228. Kato M Maki Y Inoue N Omata Y Claveria FG Igarashi I Toxoplasma lysate antigen (TLA144)-ig8 antigenic component: binding and induction of cytotoxic cell activity in mouse spleen cells J Protozool Res 1994 4 4 149 157 Kato M, Maki Y, Inoue N, Omata Y, Claveria FG, Igarashi I, et al. Toxoplasma lysate antigen (TLA144)-ig8 antigenic component: binding and induction of cytotoxic cell activity in mouse spleen cells. J Protozool Res. 1994;4(4):149–57.

229. Raab M Podar K Breitkreutz I Richardson P Anderson K Multiple myeloma Lancet 2009 374 9686 324 339 10.1016/S0140-6736(09)60221-X 19541364 Raab M, Podar K, Breitkreutz I, Richardson P, Anderson K. Multiple myeloma. Lancet. 2009;374(9686):324–39. 19541364 10.1016/S0140-6736(09)60221-X

230. Khorsand J. Plasma cell neoplasms (including multiple myeloma) treatment (PDQ®). Treatment-Health Professional Information NCI 29. 2016.

231. Gong P Zhang J Cao L Nan Z Li J Yang J Identification and characterization of myeloma-associated antigens in Trichinella spiralis Exp Parasitol 2011 127 4 784 788 10.1016/j.exppara.2010.12.001 21232537 Gong P, Zhang J, Cao L, Nan Z, Li J, Yang J, et al. Identification and characterization of myeloma-associated antigens in Trichinella spiralis . Exp Parasitol. 2011;127(4):784–8. 10.1016/j.exppara.2010.12.001. 21232537 10.1016/j.exppara.2010.12.001

232. Duan L Li J Cheng B Lv Q Gong P-T Su L-B Identification of a novel gene product expressed by Trichinella spiralis that binds antiserum to Sp2/0 myeloma cells Vet Parasitol 2013 194 2–4 183 185 10.1016/j.vetpar.2013.01.051 23465747 Duan L, Li J, Cheng B, Lv Q, Gong P-T, Su L-B, et al. Identification of a novel gene product expressed by Trichinella spiralis that binds antiserum to Sp2/0 myeloma cells. Vet Parasitol. 2013;194(2–4):183–5. 10.1016/j.vetpar.2013.01.051. 23465747 10.1016/j.vetpar.2013.01.051

233. Deng B Gong P Li J Cheng B Ren W Yang J Identification of the differentially expressed genes in SP2/0 myeloma cells from Balb/c mice infected with Trichinella spiralis Vet Parasitol 2013 194 2–4 179 182 10.1016/j.vetpar.2013.01.050 23473833 Deng B, Gong P, Li J, Cheng B, Ren W, Yang J, et al. Identification of the differentially expressed genes in SP2/0 myeloma cells from Balb/c mice infected with Trichinella spiralis . Vet Parasitol. 2013;194(2–4):179–82. 10.1016/j.vetpar.2013.01.050. 23473833 10.1016/j.vetpar.2013.01.050

234. Ahmed A Jan A Mastocytoma. StatPearls 2023 Treasure Island StatPearls Publishing Ahmed A, Jan A. Mastocytoma. StatPearls. Treasure Island: StatPearls Publishing; 2023.

235. Azaña JM Torrelo A Matito A Update on mastocytosis (part 2): categories, prognosis, and treatment Actas Dermosifiliogr (Engl Ed) 2016 107 1 15 22 10.1016/j.ad.2015.09.009 26525106 Azaña JM, Torrelo A, Matito A. Update on mastocytosis (part 2): categories, prognosis, and treatment. Actas Dermosifiliogr (Engl Ed). 2016;107(1):15–22. 10.1016/j.ad.2015.09.009. 10.1016/j.ad.2015.09.009 26525106

236. Longo DL Fauci AS Kasper DL Hauser SL Jameson JL Loscalzo J Harrison’s principles of internal medicine 2014 19 New York McGraw-Hill Medical Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. Harrison’s principles of internal medicine. 19th ed. New York: McGraw-Hill Medical; 2014.

237. Augsburger D Nelson PJ Kalinski T Udelnow A Knösel T Hofstetter M Current diagnostics and treatment of fibrosarcoma—perspectives for future therapeutic targets and strategies Oncotarget 2017 8 61 104638 10.18632/oncotarget.20136 29262667 PMC5732833 Augsburger D, Nelson PJ, Kalinski T, Udelnow A, Knösel T, Hofstetter M, et al. Current diagnostics and treatment of fibrosarcoma—perspectives for future therapeutic targets and strategies. Oncotarget. 2017;8(61): 104638. 10.18632/oncotarget.20136. 29262667 10.18632/oncotarget.20136 PMC5732833

238. Folpe AL Fibrosarcoma: a review and update Histopathology 2014 64 1 12 25 10.1111/his.12282 24266941 Folpe AL. Fibrosarcoma: a review and update. Histopathology. 2014;64(1):12–25. 10.1111/his.12282. 24266941 10.1111/his.12282

239. Gronchi A Miah A Dei Tos A Abecassis N Bajpai J Bauer S Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 2021 32 11 1348 1365 10.1016/j.annonc.2021.07.006 34303806 Gronchi A, Miah A, Dei Tos A, Abecassis N, Bajpai J, Bauer S, et al. Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(11):1348–65. 10.1016/j.annonc.2021.07.006. 34303806 10.1016/j.annonc.2021.07.006

240. Frezza AM Stacchiotti S Gronchi A Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new BMC Med 2017 15 1 1 12 10.1186/s12916-017-0872-y 28571564 PMC5455204 Frezza AM, Stacchiotti S, Gronchi A. Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new. BMC Med. 2017;15(1):1–12. 10.1186/s12916-017-0872-y. 28571564 10.1186/s12916-017-0872-y PMC5455204

241. Pereira FEL Raso P Coelho PMZ Evolution of sarcoma 180 (ascitic tumor) in mice infected with Schistosoma mansoni Rev Soc Bras Med Trop 1986 19 39 42 10.1590/s0037-86821986000100009 3120251 Pereira FEL, Raso P, Coelho PMZ. Evolution of sarcoma 180 (ascitic tumor) in mice infected with Schistosoma mansoni . Rev Soc Bras Med Trop. 1986;19:39–42. 10.1590/s0037-86821986000100009. 3120251 10.1590/s0037-86821986000100009

242. Yousofi Darani H Soozangar N Khorami S Taji F Yousofi M Shirzad H Hydatid cyst protoscolices induce cell death in WEHI-164 fibrosarcoma cells and inhibit the proliferation of baby hamster kidney fibroblasts in vitro J Parasitol Res 2012 10.1155/2012/304183 PMC3306915 22496957 Yousofi Darani H, Soozangar N, Khorami S, Taji F, Yousofi M, Shirzad H. Hydatid cyst protoscolices induce cell death in WEHI-164 fibrosarcoma cells and inhibit the proliferation of baby hamster kidney fibroblasts in vitro. J Parasitol Res. 2012. 10.1155/2012/304183. 10.1155/2012/304183 PMC3306915 22496957

243. Lubiniecki A Cypess R Quantitative study of the effect of previous Trichinella spiralis infection on sarcoma 180 ascitic tumor formation in mice Trop Med Parasitol 1975 26 3 329 334 1189027 Lubiniecki A, Cypess R. Quantitative study of the effect of previous Trichinella spiralis infection on sarcoma 180 ascitic tumor formation in mice. Trop Med Parasitol. 1975;26(3):329–34. 1189027

244. Molinari J Carrick L Jr Lubiniecki A Influence of Trichinella spiralis infection on development of sarcoma-180 ascites tumors Trop Med Parasitol 1979 30 4 429 433 538817 Molinari J, Carrick L Jr, Lubiniecki A. Influence of Trichinella spiralis infection on development of sarcoma-180 ascites tumors. Trop Med Parasitol. 1979;30(4):429–33. 538817

245. Darani HY Shirzad H Mansoori F Zabardast N Mahmoodzadeh M Effects of Toxoplasma gondii and Toxocara canis antigens on WEHI-164 fibrosarcoma growth in a mouse model Korean J Parasitol 2009 47 2 175 10.3347/kjp.2009.47.2.175 19488426 PMC2688801 Darani HY, Shirzad H, Mansoori F, Zabardast N, Mahmoodzadeh M. Effects of Toxoplasma gondii and Toxocara canis antigens on WEHI-164 fibrosarcoma growth in a mouse model. Korean J Parasitol. 2009;47(2):175. 10.3347/kjp.2009.47.2.175. 19488426 10.3347/kjp.2009.47.2.175 PMC2688801

246. Hla T Signaling and biological actions of sphingosine 1-phosphate Pharmacol Res 2003 47 5 401 407 10.1016/s1043-6618(03)00046-x 12676514 Hla T. Signaling and biological actions of sphingosine 1-phosphate. Pharmacol Res. 2003;47(5):401–7. 10.1016/s1043-6618(03)00046-x. 12676514 10.1016/s1043-6618(03)00046-x

247. Das S Chatterjee N Bose D Banerjee S Jha T Das SK Antineoplastic impact of leishmanial sphingolipid in tumour growth with regulation of angiogenic event and inflammatory response Apoptosis 2015 20 869 882 10.1007/s10495-015-1121-5 25828883 Das S, Chatterjee N, Bose D, Banerjee S, Jha T, Das SK. Antineoplastic impact of leishmanial sphingolipid in tumour growth with regulation of angiogenic event and inflammatory response. Apoptosis. 2015;20:869–82. 10.1007/s10495-015-1121-5. 25828883 10.1007/s10495-015-1121-5

248. Das S Chatterjee N Bose D Banerjee S Jha T Saha KD Leishmanial sphingolipid induces apoptosis in Sarcoma 180 cancer cells through regulation of tumour growth via angiogenic switchover Tumour Biol 2015 36 3109 3118 10.1007/s13277-014-2947-0 25524576 Das S, Chatterjee N, Bose D, Banerjee S, Jha T, Saha KD. Leishmanial sphingolipid induces apoptosis in Sarcoma 180 cancer cells through regulation of tumour growth via angiogenic switchover. Tumour Biol. 2015;36:3109–18. 10.1007/s13277-014-2947-0. 25524576 10.1007/s13277-014-2947-0

249. Amari A Razavi A Jamali A AminiSardrod A Motamedi M Shojaee S Effects of dendritic cell vaccine activated with protein components of Toxoplasma gondii on tumor specific CD8+ T-cells Tehran Univ Med J 2009 67 9 615 622 Amari A, Razavi A, Jamali A, AminiSardrod A, Motamedi M, Shojaee S, et al. Effects of dendritic cell vaccine activated with protein components of Toxoplasma gondii on tumor specific CD8+ T-cells. Tehran Univ Med J. 2009;67(9):615–22.

250. Motamedi M Arab S Moazzeni SM Khamis Abadi M Hadjati J Improvement of a dendritic cell-based therapeutic cancer vaccine with components of Toxoplasma gondii Clin Vaccine Immunol 2009 16 10 1393 1398 10.1128/CVI.00199-09 19656994 PMC2756855 Motamedi M, Arab S, Moazzeni SM, Khamis Abadi M, Hadjati J. Improvement of a dendritic cell-based therapeutic cancer vaccine with components of Toxoplasma gondii . Clin Vaccine Immunol. 2009;16(10):1393–8. 10.1128/CVI.00199-09. 19656994 10.1128/CVI.00199-09 PMC2756855

251. Pyo K-H Jung B-K Chai J-Y Shin E-H Suppressed CD31 expression in sarcoma-180 tumors after injection with Toxoplasma gondii lysate antigen in BALB/c mice Korean J Parasitol 2010 48 2 171 10.3347/kjp.2010.48.2.171 20585536 PMC2892575 Pyo K-H, Jung B-K, Chai J-Y, Shin E-H. Suppressed CD31 expression in sarcoma-180 tumors after injection with Toxoplasma gondii lysate antigen in BALB/c mice. Korean J Parasitol. 2010;48(2):171. 20585536 10.3347/kjp.2010.48.2.171 PMC2892575

252. Shirzad H Khorami S Soozangar N Yousefi M Darani HY Toxoplasma gondii but not Leishmania major or Trichomonas vaginalis decreases cell proliferation and increases cell death on fibrosarcoma cancer cells in culture medium World J Vaccines 2012 2 2 105 108 10.4236/wjv.2012.22014 Shirzad H, Khorami S, Soozangar N, Yousefi M, Darani HY. Toxoplasma gondii but not Leishmania major or Trichomonas vaginalis decreases cell proliferation and increases cell death on fibrosarcoma cancer cells in culture medium. World J Vaccines. 2012;2(2):105–8. 10.4236/wjv.2012.22014.

253. Rosenberg B Juckett DA Aylsworth CF Dimitrov NV Ho SC Judge JW Protein from intestinal Eimeria protozoan stimulates IL-12 release from dendritic cells, exhibits anti-tumor properties in vivo and is correlated with low intestinal tumorigenicity Int J Cancer 2005 114 5 756 765 10.1002/ijc.20801 15609305 Rosenberg B, Juckett DA, Aylsworth CF, Dimitrov NV, Ho SC, Judge JW, et al. Protein from intestinal Eimeria protozoan stimulates IL-12 release from dendritic cells, exhibits anti-tumor properties in vivo and is correlated with low intestinal tumorigenicity. Int J Cancer. 2005;114(5):756–65. 10.1002/ijc.20801. 15609305 10.1002/ijc.20801

254. Soft tissue and bone tumours: WHO classification of tumours: International agency for research on cancer; 2020.

255. Rajani R, Quinn RH. Bone tumor—types and treatments. OrthoInfo-AAOS; 2021. www.orthoinfo.org .

256. Hajizadeh M, Amni F, Sahlolbei M, Tavakoli-yaraki M, Mamaghani AJ, Sefiddashti RR, et al. Antigen similarity in hydatid cyst wall and human bone tumours: a short report. Pre-Print. 2021. 10.21203/rs.3.rs-411912/v1.

257. Leonardi GC Falzone L Salemi R Zanghì A Spandidos DA Mccubrey JA Cutaneous melanoma: from pathogenesis to therapy Int J Oncol 2018 52 4 1071 1080 29532857 10.3892/ijo.2018.4287 PMC5843392 Leonardi GC, Falzone L, Salemi R, Zanghì A, Spandidos DA, Mccubrey JA, et al. Cutaneous melanoma: from pathogenesis to therapy. Int J Oncol. 2018;52(4):1071–80. 29532857 10.3892/ijo.2018.4287 PMC5843392

258. Dzwierzynski WW Melanoma risk factors and prevention Clin Plast Surg 2021 48 4 543 550 10.1016/j.cps.2021.05.001 34503715 Dzwierzynski WW. Melanoma risk factors and prevention. Clin Plast Surg. 2021;48(4):543–50. 10.1016/j.cps.2021.05.001. 34503715 10.1016/j.cps.2021.05.001

259. Luis R Brito C Pojo M Melanoma metabolism: cell survival and resistance to therapy Tumor microenvironment. The main driver of metabolic adaptation 2020 Cham Springer 203 223 10.1007/978-3-030-34025-4_11 32130701 Luis R, Brito C, Pojo M. Melanoma metabolism: cell survival and resistance to therapy. In: Tumor microenvironment. The main driver of metabolic adaptation, vol. 1219. Advances in experimental medicine and biology. Cham: Springer; 2020. p. 203–23. 10.1007/978-3-030-34025-4_11. 10.1007/978-3-030-34025-4_11 32130701

260. Rashid S Shaughnessy M Tsao H Melanoma classification and management in the era of molecular medicine Dermatol Clin 2023 41 1 49 63 10.1016/j.det.2022.07.017 36410983 Rashid S, Shaughnessy M, Tsao H. Melanoma classification and management in the era of molecular medicine. Dermatol Clin. 2023;41(1):49–63. 10.1016/j.det.2022.07.017. 36410983 10.1016/j.det.2022.07.017

261. Chookami MB Sharafi SM Sefiddashti RR Jafari R Bahadoran M Pestechian N Effect of two hydatid cyst antigens on the growth of melanoma cancer in C57/black mice J Parasit Dis 2016 40 1170 1173 10.1007/s12639-015-0643-7 27876908 PMC5118269 Chookami MB, Sharafi SM, Sefiddashti RR, Jafari R, Bahadoran M, Pestechian N, et al. Effect of two hydatid cyst antigens on the growth of melanoma cancer in C57/black mice. J Parasit Dis. 2016;40:1170–3. 10.1007/s12639-015-0643-7. 27876908 10.1007/s12639-015-0643-7 PMC5118269

262. Badri-Chookami M Sharafi SM Rafeie R Bahadoran M Pestechian N Yousofi-Darani H Effect of alive protoscoleces of hydatid cyst on the growth of melanoma cells in mouse model IUMS 2014 32 281 486 492 Badri-Chookami M, Sharafi SM, Rafeie R, Bahadoran M, Pestechian N, Yousofi-Darani H. Effect of alive protoscoleces of hydatid cyst on the growth of melanoma cells in mouse model. IUMS. 2014;32(281):486–92.

263. Rad SR Daneshpour S Reza Mofid M Andalib A Eskandariyan A Darani HY Effect of hydatid cyst antigens on inhibition of melanoma cancer growth in mouse model Cell Mol Biol 2018 64 12 1 5 10.14715/cmb/2018.64.12.1 30301493 Rad SR, Daneshpour S, Reza Mofid M, Andalib A, Eskandariyan A, Darani HY. Effect of hydatid cyst antigens on inhibition of melanoma cancer growth in mouse model. Cell Mol Biol. 2018;64(12):1–5. 30301493

264. Barati N Tanzadehpanah H Asl SS Khazaei S Motavallihaghi S Anticancer Activity of Antigen B from hydatid cyst fluid of Echinococcus granulosus on melanoma cancer cell line Chemo Open Access 2022 11 2 1 7 Barati N, Tanzadehpanah H, Asl SS, Khazaei S, Motavallihaghi S. Anticancer Activity of Antigen B from hydatid cyst fluid of Echinococcus granulosus on melanoma cancer cell line. Chemo Open Access. 2022;11(2):1–7.

265. Mohammadi M Spotin A Mahami-Oskouei M Shanehbandi D Ahmadpour E Casulli A MicroRNA-365 promotes apoptosis in human melanoma cell A375 treated with hydatid cyst fluid of Echinococcus granulosus sensu stricto Microb Pathog 2021 153 104804 10.1016/j.micpath.2021.104804 33609644 Mohammadi M, Spotin A, Mahami-Oskouei M, Shanehbandi D, Ahmadpour E, Casulli A, et al. MicroRNA-365 promotes apoptosis in human melanoma cell A375 treated with hydatid cyst fluid of Echinococcus granulosus sensu stricto. Microb Pathog. 2021;153: 104804. 10.1016/j.micpath.2021.104804. 33609644 10.1016/j.micpath.2021.104804

266. Pérez-Torres A Vera-Aguilera J Hernaiz-Leonardo JC Moreno-Aguilera E Monteverde-Suarez D Vera-Aguilera C The synthetic parasite-derived peptide GK1 increases survival in a preclinical mouse melanoma model Cancer Biother Radiopharm 2013 28 9 682 690 23841709 10.1089/cbr.2012.1438 PMC3793655 Pérez-Torres A, Vera-Aguilera J, Hernaiz-Leonardo JC, Moreno-Aguilera E, Monteverde-Suarez D, Vera-Aguilera C, et al. The synthetic parasite-derived peptide GK1 increases survival in a preclinical mouse melanoma model. Cancer Biother Radiopharm. 2013;28(9):682–90. 23841709 10.1089/cbr.2012.1438 PMC3793655

267. Vera-Aguilera J Perez-Torres A Beltran D Villanueva-Ramos C Wachtel M Moreno-Aguilera E Novel treatment of melanoma: combined parasite-derived peptide GK-1 and anti-programmed death ligand 1 therapy Cancer Biother Radiopharm 2017 32 2 49 56 10.1089/cbr.2016.2123 28301259 Vera-Aguilera J, Perez-Torres A, Beltran D, Villanueva-Ramos C, Wachtel M, Moreno-Aguilera E, et al. Novel treatment of melanoma: combined parasite-derived peptide GK-1 and anti-programmed death ligand 1 therapy. Cancer Biother Radiopharm. 2017;32(2):49–56. 10.1089/cbr.2016.2123. 28301259 10.1089/cbr.2016.2123

268. Molinari J Ebersole J Antineoplastic effects of long-term Trichinella spiralis infection on B-16 melanoma Int Arch Allergy Immunol 1977 55 1–6 444 448 10.1159/000231956 591108 Molinari J, Ebersole J. Antineoplastic effects of long-term Trichinella spiralis infection on B-16 melanoma. Int Arch Allergy Immunol. 1977;55(1–6):444–8. 10.1159/000231956 591108

269. Kang Y-J Jo J-O Cho M-K Yu H-S Leem S-H Song KS Trichinella spiralis infection reduces tumor growth and metastasis of B16–F10 melanoma cells Vet Parasitol 2013 196 1–2 106 113 10.1016/j.vetpar.2013.02.021 23499484 Kang Y-J, Jo J-O, Cho M-K, Yu H-S, Leem S-H, Song KS, et al. Trichinella spiralis infection reduces tumor growth and metastasis of B16–F10 melanoma cells. Vet Parasitol. 2013;196(1–2):106–13. 10.1016/j.vetpar.2013.02.021. 23499484 10.1016/j.vetpar.2013.02.021

270. Vasilev S Ilic N Gruden-Movsesijan A Vasilijic S Bosic M Sofronic-Milosavljevic L Experimental immunology necrosis and apoptosis in Trichinella spiralis -mediated tumour reduction Cent Eur J Immunol 2015 40 1 42 53 10.5114/ceji.2015.50832 26155183 PMC4472539 Vasilev S, Ilic N, Gruden-Movsesijan A, Vasilijic S, Bosic M, Sofronic-Milosavljevic L. Experimental immunology necrosis and apoptosis in Trichinella spiralis -mediated tumour reduction. Cent Eur J Immunol. 2015;40(1):42–53. 10.5114/ceji.2015.50832. 26155183 10.5114/ceji.2015.50832 PMC4472539

271. Pocock D Meerovitch E The anti-neoplastic effect of trichinellosis in a syngeneic murine model Parasitology 1982 84 3 463 473 10.1017/S0031182000052768 7099711 Pocock D, Meerovitch E. The anti-neoplastic effect of trichinellosis in a syngeneic murine model. Parasitology. 1982;84(3):463–73. 10.1017/S0031182000052768. 7099711 10.1017/s0031182000052768

272. Ratha J Majumdar KN Dhara K Singh SK Saha KD Bhadra R Attenuated Leishmanial sphingolipid induces apoptosis in A375 human melanoma cell via both caspase-dependent and-independent pathways Mol Cell Biochem 2007 304 143 154 10.1007/s11010-007-9495-5 17530191 Ratha J, Majumdar KN, Dhara K, Singh SK, Saha KD, Bhadra R. Attenuated Leishmanial sphingolipid induces apoptosis in A375 human melanoma cell via both caspase-dependent and-independent pathways. Mol Cell Biochem. 2007;304:143–54. 10.1007/s11010-007-9495-5. 17530191 10.1007/s11010-007-9495-5

273. Ratha J Majumdar KN Mandal SK Bera R Sarkar C Saha B A sphingolipid rich lipid fraction isolated from attenuated Leishmania donovani promastigote induces apoptosis in mouse and human melanoma cells in vitro Mol Cell Biochem 2006 290 113 123 10.1007/s11010-024-05079-w 16718368 Ratha J, Majumdar KN, Mandal SK, Bera R, Sarkar C, Saha B, et al. A sphingolipid rich lipid fraction isolated from attenuated Leishmania donovani promastigote induces apoptosis in mouse and human melanoma cells in vitro. Mol Cell Biochem. 2006;290:113–23. 10.1007/s11010-024-05079-w. 16718368 10.1007/s11010-006-9174-y

274. Baig AM Granulomatous amoebic encephalitis: ghost response of an immunocompromised host? J Med Microbiol 2014 63 12 1763 10.1099/jmm.0.081315-0 25239626 Baig AM. Granulomatous amoebic encephalitis: ghost response of an immunocompromised host? J Med Microbiol. 2014;63(12):1763. 10.1099/jmm.0.081315-0. 25239626 10.1099/jmm.0.081315-0

275. Pidherney MS Alizadeh H Stewart GL McCulley JP Niederkorn JY In vitro and in vivo tumoricidal properties of a pathogenic/free-living amoeba Cancer Lett 1993 72 1–2 91 98 10.1016/0304-3835(93)90016-3 8402581 Pidherney MS, Alizadeh H, Stewart GL, McCulley JP, Niederkorn JY. In vitro and in vivo tumoricidal properties of a pathogenic/free-living amoeba. Cancer Lett. 1993;72(1–2):91–8. 8402581 10.1016/0304-3835(93)90016-3

276. Aguilar-Guzman L Lobos-Gonzalez L Rosas C Vallejos G Falcon C Sosoniuk E Human survivin and Trypanosoma cruzi calreticulin act in synergy against a murine melanoma in vivo PLoS One 2014 9 4 e95457 10.1371/journal.pone.0095457 24755644 PMC3995754 Aguilar-Guzman L, Lobos-Gonzalez L, Rosas C, Vallejos G, Falcon C, Sosoniuk E, et al. Human survivin and Trypanosoma cruzi calreticulin act in synergy against a murine melanoma in vivo. PLoS One. 2014;9(4):e95457. 10.1371/journal.pone.0095457. 24755644 10.1371/journal.pone.0095457 PMC3995754

277. Junqueira C Guerrero AT Galvão-Filho B Andrade WA Salgado APC Cunha TM Trypanosoma cruzi adjuvants potentiate T cell-mediated immunity induced by a NY-ESO-1 based anti-tumor vaccine PLoS One 2012 7 5 e36245 10.1371/journal.pone.0036245 22567144 PMC3342165 Junqueira C, Guerrero AT, Galvão-Filho B, Andrade WA, Salgado APC, Cunha TM, et al. Trypanosoma cruzi adjuvants potentiate T cell-mediated immunity induced by a NY-ESO-1 based anti-tumor vaccine. PLoS One. 2012;7(5):e36245. 10.1371/journal.pone.0036245. 22567144 10.1371/journal.pone.0036245 PMC3342165

278. Junqueira C Santos LI Galvão-Filho B Teixeira SM Rodrigues FG DaRocha WD Trypanosoma cruzi as an effective cancer antigen delivery vector Proc Natl Acad Sci USA 2011 108 49 19695 19700 10.1073/pnas.1110030108 22114198 PMC3241774 Junqueira C, Santos LI, Galvão-Filho B, Teixeira SM, Rodrigues FG, DaRocha WD, et al. Trypanosoma cruzi as an effective cancer antigen delivery vector. Proc Natl Acad Sci USA. 2011;108(49):19695–700. 22114198 10.1073/pnas.1110030108 PMC3241774

279. Dos Santos LI Galvao-Filho B de Faria PC Junqueira C Dutra MS Teixeira SMR Blockade of CTLA-4 promotes the development of effector CD8 + T lymphocytes and the therapeutic effect of vaccination with an attenuated protozoan expressing NY-ESO-1 Cancer Immunol Immunother 2015 64 311 323 10.1007/s00262-014-1634-8 25403749 PMC11029141 Dos Santos LI, Galvao-Filho B, de Faria PC, Junqueira C, Dutra MS, Teixeira SMR, et al. Blockade of CTLA-4 promotes the development of effector CD8 + T lymphocytes and the therapeutic effect of vaccination with an attenuated protozoan expressing NY-ESO-1. Cancer Immunol Immunother. 2015;64:311–23. 10.1007/s00262-014-1634-8. 25403749 10.1007/s00262-014-1634-8 PMC11029141

280. Ji-Chen Q Hui Z Yu-Ming J Yu-Ting Y Jia-Jun D Zheng-Zheng W Anti-tumor effect of Plasmodium yoelii infection on melanoma in mice Chin J Schisto Control 2017 29 3 315 10.16250/j.32.1374.2017040 29469521 Ji-Chen Q, Hui Z, Yu-Ming J, Yu-Ting Y, Jia-Jun D, Zheng-Zheng W, et al. Anti-tumor effect of Plasmodium yoelii infection on melanoma in mice. Chin J Schisto Control. 2017;29(3):315. 10.16250/j.32.1374.2017040. 10.16250/j.32.1374.2017040 29469521

281. Pihl J Clausen TM Zhou J Krishnan N Ørum-Madsen MS Gustavsson T Malaria biomimetic for tumor targeted drug delivery ACS Nano 2023 17 14 13500 13509 10.1021/acsnano.3c01910 37435892 Pihl J, Clausen TM, Zhou J, Krishnan N, Ørum-Madsen MS, Gustavsson T, et al. Malaria biomimetic for tumor targeted drug delivery. ACS Nano. 2023;17(14):13500–9. 10.1021/acsnano.3c01910. 37435892 10.1021/acsnano.3c01910

282. Zhou M Lai W Li G Wang F Liu W Liao J Platelet membrane-coated and VAR2CSA malaria protein-functionalized nanoparticles for targeted treatment of primary and metastatic cancer ACS Appl Mater Interfaces 2021 13 22 25635 25648 10.1021/acsami.1c02581 34038097 Zhou M, Lai W, Li G, Wang F, Liu W, Liao J, et al. Platelet membrane-coated and VAR2CSA malaria protein-functionalized nanoparticles for targeted treatment of primary and metastatic cancer. ACS Appl Mater Interfaces. 2021;13(22):25635–48. 10.1021/acsami.1c02581. 34038097 10.1021/acsami.1c02581

283. Hunter CA Yu D Gee M Ngo CV Sevignani C Goldschmidt M Cutting edge: systemic inhibition of angiogenesis underlies resistance to tumors during acute toxoplasmosis J Immun 2001 166 10 5878 5881 10.4049/jimmunol.166.10.5878 11342601 Hunter CA, Yu D, Gee M, Ngo CV, Sevignani C, Goldschmidt M, et al. Cutting edge: systemic inhibition of angiogenesis underlies resistance to tumors during acute toxoplasmosis. J Immun. 2001;166(10):5878–81. 10.4049/jimmunol.166.10.5878. 11342601 10.4049/jimmunol.166.10.5878

284. Jiao YM Zhang L Ge YY Liang YJ Yong W Effects of excreted/secreted antigens of Toxoplasma gondii on CD4+ CD25+ Foxp3+ T cells and NK cells of melanoma-bearing mice Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi 2011 23 3 301 306 22164498 Jiao YM, Zhang L, Ge YY, Liang YJ, Yong W. Effects of excreted/secreted antigens of Toxoplasma gondii on CD4+ CD25+ Foxp3+ T cells and NK cells of melanoma-bearing mice. Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. 2011;23(3):301–6. 22164498

285. Boghozian R Saei A Mirzaei R Jamali A Vaziri B Razavi A Identification of Toxoplasma gondii protein fractions induce immune response against melanoma in mice APMIS 2015 123 9 800 809 10.1111/apm.12420 26152792 Boghozian R, Saei A, Mirzaei R, Jamali A, Vaziri B, Razavi A, et al. Identification of Toxoplasma gondii protein fractions induce immune response against melanoma in mice. APMIS. 2015;123(9):800–9. 10.1111/apm.12420. 26152792 10.1111/apm.12420

286. Baird JR Byrne KT Lizotte PH Toraya-Brown S Scarlett UK Alexander MP Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge J Immun 2013 190 1 469 478 10.4049/jimmunol.1201209 23225891 PMC3529845 Baird JR, Byrne KT, Lizotte PH, Toraya-Brown S, Scarlett UK, Alexander MP, et al. Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge. J Immun. 2013;190(1):469–78. 10.4049/jimmunol.1201209. 23225891 10.4049/jimmunol.1201209 PMC3529845

287. Li Y Zhang Y Xia N Zhou T Shen B Antitumor effects of a Toxoplasma mutant lacking lactate dehydrogenases Parasitol Res 2021 120 3335 3339 10.1007/s00436-021-07283-9 34405281 Li Y, Zhang Y, Xia N, Zhou T, Shen B. Antitumor effects of a Toxoplasma mutant lacking lactate dehydrogenases. Parasitol Res. 2021;120:3335–9. 10.1007/s00436-021-07283-9. 34405281 10.1007/s00436-021-07283-9

288. Li X Qi M He K Liu H Yan W Zhao L Neospora caninum inhibits tumor development by activating the immune response and destroying tumor cells in a B16F10 melanoma model Parasites Vectors 2022 15 1 332 10.1186/s13071-022-05456-8 36138417 PMC9503190 Li X, Qi M, He K, Liu H, Yan W, Zhao L, et al. Neospora caninum inhibits tumor development by activating the immune response and destroying tumor cells in a B16F10 melanoma model. Parasites Vectors. 2022;15(1):332. 10.1186/s13071-022-05456-8. 36138417 10.1186/s13071-022-05456-8 PMC9503190

289. Battistoni A Lantier L di Tommaso A Ducournau C Lajoie L Samimi M Nasal administration of recombinant Neospora caninum secreting IL-15/IL-15Rα inhibits metastatic melanoma development in lung J Immunother Cancer 2023 11 5 e006683 10.1136/jitc-2023-006683 37192784 PMC10193056 Battistoni A, Lantier L, di Tommaso A, Ducournau C, Lajoie L, Samimi M, et al. Nasal administration of recombinant Neospora caninum secreting IL-15/IL-15Rα inhibits metastatic melanoma development in lung. J Immunother Cancer. 2023;11(5): e006683. 10.1136/jitc-2023-006683. 37192784 10.1136/jitc-2023-006683 PMC10193056

290. Krause PJ Human babesiosis Int J Parasitol 2019 49 2 165 174 10.1016/j.ijpara.2018.11.007 30690090 Krause PJ. Human babesiosis. Int J Parasitol. 2019;49(2):165–74. 10.1016/j.ijpara.2018.11.007. 30690090 10.1016/j.ijpara.2018.11.007

291. Shu X Nie Z Luo W Zheng Y Han Z Zhang H Babesia microti infection inhibits melanoma growth by activating macrophages in mice Front Microbiol 2022 13 862894 10.3389/fmicb.2022.862894 35814662 PMC9257138 Shu X, Nie Z, Luo W, Zheng Y, Han Z, Zhang H, et al. Babesia microti infection inhibits melanoma growth by activating macrophages in mice. Front Microbiol. 2022;13: 862894. 10.3389/fmicb.2022.862894. 35814662 10.3389/fmicb.2022.862894 PMC9257138

292. Emge DA Cardones AR Updates on merkel cell carcinoma Dermatol Clin 2019 37 4 489 503 10.1016/j.det.2019.06.002 31466589 Emge DA, Cardones AR. Updates on merkel cell carcinoma. Dermatol Clin. 2019;37(4):489–503. 31466589 10.1016/j.det.2019.06.002

293. Becker JC Stang A DeCaprio JA Cerroni L Lebbé C Veness M Merkel cell carcinoma Nat Rev Dis Prim 2017 3 1 1 17 10.1038/nrdp.2017.77 PMC6054450 29072302 Becker JC, Stang A, DeCaprio JA, Cerroni L, Lebbé C, Veness M, et al. Merkel cell carcinoma. Nat Rev Dis Prim. 2017;3(1):1–17. 10.1038/nrdp.2017.77. 10.1038/nrdp.2017.77 PMC6054450 29072302

294. Lantier L Poupée-Beaugé A Di Tommaso A Ducournau C Epardaud M Lakhrif Z Neospora caninum : a new class of biopharmaceuticals in the therapeutic arsenal against cancer J Immunother Cancer 2020 8 2 e001242 10.1136/jic-2020-001242 33257408 PMC7705568 Lantier L, Poupée-Beaugé A, Di Tommaso A, Ducournau C, Epardaud M, Lakhrif Z, et al. Neospora caninum : a new class of biopharmaceuticals in the therapeutic arsenal against cancer. J Immunother Cancer. 2020;8(2): e001242. 10.1136/jic-2020-001242. 33257408 10.1136/jitc-2020-001242 PMC7705568

295. Modugno F Edwards RP Ovarian cancer: prevention, detection and treatment of the disease and its recurrence. Molecular mechanisms and personalized medicine meeting report IJGC 2012 22 8 S45 23013733 10.1097/IGC.0b013e31826bd1f2 PMC3460381 Modugno F, Edwards RP. Ovarian cancer: prevention, detection and treatment of the disease and its recurrence. Molecular mechanisms and personalized medicine meeting report. IJGC. 2012;22(8):S45. 23013733 10.1097/IGC.0b013e31826bd1f2 PMC3460381

296. Mancari R Cutillo G Bruno V Vincenzoni C Mancini E Baiocco E Development of new medical treatment for epithelial ovarian cancer recurrence Gland Surg 2020 9 4 1149 10.21037/gs-20-413 32953630 PMC7475356 Mancari R, Cutillo G, Bruno V, Vincenzoni C, Mancini E, Baiocco E, et al. Development of new medical treatment for epithelial ovarian cancer recurrence. Gland Surg. 2020;9(4):1149. 10.21037/gs-20-413. 32953630 10.21037/gs-20-413 PMC7475356

297. Li J Wang Z Liu W Tan L Yu Y Liu D Identification of metabolic biomarkers for diagnosis of epithelial ovarian cancer using internal extraction electrospray ionization mass spectrometry (iEESI-MS) Cancer Biomark 2023 37 2 67 84 10.3233/CBM-220250 37248885 PMC12412821 Li J, Wang Z, Liu W, Tan L, Yu Y, Liu D, et al. Identification of metabolic biomarkers for diagnosis of epithelial ovarian cancer using internal extraction electrospray ionization mass spectrometry (iEESI-MS). Cancer Biomark. 2023;37(2):67–84. 37248885 10.3233/CBM-220250 PMC12412821

298. Luvero D Plotti F Aloisia A Montera R Terranova C Nardone CDC Ovarian cancer relapse: from the latest scientific evidence to the best practice Crit Rev Oncol Hematol 2019 140 28 38 10.1016/j.critrevonc.2019.05.014 31176270 Luvero D, Plotti F, Aloisia A, Montera R, Terranova C, Nardone CDC, et al. Ovarian cancer relapse: from the latest scientific evidence to the best practice. Crit Rev Oncol Hematol. 2019;140:28–38. 31176270 10.1016/j.critrevonc.2019.05.014

299. Coleman RL Spirtos NM Enserro D Herzog TJ Sabbatini P Armstrong DK Secondary surgical cytoreduction for recurrent ovarian cancer NEJM 2019 381 20 1929 1939 10.1056/NEJMoa1902626 31722153 PMC6941470 Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, et al. Secondary surgical cytoreduction for recurrent ovarian cancer. NEJM. 2019;381(20):1929–39. 10.1056/NEJMoa1902626. 31722153 10.1056/NEJMoa1902626 PMC6941470

300. Baird JR Fox BA Sanders KL Lizotte PH Cubillos-Ruiz JR Scarlett UK Avirulent Toxoplasma gondii generates therapeutic anti-tumor immunity by reversing immunosuppression in the ovarian cancer microenvironment Cancer Res 2013 73 13 3842 3851 10.1158/0008-5472.can-12-1974 23704211 PMC3702636 Baird JR, Fox BA, Sanders KL, Lizotte PH, Cubillos-Ruiz JR, Scarlett UK, et al. Avirulent Toxoplasma gondii generates therapeutic anti-tumor immunity by reversing immunosuppression in the ovarian cancer microenvironment. Cancer Res. 2013;73(13):3842–51. 10.1158/0008-5472.can-12-1974. 23704211 10.1158/0008-5472.CAN-12-1974 PMC3702636

301. Fox BA Sanders KL Rommereim LM Guevara RB Bzik DJ Secretion of rhoptry and dense granule effector proteins by nonreplicating Toxoplasma gondii uracil auxotrophs controls the development of anti-tumor immunity PLoS Genet 2016 12 7 e1006189 10.1371/journal.pgen.1006189 27447180 PMC4957766 Fox BA, Sanders KL, Rommereim LM, Guevara RB, Bzik DJ. Secretion of rhoptry and dense granule effector proteins by nonreplicating Toxoplasma gondii uracil auxotrophs controls the development of anti-tumor immunity. PLoS Genet. 2016;12(7): e1006189. 10.1371/journal.pgen.1006189. 27447180 10.1371/journal.pgen.1006189 PMC4957766

302. Elikaei A Vazini H Javani F Anticancer effects of parasite extracts of leishmaniasis and Toxoplasma on resistant cell line (A2780-CP) and sensitive (A2780) to cisplatin Appl Biol 2018 31 2 5 22 10.22051/jab.2017.16470.1162219- Elikaei A, Vazini H, Javani F. Anticancer effects of parasite extracts of leishmaniasis and Toxoplasma on resistant cell line (A2780-CP) and sensitive (A2780) to cisplatin. Appl Biol. 2018;31(2):5–22. 10.22051/jab.2017.16470.1162219-.

303. World Health Organization. World cancer report. 5, 2014.

304. Tsocheva-Gaytandzhieva N Toshkova R Gardeva E Yossifova L Petkova S Nanev V Antiproliferative activity against tumour cells of biologically active substances isolated from livers of healthy and Trichinella spiralis infected rats C R Acad Bulg Sci 2016 69 11 1443 1448 Tsocheva-Gaytandzhieva N, Toshkova R, Gardeva E, Yossifova L, Petkova S, Nanev V. Antiproliferative activity against tumour cells of biologically active substances isolated from livers of healthy and Trichinella spiralis infected rats. C R Acad Bulg Sci. 2016;69(11):1443–8.

305. Zhu Z Zhao L Brittingham A Bai Q Wakefield MR Fang Y Trichomonas vaginalis inhibits HeLa cell growth through modulation of critical molecules for cell proliferation and apoptosis Anticancer Res 2018 38 9 5079 5086 10.21873/anticanres.12827 30194152 Zhu Z, Zhao L, Brittingham A, Bai Q, Wakefield MR, Fang Y. Trichomonas vaginalis inhibits HeLa cell growth through modulation of critical molecules for cell proliferation and apoptosis. Anticancer Res. 2018;38(9):5079–86. 10.21873/anticanres.12827. 30194152 10.21873/anticanres.12827

306. Quan J-H Kang B-H Cha G-H Zhou W Koh Y-B Yang J-B Trichonomas vaginalis metalloproteinase induces apoptosis of SiHa cells through disrupting the Mcl-1/Bim and Bcl-xL/Bim complexes PLoS ONE 2014 9 10 e110659 10.1371/journal.pone.0110659 25343522 PMC4208800 Quan J-H, Kang B-H, Cha G-H, Zhou W, Koh Y-B, Yang J-B, et al. Trichonomas vaginalis metalloproteinase induces apoptosis of SiHa cells through disrupting the Mcl-1/Bim and Bcl-xL/Bim complexes. PLoS ONE. 2014;9(10): e110659. 25343522 10.1371/journal.pone.0110659 PMC4208800

307. Quan J-H Kang B-H Yang J-B Rhee Y-E Noh H-T Choi I-W Trichomonas vaginalis induces SiHa cell apoptosis by NF-κB inactivation via reactive oxygen species Biomed Res Int 2017 10.1155/2017/3904870 PMC5748870 29410962 Quan J-H, Kang B-H, Yang J-B, Rhee Y-E, Noh H-T, Choi I-W, et al. Trichomonas vaginalis induces SiHa cell apoptosis by NF-κB inactivation via reactive oxygen species. Biomed Res Int. 2017. 10.1155/2017/3904870. 10.1155/2017/3904870 PMC5748870 29410962

308. Gao FF Quan J-H Lee MA Ye W Yuk J-M Cha G-H Trichomonas vaginalis induces apoptosis via ROS and ER stress response through ER–mitochondria crosstalk in SiHa cells Parasites Vectors 2021 14 1 603 10.1186/s13071-021-05098-2 34895315 PMC8665556 Gao FF, Quan J-H, Lee MA, Ye W, Yuk J-M, Cha G-H, et al. Trichomonas vaginalis induces apoptosis via ROS and ER stress response through ER–mitochondria crosstalk in SiHa cells. Parasites Vectors. 2021;14(1):603. 10.1186/s13071-021-05098-2. 34895315 10.1186/s13071-021-05098-2 PMC8665556

309. Attard GPC Eeles RA Schröder F Tomlins SA Tannock I Drake CG de Bono JS Prostate cancer Nat Rev Urol 2016 387 70 82 10.1016/S0140-6736(14)61947-4 26074382 Attard GPC, Eeles RA, Schröder F, Tomlins SA, Tannock I, Drake CG, de Bono JS. Prostate cancer. Nat Rev Urol. 2016;387:70–82. 10.1016/S0140-6736(14)61947-4. ( Epub 2015 Jun 11 ). 10.1016/S0140-6736(14)61947-4 26074382

310. Verze P Cai T Lorenzetti S The role of the prostate in male fertility, health and disease Nat Rev Urol 2016 13 7 379 386 10.1038/nrurol.2016.89 27245504 Verze P, Cai T, Lorenzetti S. The role of the prostate in male fertility, health and disease. Nat Rev Urol. 2016;13(7):379–86. 10.1038/nrurol.2016.89. 27245504 10.1038/nrurol.2016.89

311. Rebello RJ Oing C Knudsen KE Loeb S Johnson DC Reiter RE Prostate cancer Nat Rev Dis Prim 2021 7 1 9 10.1038/s41572-020-00243-0 33542230 Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, et al. Prostate cancer. Nat Rev Dis Prim. 2021;7(1):9. 10.1038/s41572-020-00243-0. 33542230 10.1038/s41572-020-00243-0

312. Zhu Z Davidson KT Brittingham A Wakefield MR Bai Q Xiao H Trichomonas vaginalis : a possible foe to prostate cancer Med Oncol 2016 33 1 8 10.1007/s12032-016-0832-y 27613161 Zhu Z, Davidson KT, Brittingham A, Wakefield MR, Bai Q, Xiao H, et al. Trichomonas vaginalis : a possible foe to prostate cancer. Med Oncol. 2016;33:1–8. 10.1007/s12032-016-0832-y. 27613161 10.1007/s12032-016-0832-y

313. Lee JH Wee CW Treatment of adult gliomas: a current update Brain Neurorehabil 2022 15 3 e24 10.12786/bn.2022.15.e24 36742086 PMC9833488 Lee JH, Wee CW. Treatment of adult gliomas: a current update. Brain Neurorehabil. 2022;15(3): e24. 10.12786/bn.2022.15.e24. 36742086 10.12786/bn.2022.15.e24 PMC9833488

314. Lee JH Lee JE Kahng JY Kim SH Park JS Yoon SJ Human glioblastoma arises from subventricular zone cells with low-level driver mutations Nature 2018 560 7717 243 247 10.1038/s41586-018-0389-3 30069053 Lee JH, Lee JE, Kahng JY, Kim SH, Park JS, Yoon SJ, et al. Human glioblastoma arises from subventricular zone cells with low-level driver mutations. Nature. 2018;560(7717):243–7. 10.1038/s41586-018-0389-3. 30069053 10.1038/s41586-018-0389-3

315. Liu J Sun J Liu L Du Z Liu Z Wang X Observation of Trichinella on C6 glioma in BALB/c mice J Apoplexy Nerv Dis 2008 6 722 724 Liu J, Sun J, Liu L, Du Z, Liu Z, Wang X, et al. Observation of Trichinella on C6 glioma in BALB/c mice. J Apoplexy Nerv Dis. 2008;6:722–4.

316. Parker WB Allan PW Waud WR Hong J Gilbert-Ross M Achyut B The use of Trichomonas vaginalis purine nucleoside phosphorylase to activate fludarabine in the treatment of solid tumors Cancer Chemother Pharmacol 2020 85 573 583 10.1007/s00280-019-04018-7 31915968 PMC7039746 Parker WB, Allan PW, Waud WR, Hong J, Gilbert-Ross M, Achyut B, et al. The use of Trichomonas vaginalis purine nucleoside phosphorylase to activate fludarabine in the treatment of solid tumors. Cancer Chemother Pharmacol. 2020;85:573–83. 10.1007/s00280-019-04018-7. 31915968 10.1007/s00280-019-04018-7 PMC7039746

317. Choo J-D Lee J-S Kang J-S Lee H-S Yeom J-Y Lee Y-H Inhibitory effects of Toxoplasma antigen on proliferation and invasion of human glioma cells J Korean Neurosurg Soc 2005 37 2 129 136 Choo J-D, Lee J-S, Kang J-S, Lee H-S, Yeom J-Y, Lee Y-H. Inhibitory effects of Toxoplasma antigen on proliferation and invasion of human glioma cells. J Korean Neurosurg Soc. 2005;37(2):129–36.

318. Choi JY Medulloblastoma: current perspectives and recent advances Brain Tumor Res Treat 2023 11 1 28 38 10.14791/btrt.2022.0046 36762806 PMC9911713 Choi JY. Medulloblastoma: current perspectives and recent advances. Brain Tumor Res Treat. 2023;11(1):28–38. 10.14791/btrt.2022.0046. 36762806 10.14791/btrt.2022.0046 PMC9911713

319. Nguyen Y Zhao X Ewald S Harris T Zong H Harness the immune-modulatory activities of Toxoplasma gondii to improve lymphocyte infiltration into brain tumors Cancer Immunol Res 2022 10 1_Supplement 40 10.1158/2326-6074.Tumimm21-p040 Nguyen Y, Zhao X, Ewald S, Harris T, Zong H. Harness the immune-modulatory activities of Toxoplasma gondii to improve lymphocyte infiltration into brain tumors. Cancer Immunol Res. 2022;10(1_Supplement):40. 10.1158/2326-6074.Tumimm21-p040.34795032

320. Thong PM Minh DN Malignant ependymoblastoma mimicking a benign pilocytic astrocytoma Neurol Int 2020 12 3 41 47 10.3390/neurolint12030010 33143022 PMC7768421 Thong PM, Minh DN. Malignant ependymoblastoma mimicking a benign pilocytic astrocytoma. Neurol Int. 2020;12(3):41–7. 10.3390/neurolint12030010. 33143022 10.3390/neurolint12030010 PMC7768421

321. Nowak J Seidel C Pietsch T Alkonyi B Fuss TL Friedrich C Systematic comparison of MRI findings in pediatric ependymoblastoma with ependymoma and CNS primitive neuroectodermal tumor not otherwise specified Neuro Oncol 2015 17 8 1157 1165 10.1093/neuonc/nov063 25916887 PMC4490876 Nowak J, Seidel C, Pietsch T, Alkonyi B, Fuss TL, Friedrich C, et al. Systematic comparison of MRI findings in pediatric ependymoblastoma with ependymoma and CNS primitive neuroectodermal tumor not otherwise specified. Neuro Oncol. 2015;17(8):1157–65. 10.1093/neuonc/nov063. 25916887 10.1093/neuonc/nov063 PMC4490876

322. Conley FK Remington JS Nonspecific inhibition of tumor growth in the central nervous system: observations of intracerebral ependymoblastoma in mice with chronic Toxoplasma infection J Natl Cancer Inst 1977 59 3 963 973 10.1093/jnci/59.3.963 894752 Conley FK, Remington JS. Nonspecific inhibition of tumor growth in the central nervous system: observations of intracerebral ependymoblastoma in mice with chronic Toxoplasma infection. J Natl Cancer Inst. 1977;59(3):963–73. 10.1093/jnci/59.3.963. 894752 10.1093/jnci/59.3.963

323. Maris JM Recent advances in neuroblastoma N Engl J Med 2010 362 23 2202 2211 10.1056/NEJMra0804577 20558371 PMC3306838 Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362(23):2202–11. 10.1056/NEJMra0804577. 20558371 10.1056/NEJMra0804577 PMC3306838

324. Maris J Hogarty M Bagatell R Cohn S Neuroblastoma Lancet 2007 369 9579 2106 2120 10.1016/S0140-6736(07)60983-0 17586306 Maris J, Hogarty M, Bagatell R, Cohn S. Neuroblastoma. Lancet. 2007;369(9579):2106–20. 17586306 10.1016/S0140-6736(07)60983-0

325. Riedel RF Burfeind WR Jr Thymoma: Benign appearance, malignant potential Oncologist 2006 11 8 887 894 10.1634/theoncologist.11-8-887 16951392 Riedel RF, Burfeind WR Jr. Thymoma: Benign appearance, malignant potential. Oncologist. 2006;11(8):887–94. 10.1634/theoncologist.11-8-887. 16951392 10.1634/theoncologist.11-8-887

326. Johnson DE Burtness B Leemans CR Lui VWY Bauman JE Grandis JR Head and neck squamous cell carcinoma Nat Rev Dis Prim 2020 6 1 92 10.1038/s41572-020-00224-3 33243986 PMC7944998 Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Prim. 2020;6(1):92. 10.1038/s41572-020-00224-3. 33243986 10.1038/s41572-020-00224-3 PMC7944998